 
Official Title:   
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel - 
Group Two Year Study to Evaluate the Effect of Subcutaneous  
RO4909832 on Cognition and Function in Prodromal Alzheimer's  
Disease With Option for up to an Additional Two Years of Treatment 
and an Open-Label Extension With Active Study Treatment 
Study ID: [REMOVED] 
Document Date : Protocol Version H: 09-July -2018  
 
 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
Protocol W N25203, Version HCLINICA L STUDY PROTOCOL
PROTOCOL NUMBER WN25 203H
RO4909832
EUDRA CT NO.: 2010-019895 -66
IND 102,266
Multicenter, Randomized, Double -Blind, Placebo -Controlled, 
Parallel -Group Two Year Study to Evaluate the Effect of Subcutaneous 
RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease 
with Option for up to an Additional Two Years of Treatment and an 
Open -Label Extension with Active Study Treatment
PROTOCOL APPROVA L
Protocol Number/Version: WN25203H
Date:   See last date in electronic signature manifestation below .
Protocol approved b y:  See electronic signature manifestation below.
Confidentiality Statement
The information contained in this document, especiall y unpublished data, is the propert y 
of Roche (or under its control), and therefore provided to you in confidence as an 
investigator, potential investigator or consultant, for review by you, your staff and an 
applicable Independent Ethics Committee/I nstitutional Review Board. It is understood 
that this information will not be disclosed to others without written authorization from 
Roche except to the extent necessary  to obtain informed consent from those persons to 
whom the drug may  be admi nistered.
 
09-Jul-2018 21:03:07
Title
Approver's Name
Company Signatory
Date and Time (UTC)

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
2/Protocol W N25203, Version HPROTOCOL AMENDMENT, VERSION H:
RATIONALE
Protocol WN25203 has been amended to allow patients to continue receiving open -label 
gantenerumab until July 2020, at which time anticipated results from other relevant 
monoclonal antibody  treatments targeting amyloid-will be available.  Relevant sections 
updated include the following:
Section 1.2.4 (Rationale for Prolonging Open- label Extension [Part 3])
Section 3.1 (Overview of Study  Design and Dosing Regimen)
Section 5 (Table 9, Schedule of Assessments –Open -Label Extension Year s4 and 5 
for Participa nts Continuing Part 3 until July 2020)
Section 5.1.6 (Part 3 – the Open -Label Extension) 
Section 5.2 (Assessments and Procedures)
Section 8.7 ( Anal ysis Considerations for Data Collected during Part 3 –the 
Open -Label Extension)
Section 10.1.2 ( Independent Data Monitoring Committee)
Additional changes to the protocol are as follows:
Gantenerumab information has been updated (Section 1.1.2, Gantenerumab)
An overview the of clinical safet y, and pharmacodynamics PET am yloid results from 
the ongoing open -label Studies WN25203 and WN28745 have been added (Section 
1.1.2.4, WN28745; Section 1.1.2.5, WN25203 and WN28745 Open- Label 
Extension Studies; Section 1.3.2, Reduction in Brain Aβ by  Gantenerumab)
MRI  findings have been updated (Section 1.3.3, MRI  Findings).
Section 2.5 (Objectives of Part 3 [Open- Label Extension]) has been updated to clarify  
which objectives for Part 3 will be evaluated during the initial 3 years of Part 3.
Observation period after dosing has been adjusted to correspond with Study File 
Note 14 (Section 5.1.6, Part 3 –the Open -Label Extension)
Storage parameters of solution at ambient temperature has been adjusted from 
6to4hours to correspond with Study  File Note 12 (Section 6.3.2, Preparation and 
Administration of I MP in Part 3)
Conditions for recording MRI  observations has been adjusted to correspond with 
Study  File Note 12(Section 7.1.4, MRI  Observations)
To further strengthen safety monitoring and reporting, Section 7 ( Safety  Instructions 
and Guidance )has been updated to provide clarif ication on reporting of findings that 
may result in an adverse event (laboratory  abnormalities, vital signs, MRI  
observations [as indicated above], events associated with overdose or medication 
error), to provide clarification of deaths to specify events that require immediate 
reporting to the Sponsor (serious adverse events, adverse events of special interest, 
pregnancies and medical device complaints), and to provide more information on 
expedite reporting, on recording of adverse events in the eCRF, and on follow -up of 
adverse events.  The Safety  Plan(Section 7.3)has been included to address risks,
replacing the warning sand precautions section .  The following sections have been 
clarified or added:
– Section 7.1.1 (Clinical Adverse Events)
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
3/Protocol W N25203, Version H– Section 7.1.1.1 (Intensity)
–Section 7.1.1.2 (Drug -Adverse Relationship 
[Assessment of Causality  of Adverse 
Events])
– Section 7.1.1.3 ( Serious Adverse Events [I mmediately  Reportable to Sponsor])
–Section 7.1.1.4 (Adverse Events of Special Interest ([I mmediatel y Reportable to
Sponsor])
– Section 7.1.2 ( Laboratory Test Abnormalities)
–Section 7.1.2.1 (Follow -up of Abnormal Laboratory  Tests Values)
–Section 7.1.3 (Abnormal Vital Sign Values)
– Section 7.1.5 (Adverse Events Associated with an Overdose or Error in Drug 
Administration)
– S ection 7.1.6 (Deaths)
– Section 7.2.2 (Reporting of Serious Adverse Events and Adverse Events of 
Special Interest [I mmediately  Reportable])
– Section 7.2.3 ( Reporting of Pregnancy )
– Section 7.2.4 (Reporting Requirements for Medical Device Complaints)
– Section 7.2.5 (Expedited reporting to Health Authorities, I nvestigators, 
Institutional Review Boards and Ethics Committee)
–
Section 7.2.6 (Recording Adverse Events on the eCRF)
–Section 7.2.7 (Follow -up of Patients after Adverse Events)
–Section 7.3 (Safet y Plan)
Protocol deviation assessment and reporting have been clarified (Section 13, 
Conditions for Modify ing the Protocol) 
Additional minor changes have been made to improve clarity  and consistency .  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
4/Protocol W N25203, Version HTABLE OF CONTENTS
PROTOCOL AMENDMENT A CCEPTANCE FORM ................................................................ 13
1. BACKGROUND AND RATIO NALE ................................................................................. 24
1.1 Background (Additional Information May Be Found in the 
Investiga tor’s Brochure) ............................................................................. 24
1.1.1 Alzheimer’s Disease ................................................................................... 24
1.1.2 Gantenerumab ............................................................................................. 25
1.1.2.1 NN19866: Clinical Multiple Ascending Dose Study 
(MAD) ........................................................................................................ 25
1.1.2.2 Clinical Pharmacokinetics following Subcutaneous Dosing ...................... 27
1.1.2.3 WN25203.................................................................................................... 27
1.1.2.4 WN28745.................................................................................................... 29
1.1.2.5 WN25203 and WN28745 Open -Label Extension Studies .......................... 29
1.2 Rationale for the Study ............................................................................... 29
1.2.1 Rationale for Part 1 of the Study ................................................................ 29
1.2.2 Rationale for Part 2 of the Study ................................................................ 31
1.2.3 Rationale for the Open -Label Extension (Part 3) ....................................... 31
1.2.4 Rationale for Prolongi ng Open -Label Extension (Part 3)........................... 35
1.3 Overall Benefit -Risk Assessment ............................................................... 35
1.3.1 Selecting Prodromal AD Subjects for Study WN25203 ............................. 36
1.3.1.1 Adjustment of CSF A β1-42 Cutoff .............................................................. 38
1.3.2 Reduction in Brain Aβ by Gantenerumab .................................................. 39
1.3.3 MRI Findings .............................................................................................. 45
48
1.3.5 Risk to Subjects without AD Pa thology ..................................................... 48
1.3.6 Part 2 (Optional Extension Phase) .............................................................. 48
1.3.7 Part 3 (Open -Label Extension) ................................................................... 49
1.3.8 Overall Benefit Risk Summation ................................................................ 50
2. OBJECTIVES OF PART 1 (THE FIRST 2 YEARS OF THE STUDY) ............................. 50
2.1 Primary Objective ....................................................................................... 50
2.2 Secondary Objectives ................................................................................. 50
2.2.1 Cognit ion.................................................................................................... 50
2.2.2 Global ......................................................................................................... 50
2.2.3 Functioning ................................................................................................. 50
2.2.4 Neur opsychiatric Functioning .................................................................... 50

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
5/Protocol W N25203, Version H2.2.5 Dementia Assessment ................................................................................. 50
2.2.6 Safety and Tolerability ............................................................................... 51
2.2.7 Brain MRI ................................................................................................... 51
2.2.8 Cerebrospinal Fluid Biomarkers ................................................................. 51
2.2.9 Pharmacokinetics ........................................................................................ 51
2.2.10 Anti- Drug Antibodies ................................................................................. 51
2.3 Exploratory Objectives ............................................................................... 51
2.3.1 Plasma Biomarkers ..................................................................................... 51
2.3.2 Clinical Genotyping .................................................................................... 51
2.3.3 Roche Clinical Repository .......................................................................... 52
2.4 Objectives of Part 2 (Optional Extension) .................................................. 52
2.4.1 Cognition .................................................................................................... 52
2.4.2 Global ......................................................................................................... 52
2.4.3 Functioning ................................................................................................. 53
2.4.4 Neuropsychiatric Functioning .................................................................... 53
2.4.5 Dementia Assessment ................................................................................. 53
2.4.6 Safety and Tolerability ............................................................................... 53
2.4.7 Brain MRI ................................................................................................... 53
2.4.8 Cerebr ospinal Fluid Biomarkers ................................................................. 53
2.5 Objectives of Part 3 (Open -Label Extension) ............................................. 53
2.5.1 Safety and Tolerability ............................................................................... 53
2.5.2 Brain MRI Volumetry ................................................................................. 53
2.5.3 Brain Amyloid Load by PET Imaging ........................................................ 54
2.5.4 Cognition .................................................................................................... 54
2.5.5 Global Measures of Cognition and Function .............................................. 54
2.5.6 Functioning ................................................................................................. 54
2.5.7 Dementia Assessment ................................................................................. 54
2.5.8 Pharmacokinetics ........................................................................................ 54
2.5.9 Anti- Drug Antibodies ................................................................................. 54
3. STUDY DESIGN ................................................................................................................. 54
3.1 Overview of Study Design and Dosing Regimen ....................................... 54
3.1.1 Use of Symptomatic Treatments for AD in Part 1 ...................................... 55
3.1.2 Use of Symptomatic Treatments for AD in Part 2 ...................................... 56
3.1.3 Use of Symptomatic Treatments for AD in Part 3 ...................................... 56
3.1.4 Rationale for Dose Selection Parts 1 and 2 ................................................. 56
3.1.4.1 Dosing in Subjects Who Are 0 4 and 1 4.................................................. 56
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
6/Protocol W N25203, Version H3.1.4.2 Dosing in Subjects Who Are 2 4 ............................................................... 57
3.1.5 Rationale for Dose Selection for the Open -Label Extension 
(Part 3) ........................................................................................................ 57
3.1.5.1 Dosing in APOE 4 carriers (1 4 and 2 4 genotypes) 
previously on placebo, 105 mg Gantenerumab, and 225 mg 
Gantenerumab meeting criteria for dose reduction due to 
ARIAs ......................................................................................................... 58
3.1.5.2 Dosing in APOE 4 non- carriers (0 4 genotype) and in 
APOE 4 carriers receiving 225 mg Gantenerumab until the 
end of double -blind treatment (1 4 genotype) ............................................ 58
3.2 End of Study ............................................................................................... 58
3.3 Number of Subjects / Assignment to Treatment Groups in 
Part 1 ........................................................................................................... 58
3.4 Centers ........................................................................................................ 59
4. STUDY POPULATION ....................................................................................................... 59
4.1 Overview .................................................................................................... 59
4.2 Inclusion Criteria ........................................................................................ 59
4.3 Exclusion Criteria ....................................................................................... 60
4.4 Eligibility for the Open -Label Extension (Part 3) ...................................... 64
4.5 Concomitant Medication and Treatment .................................................... 64
4.6 Criteria for Premature Withdrawal .............................................................
65
4.6.1 Withdrawal from Study Drug ..................................................................... 65
4.6.2 Withdrawal of Subjects from the Roche Clinical 
Repository (RCR) ....................................................................................... 66
4.7 Replacement Policy [Ensuring Adequate Numbers of 
Evaluable Subjects] .................................................................................... 66
4.7.1 For Subjects ................................................................................................ 66
4.7.2 For Centers ................................................................................................. 66
5. SCHEDULE OF ASSESSME NTS AND PROCEDURES .................................................. 67
5.1 General Instructions by Study Phase .......................................................... 79
5.1.1 Assessors for Clinical Scales and Order of Assessments ........................... 79
5.1.2 Screening Period ......................................................................................... 79
5.1.3 Treatment Period during Part 1 of the Study (Including 
Day of First Dose) ...................................................................................... 80
5.1.3.1 Procedures for New MRI Findings in Part 1 of the Study .......................... 81
5.1.4 Part 2 - Extension Period for Continued Double- Blind 
Treatment .................................................................................................... 83
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
7/Protocol W N25203, Version H5.1.4.1 Procedures to Follow for Subjects who reach the Week 104 
Visit prior to Approval of Amendment D ................................................... 83
5.1.4.2 Procedures to Follow for Subjects who reach the Week 104 
or 112 Visit without having made a Decision to Continue 
in Part 2 of the Study .................................................................................. 84
5.1.4.3 Dosing during Part 2 of the Study .............................................................. 84
5.1.4.4 Procedures for new MRI findings in Part 2 of the Study ............................ 84
5.1.5 Treatment -Free Follow -Up......................................................................... 84
5.1.6 Part 3 – the Open- Label Extension ............................................................. 84
5.1.6.1 Procedures for new MRI findings in Part 3 of the Study ............................ 86
5.2 Assessments and Procedures ...................................................................... 87
5.2.1 CDR ............................................................................................................ 87
5.2.2 Functional Activities Questionnaire (FAQ) ................................................ 87
5.2.3 MMSE ........................................................................................................ 87
5.2.4 Neuropsychiatric Inventory (NPI -Q).......................................................... 87
5.2.5 Alzheimer Disease Assessment Scale -Cognition 
(ADAS -Cog) ............................................................................................... 88
5.2.6 Free and Cued Selective Reminding Test (FCSRT -IR).............................. 88
5.2.7 Cambridge Neuropsychological Test Automated Battery .......................... 88
5.2.8 Dementia Assessment ................................................................................. 88
5.2.9 Modified Hachinski Ischemia Scale ........................................................... 88
5.2.10 MRI ............................................................................................................. 89
5.2.10.1 Healthy Volunteer MRI Scans for Site Qualification ................................. 89
5.2.11 Pharmacokinetic [PK] Sampling ................................................................ 90
5.2.11.1 Plasma Gantenerumab ................................................................................ 90
5.2.11.2 CSF Gantenerumab (Parts 1 and 2) ............................................................ 90
5.2.12 Anti- Drug Antibody Sampling ................................................................... 90
5.2.13 Clinical Genotyping .................................................................................... 91
5.2.14 CSF and Plasma Biomarker Sampling (Parts 1 and 2) ............................... 91
5.2.14.1 Plasma Biomarkers Sampling ..................................................................... 91
5.2.14.2 CSF Sampling ............................................................................................. 91
5.2.15 Roche Clinical Repository Specimen(s) ..................................................... 92
5.2.15.1 Specimen Types [the following list is not exhaustive] ............................... 93
5.2.16 Safety.......................................................................................................... 94
5.2.16.1 Physical Examination ................................................................................. 94
5.2.16.2 Neurological Examination .......................................................................... 94
5.2.16.3 G DS............................................................................................................ 94
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
8/Protocol W N25203, Version H5.2.16.4 Vital Signs .................................................................................................. 94
5.2.16.5 ECG ............................................................................................................ 94
5.2.16.6 Laborat ory Assessments ............................................................................. 95
5.2.16.7 Columbia -Suicide Severity Rating Scale (C -SSRS) ................................... 95
6. INVESTIGATIONAL MEDI CINAL PRODUCT ............................................................... 96
6.1 Formulation, Packaging and Labeling ........................................................ 96
6.2 Dose and Schedule of IMP ......................................................................... 96
6.2.1 Dose Modifications, Interruptions, and Delays .......................................... 96
6.3 Preparation and Administration of the IMP ................................................ 96
6.3.1 Preparation and Administration of the IMP in Parts 1 and 2 ...................... 96
6.3.2 Preparation and Administration of the IMP in Part 3 ................................. 97
6.4 Randomization, Blinding, and Unblinding ................................................. 97
6.5 Accountability of IMP and Assessment of Compliance ............................. 99
6.5.1 Accountability of IMP ................................................................................ 99
6.5.2 Assessment of Compliance ......................................................................... 99
6.6 Destruction of the IMP/Comparator ........................................................... 99
7. SAFETY INSTRUCTIONS AND GUIDANCE ................................................................ 100
7.1 Adverse Events (AEs) ............................................................................... 100
7.1.1 Clinical Adverse Events ........................................................................... 100
7.1.1.1 Intensity .................................................................................................... 101
7.1.1.2 DrugAdverse Event Relationship (Assessment of 
Causality of Adverse Events) ................................................................... 101
7.1.1.3 Serious Adve rse Events [Immediately Reportable to 
Sponsor] .................................................................................................... 102
7.1.1.4 Adverse Events of Special Interest (Immediately 
Reportable to the Spon sor)....................................................................... 103
7.1.2 Laboratory Test Abnormalities ................................................................. 104
7.1.2.1 Follow -Up of Abnormal Laboratory Test Values .................................... 105
7.1.3 Abnormal Vital Sign Values ..................................................................... 105
7.1.4 MRI Observations ..................................................................................... 105
7.1.5 Adverse Events Associated with an Overdose or Error in 
Drug Administration ................................................................................. 106
7.1.6 Deaths ....................................................................................................... 106
7.2 Handling of Safety Parameters ................................................................. 107
7.2.1 Reporting of Adverse Events ................................
.................................... 107
7.2.2 Reporting of Serious Adverse Events and Adverse Events 
of Special Interest [Immediately Reportable] ...........................................
107
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
9/Protocol W N25203, Version H7.2.3 Reporting of Pregnancy ............................................................................ 108
7.2.4 Reporting Requirements for Medical Device Complaints ........................ 108
7.2.5 Expedited Reporting to Health Authorities, Investigators, 
Institutional Review Boards, and Ethics Committees .............................. 108
7.2.6 Recording Adverse Events on the eCRF .................................................. 109
7.2.7 Follow -Up of Patients after Adverse Events ............................................ 110
7.2.7.1 Investigator Follow -Up............................................................................. 110
7.2.7.2 Sponsor Follow -Up................................................................................... 111
7.3 Safety Plan ................................................................................................ 111
8. STATISTICAL CONSIDER ATIONS AND ANALYTICAL P LAN ................................ 111
8.1 Primary and Secondary Study Endpoints ................................................. 111
8.1.1 Primary Efficacy Endpoint ....................................................................... 111
8.1.2 Secondary Efficacy Endpoints .................................................................. 112
8.1.2.1 Cognition – Change from Baseline at Week 104 in the 
f
ollowing ..................................................................................................
. 112
8.1.2.2 Global ....................................................................................................... 112
8.1.2.3 Functioning ............................................................................................... 112
8.1.2.4 Neuropsychiatric Functioning .................................................................. 112
8.1.2.5 Dementia Assessment ............................................................................... 112
8.1.2.6 MRI Volumetric Measures ....................................................................... 112
8.1.2.7 Cerebrospinal Fluid Biomarker Measures ................................................ 112
8.1.3 Safety........................................................................................................ 113
8.1.4 Pharmacokinetics ...................................................................................... 113
8.1.5 Exploratory Endpoints .............................................................................. 113
8.1.5.1 Plasma Biomarkers ................................................................................... 113
8.1.5.2 Genotype ................................................................................................... 113
8.2 Statistical and Analytical Methods ........................................................... 113
8.2.1 Efficacy Data ............................................................................................ 114
8.2.1.1 Primary Efficacy Variable ........................................................................ 114
8.2.1.2 Secondary Efficacy Variables ................................................................... 115
8.2.2 Safety Data ............................................................................................... 115
8.2.3 Exploratory Analysis ................................................................................ 116
8.2.4 Subgroup Analyses ................................................................................... 116
8.3 Sample Size .............................................................................................. 116
8.3.1 Analysis Populations ................................................................................ 117
8.3.1.1 Safety Population ...................................................................................... 117
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
10/Protocol WN25203 , Version H8.3.1.2 Intent -to-Treat Population ........................................................................ 117
8.3.1.3 Per- Protocol Population ............................................................................ 117
8.4 Interim Analysis ....................................................................................... 117
8.5 Other Analyses ......................................................................................... 117
8.5.1 Pharmacokinetic Analysis ........................................................................ 117
8.6 Analysis Considerations for Data Collected during Part 2, 
the Extension Period for Continued Double- Blind 
Treatment .................................................................................................. 118
8.7 Analysis Considerations for Data Collected during Part 3 –
the Open- Label Extension ........................................................................ 118
9. DATA COLLECTION, MAN AGEMENT AND QUALITY ASSURANCE ................... 118
9.1 Assignment of Preferred Terms and Original Terminology ..................... 119
10. REVIEW OF RESULTS DU RING THE CONDUCT OF THE STUDY .......................... 119
10.1 Review of Safety Data .............................................................................. 119
10.1.1 MRI Review Committee ........................................................................... 119
10.1.2 Independent Data Monitoring Committee ................................................ 119
10.2 Interim Analysis ....................................................................................... 120
10.2.1 Administrative Interim Analysis ............................................................... 120
10.2.2 Sample Size Adjustment ........................................................................... 120
10.2.3 Futility Analysis ....................................................................................... 121
11. REFERENCES ................................................................................................................... 122
12. ETHICAL ASPECTS ......................................................................................................... 126
12.1 Local Regulations/Declaration of Helsinki ............................................... 126
12.2 Informed Consent ..................................................................................... 126
12.2.1 Main Study Informed Consent .................................................................. 126
12.2.2 Written Informed Consent from the Study Partner ................................... 126
12.2.3 RCR Informed Consent ............................................................................ 126
12.2.4 Death or Loss of Competence of Participant who Has 
Donated a Specimen(s) That is Stored in the RCR .................................. 127
12.3 Independent Ethics Committee(IEC)/Institutional Review 
Board(IRB) ............................................................................................... 127
12.4 Role of the Science and Ethics Advisory Group (SEAG) ........................ 128
13. CONDIT IONS FOR MODIF YING THE PROTOCOL ..................................................... 128
14. CONDIT IONS FOR TERMI NAT ING THE STUDY ....................................................... 128
15. STUDY DOCUMENTATION, ECRFS AND RECORD KE EPING ................................ 129
15.1 Investigator's Files / Retention of Documents .......................................... 129
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
11/Protocol WN25203 , Version H15.2 Source Documents and Background Data ................................................ 129
15.3 Audits and Inspections .............................................................................. 129
15.4 Electronic Case Report Forms .................................................................. 130
15.5 Financial Disclosure ................................................................................. 130
16. MONITORING THE STUDY ............................................................................................ 130
17. CONFIDENT IALITY OF T RIAL DOCUMENTS AND S UBJECT 
RECORDS .......................................................................................................................... 131
18. CLINICAL STUDY REPOR T (CSR) ................................................................................ 131
19. PUBLICAT ION OF DATA AND PROTECTION OF TR ADE SECRETS ...................... 131
LIST OF TABLES
Table 1 Schedule of Assessments –First Year ................................ ............. 67
Table 2 Schedule of Assessments –Second Year ........................................68
Table 3 Schedule of Assessments –
Extension Year 1 ................................70
Table 4 Schedule of Assessments –
Extension Year 2 ................................71
Table 5 Schedule of Assessments –
Open-Label Extension Year 1 -
for ApoE 4 carriers previously on:  1) Placebo, 2) 105 mg 
Gantenerumab and 3) 225 mg Gantenerumab meeting 
Criteria for Dose Reduction due to ARIAs ........................................72
Table 6 Schedule of Assessments –
Open- Label Extension Year 1 -
for:  1) ApoE 4 non -carriers and 2) ApoE 4 Carriers 
receiving 225 mg Gantenerumab until the End of Double -
blind Treatment .....................................................................................73
Table 7 Schedule of Assessments –
Open-Label Extension Year 2 
for all Participants .................................................................................74
Table 8 Schedule of Assessments –
Open-Label Extension Year 3 
for all Participants .................................................................................75
Table 9 Schedule of Assessments –Open -Label Extension Years 4 
and 5 for Participants Continuing Part 3 until July 2020 ............77
LIST OF FIGURES
Figure 1 Treatment Response in ADAS -Cog-13 by  Gantenerumab Serum 
Concentration, 2 -Year Completing Fast Progressors ..............................33
Figure 2
Mean Percent Changes from Baseline after 2 Years of Treatment in 
(A) CSF P -Tau and (B) T -Tau (ITT population).....................................34
Figure 3 CSF Biomarkers at baseline in MCI  subjects (taken from [8]) ...............36
Figure 4 Kaplan -
Meier Estimates of the Rate of Progression to Alzheimer's 
Disease in Patients with MCI  who Have Either Normal CSF or 
Pathological CSF at Baseline ................................ ................................ ..37
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
12/Protocol WN25203 , Version HFigure 5 A. Cerebrospinal Fluid–derived A 42 Mixture Model Applied to 
Individuals with Amnestic MCI  from the ADNI Study ..........................39
Figure 6 Median Am yloid PET Percent Change from Baseline:  Composite, 
6 Months (I TT Population) ......................................................................40
Figure 7 Mean Percent Changes from Baseline in Composite Amy loid PET 
SUVR after 2 years of Treatment (ITT Population)
................................41
Figure 8 Time Course PET SUVR during 2 Years of Treatment by 
Gantenerumab Serum Concentration Category
.......................................42
Figure 9 Voxel -Wise Changes in PET SUVR After 1 Year of Treatment 
with Gantenerumab .................................................................................43
Figure 10 Reduction of Brain Amyloid PET SUVR in Patients Exposed 
to at Least 900 mg for 6 9Months in Studies WN25203 
(SR) and WN28745 (MR) Open -Label Extens ion Studies ............45
Figure 11 ARIA Adverse Events by  APOE ε4Genot ypes ......................................46
LIST OF APPENDICES
Appendix 1 ICH Guidelines for Clinical Safet y Data Management, Definitions 
and Standards for Expedited Reporting, Topic E2
................................133
Appendix 2 CANTAB –Descriptions of tests used in this study .............................136
.139
 
140
154
158

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
13/Protocol WN25203 , Version HPROTOCOL AMENDMENT ACCEPTANCE FORM
TITLE:MULTICENTER, RANDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, PARALLEL- GROUP 
TWO YEAR STUDY TO EVALUATE THE EFFECT 
OF SUBCUTANEOUS RO4909832 ON COGNITION 
AND FUNCTION IN PRODROMAL ALZHEIMER'S 
DISEASE WITH OPTION FOR UP TO AN 
ADDITIONAL TWO YEARS OF TREATMENT AND 
AN OPEN -LABEL EXTENSION WITH ACTIVE 
STUDY TREATMENT
PROTOCOL NUMBER: WN25203
VERSION NUMBER: H
EUDRACT NUMBER: 2010-019895-66
IND NUMBER: 102,266
TEST PRODUCT: Gantenerumab (RO4909832)
MEDICAL MONITOR: , M.D., Ph.D.
SPONSOR: F. Hoffmann
-La Roche Ltd
I agree to conduct the study in accordance with the current protocol.
Principal Investigator's Name  (print)
Principal Investigator's Signature Date
Please retain the signed original of this form for your study files.  Please return a copy of the 
signed form as instructed by your local study monitor.

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
14/Protocol WN25203 , Version HSYNOPSIS OF PROTOCOL NUM BER WN25203 H
TITLE Multicenter, Randomized, Double -Blind, Placebo -Controlled, 
Parallel -Group Tw o Year Study to Evaluate the Effect of 
Subcutaneous RO4909832 on Cognition and Function in 
Prodromal Alzheimer's Disease w ith Option for up to an 
Additional T wo Years of Treatment and an Open -Label 
Extension with Active Study Treatment
SPONSOR Roche Clinical Phase 3
INDICATION Prodromal Alzheimer’s Disease
OBJECTIVES OF DOUBLE -
BLIND PART OF THE STUDY
Primary
Secondary
Cognition, global, and functioning
Safety
MRI volumetry
    
   
CSF Biomarkers
Pharm acokinetics/
Anti-Drug Antibodies
Exploratory
Plasma BiomarkersTo evaluate the effect of gantenerumab versus placebo on the 
change in the Clinical Dementia Rating scale Sum of Boxes 
(CDR -SOB), a global measure of cognition and functional 
ability.
To evaluate the effect of g antenerumab versus placebo on 
cognition (assessed with the Alzheimer Disease Assessment 
Scale -Cognition [ADAS -Cog], Mini Mental State Exam 
[MMSE], Cambridge Neuropsychological Test Automated 
Battery [CANTAB], and the Free and Cued Selective Reminding 
Test-Immediate Recall [FCSRT -IR]) on global measures (based 
on the CDR global score), and on functioning (assessed w ith the 
Functional Activities Questionnaire [FAQ]), on  
neuropsychiatric functioning (assessed with  the 
Neuropsychiatric Inventory Questionnaire [NPI- Q]) and on time 
to onset of dementia.
To assess the safety and tolerability of gantenerumab assessed 
by magnetic resonance imaging (MRI), physical and 
neurological examinations, vital signs, blood and urine safety 
tests, ECGs, Columbia -Suicide Severity Rating Scale (C -SSRS), 
Geriatric Depression Scale (GDS), and adverse event 
monitoring.
To evaluate the effect of gantenerumab versus placebo on 
hippocampal volume, whole brain volume, ventricular 
enlargement, and possibly other volumetric measure s of the 
brain.
To evaluate the effect of gantenerumab versus placebo on levels 
of cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease 
(AD) pathology (i.e., total tau [T -tau], phospho -tau [p -tau], and 
amyloid -beta (A 1-42]). 
To determine the rel ationship of plasma and CSF concentrations 
of gantenerumab on other responses. To assess incidence of
anti-gantenerumab antibodies , and if relevant, evaluate its effect
onthe pharmacokinetic (PK), pharmacodynamic (PD), efficacy. 
and safety parameters. 
To evaluate the effect of treatment on peripheral biomarkers of 
amyloid deposition and/or clearance, neurodegeneration, 
inflammation, and other markers known to be involved in the 
pathogenesis of AD.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
15/Protocol WN25203 , Version HClinical Genotyping To evaluate the effect of gene encoding apoliprotein E 
(ApoE)4 genotype and fragment crystalizable gamma receptor 
(FcR) genotype on PK/PD, efficacy, and safety parameters
OBJECTIVES OF THE 
OPEN -LABEL EXTENSION -
PART 3
Primary:
Safety:
Secondary:
Brain MRI Volumetry
Brain Amyloid Load by Positron
Emission Tomography (PET) 
Imaging
Pharm acokinetics
Anti-Drug Antibodies
Cognition, Global, Functioning, and 
Dem entia AssessmentTo assess short -term and long -term safety and tolerability of 
gantenerumab (RO4909832) given at doses up to 1200 m g 
subcutaneous (SC) every 4 weeks (Q4W) by MRI, physical and 
neurological examinations, vital signs, blood safety tests, ECGs, 
C-SSRS, and adverse event monitoring.
To evaluate the effect of gantenerumab over time on 
hippocampal volume, whole brai n volume, ventricular 
enlargement, and possibly other volumetric measures of the brain 
compared to baseline and to the start of Part 3
To assess changes i n amyloid load over time using 
Florbetapir 8F (AV -45; Amyvid ) com pared to screening 
(ifapplicable ) and to the start of Part 3.  PET scans performed 
within 12 months prior to the first study drug administration in 
Part 3 w ill be used for the baseline of Part 3.  This objective w ill 
be evaluated in a subset of consenting subjects participating in 
the PE T substudy.
To determine the relationship of plasma concentrations of 
gantenerumab on other responses
To assess the development of anti -gantenerumab antibodies and, 
if detected, explore their association with the PK, PD, efficacy, 
and safety parameters of gantenerumab. 
To evaluate the effect of gantenerumab over time as assessed 
with the CDR -SOB, the ADAS -Cog, the MMSE, the FCSRT -IR, 
the CDR global score, the FAQ compared to baseline and to the 
start of Part 3, and to determine the presence of and time to onset 
of dementia.
TRIAL DESIGN Multicenter, randomized, double -blind, placebo -controlled, 
parallel -group study, followed by open -label extension with 
active study drug treatment
NUMBER OF SUBJECTS Approximately a total of 770 subjects; 514 on gantenerumab and 
256 on placebo.  The sample size w as confirmed following a 
planned blinded evaluation of the variance in the change in the 
CDR -SOB at Week 76. The study enrolled 799 subjects, and 797 
subjects were dosed w ith double- blind treatment:  266 subjects in 
the placebo group, 271 subjects in the gantenerumab 105 mg 
group, and 260 subjects in the gantenerumab 225 mg group. 
The number of subjects enrolled in Part 3 is 154.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
16/Protocol WN25203 , Version HTARGET POPULATION Subjects who meet memory and biomarker criteria which 
indicate a strong likelihood that they are in the prodromal phase 
of Alzheimer’s Disease
LENGTH OF STUDY Double -blind treatm ent period:
Part 1:  Approximately 2 years and 2 months which includes 
8weeks for screening and 2 years (104 w eeks) of treatment.
Part 2:  Up to additional 2 years of treatment.
Dosing was suspended on 19 December 2014. As a result 
duration of the double -blind treatment period varied depending 
on the number of study weeks that subjects completed.
Treatm ent-free follow -up period:  
Twelve weeks of follow up after completion of the double -blind 
treatment in Part 1 or Part 2, with an optional follow -up visit 
approximately 1 year (52 w eeks) after the end of the double -
blind treatment.  
Appr oximate duration of the study for subjects completing both 
Part 1 and Part 2 w ith the maximum 52 -week follow -up and not 
continuing in Part 3 w ill be 5 years and 2 months.  For the last 
subjects enrolled, approximate duration of the study will be 
2years an d 2 m onths (year 1 of Part 1 and 1 year of treatment -
free follow -up).
Open -label extension
Part 3:  Up to 3 years of active study drug treatment (w ith a 
4-week follow -up visit) after treatment -free follow -up period. 
For subjects continuing in Part 3, treat ment-free follow -up period 
will last approximately between 12 and 18 months (depending on 
the approval of study protocol WN25203G by local Competent 
Authorities).   All subjects who complete 3 years of 
open -label treatment will be given the option of extend ing 
open -label treatment until July 2020 and may receive up 
to 21 additional administrations every 4 weeks during 
Years 4 and 5.  
END OF STUDY The end of the study will be considered to be the date of the last 
visit (including the last scheduled follow -up visit according to 
study protocol) of the last subject in the study.
INVESTIGATIONAL MEDICAL 
PRODUCT(S)
DOSE/ROUTE/REGIMENPart 1 and Part 2:  Gantenerumab (105 or 225 mg for the 0 4 and 
14 ApoE genotypes or 105 mg for the 2 4 ApoE genotype 
subjects) by SC injection Q4W
Part 3 (open -label extension):  Gantenerumab will be 
administered SC Q4W to the subjects using up -titration regimens 
dependent on APOE ε4 genotype (and on the dose received 
during the double -blind treatment period) that will allo w subjects 
to reach the target dose of 1200 mg gantenerumab within 10 and 
6months for titration schedules below . 
Titration schedule 1: Dosing in APOE ε4 carriers (1 4 ApoE and 
24 ApoE genotypes who were in the placebo and 105 mg 
gantenerumab groups, and in the 225 mg gantenerumab group 
meeting criteria for dose reduction due to amyloid -related 
imaging abnormalities (ARIAs) during double -blind treatment 
period):
Doses 1, 2, and 3:  105 mg 
Doses 4, 5, and 6:  225 mg 
Doses 7 and 8:  450 mg 
Doses 9 and 10 :  900 mg 
Dose 11 onw ards:  1200 mg 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
17/Protocol WN25203 , Version HTitration schedule 2: Dosing in subjects who are APOE ε4 
non-carriers (0 4 genotype) and in APOE 4 carriers receiving 
225mg gantenerumab until the end of double -blind treatment 
(14 genotype ):
Doses 1 and 2:  225 mg 
Doses 3 and 4:  450 mg 
Doses 5 and 6:  900 mg 
Dose 7 onw ards:  1200 mg  
Gantenerumab doses of 105 and 225 mg will be administered SC 
 
 
The 1200 -mg gantenerumab dose will 
be administered SC .
COMPARATOR 
DOSE/ROUTE/REGIMENPlacebo, by SC injection, Q4W in Part 1 and Part 2.
PART 3 ASSESSMENTS OF:
-EFFICACY CDR -SOB, ADAS -Cog, MMSE, FAQ, FCSRT -IR, CDR global, 
onset of dementia, during the initial 3 years of Part 3.  
After which only MMSE will be administered.
-SAFETY MRI, physical and neurological examinations, vital signs, 
laboratory assessments (blood safety tests, urine pregnancy [for 
women of childbearing potential]), Columbia -Suicide Severity 
Rating Scale (C -SSRS), ECGs, and adverse event monitoring
-PHARMACOKINETICS Gantenerumab levels in plasma
-BIOMARKERS MRI and PET, to assess changes in brain volumetry and brain 
amyloid load over time during the initial 3 years of Part 3, 
respectively.
PROCEDURES (summary):
Screening and baseline:  After written informed consent is obtained, screening 
assessments, which include general health and cognitive testing, brain MRI , and lumbar 
puncture for cerebrospinal fluid (CSF) collection, and must be completed within 8 weeks 
followed by up to 1 week for baseline assessments. (See schedule of assessments in 
protocol)
Treatment (Part 1):  In this study , all subjects will receive 26treatments (drug 
administrations) with a 4-week interval between each dose.  On each dosing day, 
gantenerumab or matching placebo will be administered as two SC injections in the 
abdominal area.  Safety and efficacy  evaluations will be performed according to the 
schedule of assessments. 
Treatment Extension (Part 2):  Subjects who complete the entire 2 years of treatment and 
the Week 104 follow -
up visit may continue to receive the same treatment that they were 
receiving at the Week 100 visit.  The double -blind treatment can resume at the Week 104 
visit after all assessments have been completed for that visit.  
Follow -up:  Subjects will be followed for 12 weeks, with an optional follow -up visit 
approximately  1 year (52 weeks) after the last dose of study  treatm entin Part 1 or Part2 
(double -blind treatment phase) . The Week 52 visit is not required for subjects entering 
Part3.

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
18/Protocol WN25203 , Version HFutility  Analysis:  A futility  interim analy sis was performed when approximately  50% of 
the sample size completed the Week 104 visit.  As the study  was declared futile, with a 
low likelihood of meeting the prespecified primary  outcome measure with the doses 
studied (105 and 225 mg), dosing was suspended on 19 December 2014.  This analysis 
did not reveal an y new safety signal.
Open -Label Extension (Part 3):  Additional analy ses of efficacy  and PD results (CSF 
biomarkers of neurodegeneration and amyloid PET standardized uptake value ratio 
[SUVR]) indicated that higher doses of gantenerumab may have clinicall y relevant effect 
on cognition and function.  Doses were modeled based on the results of the PET substudy  
(brain am yloid PET SUVR) and on the supportive results of the Phase 1b (PRI ME) study , 
investigating the effects of aducanumab on a total of 165 patients with prodromal or mild 
AD.  Aducanumab is a monoclonal antibody  with similar properties and mode of action 
as gantenerumab.  The results showed a dose-and time-dependent reduction of amyloid 
plaques in the brain that was associated with dose-dependent clinical effect, which 
reached statistical significant clinical effect with the highest aducanumab dose tested.  
Extrapolation of the data indicated that approximately  20% reduction in brain amyloid 
detected by PET may be needed to achieve clinical effect, compared to overall 
approximately  5% achieved with 225 mg gantenerumab over 2 years.
All subjects who were eligible for and enrolled into protocol WN25203 and 
had at least 
one follow -up/dropout visit after the double -blind treatment will be offered the 
opportunity  to participate in Part 3.  Subjects who meet any of the following criteria will 
be exempted:
Prematurel y discontinued from Part 1 and Part 2 for safety  reasons (e.g., MRI 
findings meeting criteria for treatment discontinuation in Part 1 and Part 2)
  
Received another investigational medication after the end of double -blind treatment
Participation in Part 3 deemed inappropriate by investigator or Sponsor
During Part 3 study , subjects 
will receive gantenerumab Q4W that will be uptitrated 
starting from 105 or 225 mg based on the ApoE genot ype to up to 1200 mg to reach the 
doses expected to give clinically  meaningful effect in a less than 1year.  The titration 
schemes were designed to optimally  manage ARIA events in ApoE e4 carriers and 
non-carriers by a PK -PD model using PK and safet y results from this study  and from 
similarly  acting anti-amyloid antibodies (aducanumab and bapineuz umab).  In addition, 
all subjects entering Part 3 at centers alread y involved in a WN25203 PET substudy  of 
brain amyloid imaging during Part 1 and Part 2 will be offered to take part in the PET 
substudy , independent of their previous participation during the double -blind treatment.  
Subjects will be followed until the end of treatment phase (4 weeks after the last dose).

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
19/Protocol WN25203 , Version HSTATISTICAL ANALYSES IN THE OPEN- LABEL EXTENSION:  
Statistical analy ses will primarily  focus on safety aspects during and after the uptitration 
phase in Part 3 of the trial.  In addition, it is planned that efficacy  analyses will be 
conducted on cognitive and functional measures as well as biomarkers.  It is planned that 
efficacies will be calculated using both, the original, drug-naïve baseline as well as the 
baseline that gets available before start of Part 3.  Results of these analy ses will be 
interpreted in an exploratory  fashion.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
20/Protocol WN25203 , Version HGLOSSA RY OF ABBREVIA TIONS
A Amy loid-beta
AChEI(s) Acetylcholinesterase Inhibitor(s)
AD Alzheimer’s disease
ADA Anti- drug antibodies
ADAS -Cog Alzheimer Disease Assessment Scale -Cognition
ADL Activities of Daily  Living
ADNI Alzheimer’s Disease Neuroimaging Initiative
AE adverse event
ApoE gene encoding Apolipoprotein E
ARIA Amy loid Related Imaging Abnormality
ARIA-E Amy loid Related Imaging Abnormality -Edema
ARIA-H Amy loid Related Imaging Abnormality -Hemosiderin
AUC area under the plasma concentration -time curve
AUC 0- area under the time -plasma concentration curve at steady  
state
AUCinf area under the plasma concentration -time curve from time 
zero extrapolated to the infinite time
CA Competent Authorities
CANTAB Cambridge Neurops ychological Test Automated Battery
CDR Clinical Dementia Rating Scale
CDR -SOB Clinical Dementia Rating –Sum of Boxes
Cmax maximum plasma concentration
Cmin minimum plasma concentration
CSF cerebrospinal fluid
CSR Clinical Study  Report
C-SSRS Columbia -Suicide Severity  Rating Scale
Ctrough trough concentrations
CV coefficient of variation
DMS Delay ed match to sample
DO dropout
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
21/Protocol WN25203 , Version HGLOSSA RY OF ABBREVIA TIONS
DSM Diagnostic and Statistical Manual of Mental Disorders
EC Ethics Committee
eCRF Electronic Case Report Form
EDC electronic data capture
EEA European Economic Area
ELISA Enzy me Linked Immunosorbent Assay
Ext extension
FAQ Functional Activities Questionnaire
FCSRT -IR Free and Cued Selective Reminding Test –Immediate 
Recall
FcR Fragment cry stalizable gamma Receptor
FDA U.S. Food and Drug Administration
FLAIR Fluid- attenuated Inversion Recovery
FU follow -up
GDS Geriatric Depression Scale
HAHA Human -antihuman antibodies
HbA1c Hemoglobin A1c (gl ycosylated hemoglobin)
HCLF high concentration liquid formulation
IB Investigator’s Brochure
ICF Informed consent form
ICH International Conference on Harmonization
iDMC Independent Data Monitoring Committee
IEC/IRB Independent Ethics Committee/I nstitutional Review Board
IgG Immunoglobulin G
IMC internal monitoring committee
IMP Investigational Medicinal Product
IND Investigational New Drug
INN International Non -proprietary  Name
ITT intent to treat
IV intravenous
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
22/Protocol WN25203 , Version HGLOSSA RY OF ABBREVIA TIONS
IVRS Interactive Voice Recognition Sy stem
IxRS Interactive Voice Recognition System or Interactive Web 
Recognition Sy stem
Kd dissociation constant
LOCF Last observation carried forward
LP Lumbar puncture
MAD Multiple Ascending Dose
MCI Mild Cognitive Impairment
MedDRA Medical Dictionary  for Regulatory  Activities
mg milligram
MMRM Mixed -effects model repeated measures
MMSE Mini Mental State Exam
MOT Motor screening test
MRI Magnetic resonance imaging
MRI -C MRI  Review Committee
NINCDS -ADRDA National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer's Disease and 
Related Disorders Association
NPI-Q Neurops ychiatric Inventory Questionnaire
OLE open -label extension
PAL Paired associates learning
PD Pharmacod ynamic
PET Positron Emission Tomograph y
PK Pharmacokinetic
PP per protocol
PRM Pattern recognition memory
PT Prothrombin time
P-tau phospho- tau

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
23/Protocol WN25203 , Version HGLOSSA RY OF ABBREVIA TIONS
Q4W every  4 weeks
QC quality  control
QTcF QT corrected with Fridericia equation
RCR Roche Clinical Repository
RTI Reaction time
RVP Rapid visual information processing
SAD Single ascending dose
SAE serious adverse event
SC subcutaneous
SD Standard deviation
SEAG Science and Ethics Advisory  Group
SMT Study  Management Team
SNRI Selective Norepinephrine Reuptake Inhibitor
SSNRI Selective Serotonin/Norepinephrine Reuptake Inhibitor
SUVR Standardized Uptake Value Ratio
SSRI Selective Serotonin Reuptake Inhibitor
SUSAR Suspected Unexpected Serious Adverse Reaction
SWM Spatial working memory
T Tesla
T4 thyroxine
Tmax maximum plasma concentration
T-tau total tau
ULN upper limit of normal
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
24/Protocol WN25203 , Version HPART I: STUDY DESIGN A ND CON DUCT
1. BACKGROUND AND RATIONA LE
1.1 Background (A dditional Information May  Be Found in the 
Investigator’s Brochure)
1.1.1 Alzheimer’ s Disease
According to the figures provided by Alzheimer’s Association in 2015, an estimated 
47million people are living with dementia, with the number projected to increase to 
76million cases in 2030.  Alzheimer’s disease (AD) is the most common cause of 
dementia, accounting for 60%–80% of cases.  In the United States it is the sixth leading 
cause of death, with the rate increased b y 71% from 2000 to 2013. 
AD is clinically  characterized by a progressive 
impairment in cognitive and executive 
abilities, which results in decreased function and gradual loss of independence [39].  
Although the course of illness will vary  from patient to patient, in general, the clinical 
picture evolves from “predementia/prodromal AD” to mild, moderate, and ultimately , 
severe AD.  The progressive decline that starts in the predementia stage of AD initially  
presents as an impairment of memor y, language, and visuospatial function, some of 
which can be explained by loss of cholinergic neurons in the basal forebrain.  This 
neuronal loss contributes to the sy mptom development of AD.  As AD advances, patients 
become progressivel y impaired and the burden on caregivers significantly  increases.  
Because of its increasing prevalence, long duration, and high cost of care, AD is expected 
to continue to represent a major public health problem.
The main pharmacological approach to treatment is aimed at ame liorating the symptoms 
and improving functioning of AD patients for 6–18 months by increasing synaptic levels 
of acetylcholine through the use of acetylcholinesterase inhibitors (AChEIs).  Currentl y 
available AChEIs include donepezil (Aricept®), galantamin
e (Reminy l®/Razady ne®), 
rivastigmine (Exelon®), and tacrine (Cognex®) [40].  Overstimulation of the N-methy l-
D-aspartate (NMDA) receptor by glutamate is also implicated in neurodegenerative 
disorders [40].  Memantine, an NMDA antagonist, provides only modest improvement in 
global measures of functioning both with and without an AChEI .  Unfortunately , none of 
these medications have an effect on the progressing neuropathology  nor significantly  
change the course of the disease [40].
Consequently , drug discover y and development in AD are focused on disease -modify ing 
treatments that target, for example, amyloid-beta (Aβ) peptide or tau pathology .  Genetic 
and pathological evidence suggests that Aβ processing and deposition play a critical role 
in the cascade of b iological events involved in the pathogenesis of AD.  Aβ accumulation 
in the brain begins well before the development of clinical dementia in AD, and studies 
have shown that while intermediate or high levels of Aβ may be present at a very early 
disease sta ge (previousl y referred to as amnestic Mild Cognitive I mpairment [MCI ]), near 
maximal amounts are generall y reached by the time dementia is evident [1].  For these 
reasons, treatments which prevent, slow, or decrease the accumulation of brain Aare 
being tested as therapeutic agents in AD.  Accumulating evidence suggests that 
monoclonal anti-Aβ antibodies can bind to Aβ and promote its clearance [16,41,42], thus 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
25/Protocol WN25203 , Version Hpotentially  reducing deposition of Aβ aggregates, reducing neurodegeneration, and, 
ultimately , slowing progression of AD. 
1.1.2 Gantenerumab
Gantenerumab or RO4909832 is a fully human anti-Aβ 
peptide antibody  developed by 
invitro maturation within a complete human immunoglobulin , subclass -1 framework 
(IgG1).  Gantenerumab recognizes a conformational e pitope of Aβ demonstrated for both 
major types of Aβ, i.e., Aβ1-40 and Aβ1-42.  In vitro, gantenerumab recognizes aggregated 
(fibrillar) Aβ with high affinity  (Kdapproximately  0.5 nM).  Based on further in vitro 
studies and studies in animal models, the pharmacologic profile suggests that in humans 
gantenerumab may prevent, inhibit, or reduce the accumulation of Athat is believed to 
play an important role in the pathogenesis of AD. 
Gantenerumab was investigated in 10 completed Phase 1 clinical trials:  three 
single -ascending -dose (SAD) studies (BN18726, JP22474, and BP30042) ;two 
multiple -ascending -dose (MAD) studies in patients with mild to moderate AD 
(NN1986 6 described in Section 1.1.2.1 and JP22431) ;and four bioavailability  studies in 
healthy  subjects, one comparing intravenous (IV) and subcutaneous (SC) formulations 
(WP22461) ,two comparing lyophilized and liquid SC formulations (WP27951 and 
BP29113) , and a relative bioavailability study (WP40052) comparing 
gantenerumab SC formulation from the G3 manufacturing process (used in the 
ongoin g WN25203 and WN28745 open label studies) to the new G4 
manufacturing process, to be used in upcoming studies.  In addition, a 
tolerability study (WP39322) investigating the association of pain with speed of 
SC administrations of gantenerumab has been completed .  A total of 543 subjects 
participated in these Phase 1 studies, of whom 406 health y volunteers and 101 patients 
with AD received gantenerumab. 
Two Phase III studies designed to examine efficacy and safety of gantenerumab 
in patients with prodromal AD (the current protocol Study WN25203) and mild 
AD (Study WN28745) have been converted to open -label extension (OLE) 
studies.  The OLE studies examining the safety and tolerability of higher doses of 
gantenerumab in prodromal AD (Study WN25203) and in mild AD (Study 
WN28745) are ongoing.  Two additional Phase III studies (WN29922 and 
WN39658) investigating the effect of gantenerumab in early (prodromal to mild) 
AD were initiated in 2018.
Inaddition, a Phase II/III study, the Dominantly -Inherited Alzheimer’s Network 
Trials Unit (DIAN -TU-001), is ongoing. 
Information on the preclinical and clinical studies can be found in the Investigator’s 
Brochure (IB) for gantenerumab.  
1.1.2.1 NN19866: Clinical Multiple A scending Dose Study  (MA D)
This study  was conduc ted in patients with mild to moderate AD and as mentioned above, 
a subset of patients had amyloid imaging via positron emission tomography (PET)
scanning.  Dosing was an IV infusion given once every  28 days for 7 administrations.  
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
26/Protocol WN25203 , Version HThere were four dosing cohorts: the 6mg and 20 mg cohor ts each included 10 patients 
(8active, 2 placebo), and the 60 mg and 200mg cohort s each included 20 patients 
(16active, 4 placebo).  Due to reports in the literature that other monoclonal antibodies 
increased cerebral microbleeds in transgenic AD model mice, patients with any 
microbleeds on the screening magnetic resonance imaging scan (MRI) were excluded. 
PET data available from the MAD substudy  suggested an amyloid-removing effect of 
gantenerumab over the period of up to6 months at doses of 60 and 200 mg IV whereb y 
the effect at the higher dose appeared larger.
Pharmacokinetics showed a terminal half-life of approximately  24 days (similar to other 
IgG molecules).  There was minimal and predictable accumulation in the periphery  and 
CSF concentrations were approximately  0.12% –0.27% of the plasma concentration 
across the treatment groups.
Monitoring for antidrug antibodies (ADAs) did not reveal an immunogenicity  signal.
No changes were seen on measures of cognition or biological fluid markers (in this 
Phase 1 study  with the small sample size and of short duration).
The main clinical safety  observations reported were amyloid-
related imaging 
abnormalities (ARIAs).  The ARIAs included edema/effusion (ARI A-E) and 
hemosiderosis (ARIA -H; [microbleeds and areas of leptomeningeal hemosiderosis]) and 
were also observed with other anti-Atherapies (see Section 1.3.3).  Standard safet y 
measures (adverse events [AEs], laboratory  tests, ECGs, and physical and neurological 
examinations) demonstrated that all doses were well tolerated. 
Six serious adverse events (SAEs) in 6 patients were reported during this study , 
two of 
which resulted in death (one case of coronary  atherosclerosis in the placebo group and 
one in the gantenerumab 6 mg group).  There were two Suspected Unexpected Serious 
Adverse Reactions (SUSARs) (i.e., serious adverse events where an association with 
treatment cannot be excluded):  cerebral microbleed and left bundle branch block.  Both 
subjects had received 200 mg of gantenerumab.  No patient withdrew prematurely  from 
the study  due to an adverse event. 
Study  NN19866 was prematurel y terminated due to MRI  findings consistent with 
ARIA-E (vasogenic oedema/inflammation) seen after two to four doses of gantenerumab 
200mg.  Two of the 16 patients in this dose group were homozy gous for ApoE4 (ε4/ε4), 
and each had distinct ARIA -E and ARIA -H; 1 patient also had associated symptoms that 
were reported as a serious adverse event (cerebral microhemorrhage) but no treatment 
was required.  Of the 11 patients who were heterozy gous for ApoE4 (ε4/ε3), two had 
minor ARIA -E findings.  There were no such MRI  findings inthe 3 patients who were 
ApoE4 non-carriers . Concomitant ARIA -H (ie,concomitant microbleeds) findings were 
only seen in the two 
patients who were homozygous for ApoE4.  No patient required 
treatment, and the ARIA-E findings spontaneously  resolved 1-4 months after 
discontinuation of gantenerumab.
Three patients had isolated microbleeds (without ARIA
-E): one placebo patient (ε4/ε3) 
had two microbleeds, and single microbleeds were seen in 1 patient at 60mg (ε4/ε4) and 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
27/Protocol WN25203 , Version H1 patient at 200mg (a non-ApoE4 carrie r).  Overall, isolated microbleeds were 
uncommon and did not show a convincing relationship to treatment.
Because microbleeds are associated with increased cerebrovascular am yloid and this may  
increase the risk for an MRI  finding, including further hemorrh ages when treated with an 
anti-
Aantibody , Study WN25203 restricts patient enrollment based on the number of 
microbleeds seen on the screening MRI.  In addition, the protocol includes an algorithm 
for adjusting treatment should ARIA -H or ARIA-E finding described above occur.  
Subjects will be monitored by  regularly  scheduled MRI s which will be centrally  read and 
any relevant new findings will be brought to the attention of an independent MRI  Review 
Committee (MRI -C) (see Section 5.1.3.1).
1.1.2.2 Clinical Pharmacokinetics following Subcutaneous Dosing
The pharmacokinetics of gantenerumab following a single SC dose  
 in healthy  subjects were compared with IV administration (Study 
WP22461) and with SC administration of the high concentration liquid formulation 
(HCLF; St udies WP27951 and BP29113).
Absorption of gantenerumab is relatively  slow after SC injection, with plasma 
concentrations reaching maximum levels generally  7days after dosing, followed by a 
subsequent monophasic decline with a terminal half -life of approxi mately  24 day s, and is 
similar to that recorded following IV administration.   
 
 
 
 
 
 
 
 
  
 
 
 
 
SC administration of gantenerumab caused minimal local erythema and transient pain.  
InStudy  WP27951, the most common adverse event was injection site erythema,  
.  It is likely  
that the injection site reactions may  be at least partly  related to the injection volume.  See 
the IB for additional information. 
1.1.2.3 WN25203
The study  enrolled 799 subjects and 797 subjects were dosed with double -blind 
treatment:  266subjects in the placebo group, 271 subjects in the gantenerumab 105mg 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
28/Protocol WN25203 , Version Hgroup and 260 subjects in the gantenerumab 225 mg group.  One hundred twelve subjects 
participated in the PET substudy . 
Randomization was based on the ApoE 4 carrier status (Section 1.3.3 ).  In the context of 
the clinical understanding of ARIAs at the time of study  design, selection of 
gantenerumab doses (105 mg for 24 genot ype and 225 mg for 04-and 14 genot ype) 
was 
largel y driven by reducing risk of MRI findings.  Baseline characteristics were well 
balanced between treatment arms in the study , as well as in the PET substudy .  Per 
protocol, subjects were to be treated for 2 years (104 weeks) with an option for additional 
2 years of double -blind treatment. 
Unblinded safet y data were reviewed on an ongoing quarterl y basis by the independent 
Data Monitoring Committee (iDMC).  A planned interim futility  analysis was performed 
by theiDMC when approximately  50% of the sample completed 104 weeks of treatment 
(see Section 10.2.3).  Following the analysis that estimated a low probability  for meeting 
the pre-
specified primary outcome measure (with the predictive probability of success of 
6%), the study  was declared futile.  As a result, dosing with originally  selected doses 
(105 mg and 225 mg) was suspended on 19 December 2014. 
This analy sis did not reveal any new safet y signals.  Approximately  90% of the patients 
experienced at least one AE, with the incidence comparable between the treatment arms.  
Incidence of SAEs was 19.5%, 17.3%, and 16.9% in the placebo -, gantenerumab 105 mg -
and gantenerumab 225 mg groups, respectively.  ARIAs and injection -site reactions 
remain the main clinical safet y findings for gantenerumab.  Comprehensive information 
on ARIA events in the study  is provided in Section 1.3.3.  Regarding injection site 
reactions, overall incidence in the study  in the safet y population (797 subjects) was 
15.4% with majority  of the events of mild intensity .  Incidence of injection site reactions 
by treatment arm was 4.5%, 18.8%, and 23.1% inthe placebo -
, gantenerumab 105mg-
and gantenerumab 225 mg groups, respectivel y, leading to withdrawal in only 2 cases.  
Notably , there was no difference in overall withdrawal rate between the treatment arms.  
The number of subjects withdrawing because of adverse event (which includes 
withdrawals due to protocol -imposed measures mandating treatment discontinuation as 
part of management of MRI  finding s) was 14 (5.3%), 23 (8.5%) and 25 (9.6%) subjects 
in the placebo-, gantenerumab 105 mg-and gantenerumab 225 mg groups, respectivel y.  
Overall, gantenerumab doses studied in the double -blind phase of Study  WN25203 were 
safe and well tolerated [49].
Additi onal analy ses indicated that higher doses of gantenerumab may have clinicall y 
relevant effects on cognition and function, prompting the Sponsor to provide subjects the 
opportunity  to be treated with higher doses of gantenerumab in an open -label extension 
(including those who were in the placebo group), as outlined in Sections 1.2.3 (Rationale 
for the Open -Label Extension) and 1.3.2 (Reduction in Brain Aβ by  Gantenerumab), with 
dosing regimen designed to minimize the risk of ARIAs (Section 1.3.3).    

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
29/Protocol WN25203 , Version H1.1.2.4 WN28745
Study WN28745 was designed as a Phase III, 2-year, double -blind, 
placebo -controlled, efficacy and safety study of gantenerumab in approximately 
1000 patients with mild AD.  Patients randomized to receive gantenerumab were 
up-titrated independent of their APOE ε4 genotype, starting at 105 mg of SC 
gantenerumab every 4weeks (Q4W) for the first 24weeks, with a subsequent 
dose increase to 225 mg, based on acceptable MRI scan results.  The study 
enrolled 389 patients, and 387 patients were treated.  Following the futility 
analysis (see Section 1.1.2.3 ) in this study (WN25203), recruitment was stopped 
but double -blind dosing continued.  In a PET substudy of brain amyloid imaging 
(WN28745 -PET), 108 patients were enrolled. The study was converted to an 
OLE study evaluating the safety and tolerability of gantenerumab dose s up to 
1200 mg. 
1.1.2.5 WN25203 and WN28745 Open -Label Extension Studies
As of 13 February 2018 , 384 patients had been enrolled in the OLE studies 
WN25203 (154 patients) and WN28745 (230 patients), with 365 patients 
exposed to gantenerumab doses higher than 225 mg (i.e., more than the highest 
repeat dose previously tested in the double -blind parts of these studies) ,and 
289 patients havereached the OLE target 1200 -mg dose. Safety data and MRI 
findings are continuously monitored by an internal monitoring committee 
(IMC). The iDMC was also reviewing relevant safety findings from both OLE 
studies on a regular basis until the majority of patients have reached the target 
dose and no new safety signal has been identified in these ongoing studies. The 
last meeting took place on 10April 2017; the iDMC reviewed the data with the 
cutoff date of 13February 2018 and recommended to continue both OLE studies 
without modification. All relevant new MRI findings are brought to the 
attention of the MRI -C, as described in Section 5.1.6.1 .The safety profile of 
gantenerumab when administered at doses up to and including 1200 mg remains 
comparable to the safety profile of gantenerumab atlower doses (investigated 
during double -blind Studies WN25203 and WN28745), with injection -site 
reactions and ARIAs remaining the only identified risks for gantenerumab.
From the open -label studies WN25203 and W28745 , 81 patients continued in the 
respective amyloid -PET subs tudies of brain amyloid imaging using 
Florbetapir18F (Amyvid ).  As of 31August 2017, 40patients treated with 
9001200 mg gantenerumab for≥6 months across both open -label studies had a 
scheduled PET scan at OLE Week 52 (see Section 1.3.2 for results). 
1.2 Rationale for the Study
1.2.1 Rationale for Part 1 of the Study
As described above, the accumulation of Agenerall y begins well before the onset of 
AD dementia and probably  even before any cognitive decline associated with AD.  It is 
therefore reasonable to think that the benefit of anti-amyloid therapy  may be greater if 
initiated before prominent symptoms ofAD manifest, such as dementia.  Consistent with 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
30/Protocol WN25203 , Version Hthis concept, this study  will enroll subjects who do not yet meet a diagnosis for 
Alzheimer's dementia but have findings that characterize the predementia or prodromal 
phase of AD [ 3].  The main selection cr iteria used here for prodromal AD are: a report of 
a recent gradual decline in memory  function, impaired episodic memory  on testing, a 
Clinical Dementia Rating scale (CDR) global score of 0.5, a CDR memory  score of 0.5 or 
1 and a CSF A1
-42level of less t han 600 pg/mL [as measured by Innogenetics Enzy me 
Linked Immunosorbent Assay  (ELISA) assay  at a central testing laboratory; the threshold 
is based on extensive literature derived from multicenter studies in the US and Europe, 
and data available at the central laboratory ].  In addition the subject cannot meet criteria 
for dementia and there can be no other better explanation for the findings than 
prodromal AD.
Many  of the selection criteria for this study  are based on the selection criteria for 
amnestic MCI subjects in the Alzheimer's Disease Neuroimaging Initiative (ADNI) 
protocol [4].  The ADNI study  itself based its selection criteria on the Alzheimer's 
Disease Cooperative MCI  Study of vitamin E and donepezil [
5].  In both studies MCI 
subjects converted toAlzheimer's dementia at a rate of approximately  16% per year with 
few subjects reverting to normal cognition or developing a dementia that was not of the 
Alzheimer's type.  The main difference in the selection criteria for this study  is the 
requirement fo r a low CSF A 1-42level.
Alzheimer’s disease is characterized by changes in CSF biomarkers which reflect the 
disease pathology .  The AD biomarker signature consists of reduced CSF Aβ1-42, a 
marker of amyloid deposition, and elevated total tau (T-tau) and phospho -tau (P-tau), 
which reflect neurodegeneration [6].  Studies, including several large multicenter ones, 
have consistently  shown that these biomarkers have a high predictive value for 
identify ing prodromal AD in patients with MCI; estimates for sensit ivity and specificit y 
vary in these studies due to different factors including the combination of biomarkers, 
patient follow up time, and inter-site assay  variability  [7, 
8, 9].  Within ADNI, CSF 
Aβ1
-42  was identified as the most sensitive marker for AD d etection using an independent 
autopsy  confirmed AD cohort (96.4% sensitivity , 95.2% negative predictive value, 78.6% 
specificit y, and 81.8% positive predictive value) [9].  When a cutoff for this marker 
defined in the above autopsy  cohort was applied to MCI patients, an incidence of an 
AD
-like profile of 86.5% was reported for the relatively  small number of MCI  patients 
who converted to dementia of the AD ty pe within a year of the study  start; in contrast the 
incidence of this biomarker profile was 74% in all MCI patients [9].  Even though future 
work will be needed to further characterize the utility  of the above CSF biomarkers, the 
accumulated body  of evidence from multiple studies indicates that they can 
be used in 
clinical trials to enrich MCI  population s with AD patients.  The fact that gantenerumab is 
an anti-amyloid agent is an additional reason to select patients based on low CSF Aβ1-42 
in this study .  As indicated above, selecting MCI subjects who have low CSF Aβ1-42 will 
increase the likelihood that they are actuall y in the early stages of Alzheimer's disease 
and therefore will likely  show cognitive decline/progress clinicall y during the study .  Due 
to the rigorous screening procedures in this study including centrali zed MRI  reading and 
CSF biomarkers assessment, and specifically  selected cognitive testing, it is expected that 
relativel y few cases of non-AD patients will be enrolled.  The amyloid based enrichment 
criterion allows the study  objective to be answered with relativel y fewer subjects and 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
31/Protocol WN25203 , Version Hincrease the possibility  to observe an effect from the therap y.  As anti-amyloid therapy  is 
not expected to provide any acute symptomatic improvement, a 2year treatment period 
was selected.
In addition, in certain centers consenting subjects will participate in a substudy  of PET 
brain amyloid imaging in an attempt to assess whether gantenerumab, at the doses 
selected, can remove fibrillar brain amyloid as determined by amyloid PET.  Details of 
this substudy  are described in a separate protocol.
1.2.2 Rationale for Part 2 of the Study
Subjects who completed Part 1 of the study  through 
the Week 104 visit could enter the 
optional extension part of the study  and continue receiving the same treatment for up to 
2additional years.  The rationale for Part 2 is to assess the long-term safety  of 
gantenerumab as well as effects on biomarkers after an additional 2 years of treatment 
(e.g., PET, brain volumes, CSF markers). 
Continuing the placebo control is important for discerning effects due to gantenerumab 
from those due to advanced age, more advanced cognitive impairment, and concurrent 
illness.  Analy ses of cognition and functioning assessed in Part 2 will be exploratory , due 
to the high rate of attrition expected in a study  in this populat ion and of this duration.  
During Part 2, approved sy mptomatic treatments for AD are permitted at the discretion of 
the Principal Investigator.  Dosing in Parts 1 and 2 of the study  was terminated on 
19December 2014 as a result of the planned futility  analysis, and subjects continued with 
treatment -free safet y follow -up as per protocol.
1.2.3 Rationale for the Open -Label Extension (Part 3)
The futility  analysis revealed low likelihood for trial success with the original doses 
studied.  The decline in the primary endpoint, Clinical Dementia Rating –Sum of Boxes 
(CDR -SOB) scale observed across treatment groups over 2 years was approximately  1.06 
(lower than expected for this population, see below).  No significant differences were 
detected between treatment arms over 2 years in the secondary  endpoints, Mini Mental 
State Exam (MMSE), Alzheimer Disease Assessm
ent Scale -Cognition (ADAS -Cog) -13 
or Functional Activities Questionnaire (FAQ).  In addition, no significant differences 
were observed across groups on any cognitive or functional measure by pre- specified 
mixed model repeated measures analysis (MMRM; Section 8.2.1).  Furthermore, 
subgroup analysis, based on larger number of baseline characteristics (demographics, 
cognitive, CSF biomarkers, and disease severity ) or ApoE 4 allele status, did 
not reveal 
any differences compared to the overall population. 
Additional analy ses indicated that the ra te of clinical decline was lower than predicted for 
this study  population (with higher than expected proportion of “slow -progressors”) and 
strongl y suggested that the doses studied in Study WN25203 (105 and 225mg) were 
sub-therapeutic and that a higher gantenerumab dose should have clinically  relevant 
effect [49]:
1.Study WN25203 was the first global study  in prodromal AD to use am yloid screening 
to enrich the patient population and create a more homogenous prodromal AD 
population, which was predicted to dec line by  approximately  1.92 points in CDR -SOB 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
32/Protocol WN25203 , Version Hover the course of the 2 -year study , compared with the observed decline of 1.06 
points.  Based on an independent ADNI -based model that identified “fast progressors” 
by baseline characteristics [43], only  one-third of the studied population would be in 
this category , whereas the majority  did not have anticipated clinical decline over the 
2-year period.  Among “slow progressors”, clinical decline was similar across 
treatment groups (3 -point change in ADAS -Cog-13). In contrast, among “fast 
progressors”, there was a clear differentiation dependent on gantenerumab exposure, 
with a 6
-point increase in the placebo group compared to a 3 -point increase in the 
group with the highest gantenerumab concentration ( Figure 1).  Similar drug 
concentration -dependent trends were observed for MMSE and Cambridge 
Neurops ychological Test Automated Battery  (CANTAB) resu lts, although no trend 
could be observed for CDR- SOB.
2.Significant treatment effect could be detected b y posthoc multi -filter analy sis in a 
subject subpopulation with a more pronounced pathology  at baseline (CDR- SOB 2, 
FAQ 4, and hippocampal volume less than median), a p- value <0.05 on ADAS -
Cog-13, and a CANTAB with 225 mg gantenerumab dose.  The limitation of this 
analysis is a relativel y small sample size with approximately  one quarter of the 
enrolled prodromal stud y population.
3.Dose -dependent changes were observed after 2 years of treatment for the biomarkers 
of neurodegeneration assessed in the cerebrospinal fluid (CSF), P- tau and T -tau.  
Reduction of P -tau reached significance with 225 mg gantenerumab versus placebo 
(p<0.01).  Mean percent changes fo r P-tau were 2.62, −4.85, −7.52, for placebo, 
125mg and 225 mg gantenerumab groups, respectively  (Figure 2A), and for T- tau 
3.11, −1.45 and −2.94 ( Figure 2 B). 
4.Decrease in amy loid load was detected in PET substudy  with 225 mg gantenerumab.  
After 2 years of treatment, mean percent change from baseline in amy loid PET 
Standardized Uptake Value Ratio (SUVR) using the cerebellum was −1.11, 0.19, and 
−5.37 in the placebo -, gantenerumab 105 mg and gantenerumab 225 mg group, 
respectivel y.  Details are provided in Section 1.3.2 (Reduction in Brain Aβ by  
Gantenerumab).
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
33/Protocol WN25203 , Version HFigure 1 Treatment Response in ADAS -Cog-13 by Gantenerumab Serum Concentration , 2-Year Completing Fast 
Progressors
Purple bold line   median; shaded 50% observations; red dotted line 5th and 95th percentile

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
34/Protocol WN25203 , Version HFigure 2 Mean Percent Changes from Baseline after 2 Years of Treatment in 
(A) CSF P -Tau and (B) T -Tau (ITT population)
A
B
Further supportive data came from the results of Ph ase 1b trial (PRIME; [STUDY_ID_REMOVED]), 
which examined effects of an anti-Amonoclonal antibody , aducanumab (Biogen) 
versus placebo (1, 3, 6, and 10 mg/kg by IV infusion every  4 weeks [Q4W]), in 
165prodromal and mild AD patients.  Aducanumab and gantenerumab display  a number 
of similar biological, PK and pharmacod ynamic (PD) features.  Both are fully  human 
antibodies of IgG1 isotype that recognize a conformational epitope at the N-terminus of 
A, binding preferentially  to the Aaggregates with a similar affin ity, have a similar 
brain penetration and exert their action by microglia- mediated clearance of amyloid 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
35/Protocol WN25203 , Version Hplaques.  PRIME results showed a significant dose-and time-dependent reduction of 
brain Aβ plaques versus placebo by PET imagin g that was associated with 
dose-dependent slowing of decline on MMSE and CDR -SOB observed at 1 year, which 
reached statistical significance with the highest aducanumab dose.  PET SUVR showed 
no changes or very minimal changes at Weeks 26 and 54 in the placebo and 1mg/kg 
treatment arms, respectively ; whereas, statistically  significant reductions were observed 
in the higher doses.  Aducanumab had an acceptable safet y profile at Week 54, the main 
findings being ARIA -Esthat were dose -and APOE  4 status dependent. 
Considering the similar properties of gantenerumab and aducanumab, PK-PD models 
were developed based on PK, PD, efficacy , and safet y results from WN25023 and 
PRIME studies, allowing prediction of clinically  effective dose and dosing regimen to 
leverage safety .  All subject s who were eligible for and enrolled in Study  WN25203 and 
had at least one follow -up/drop -out visit after double -blind treatment will be offered the 
opportunity  to receive active treatment with higher gantenerumab doses (predicted to 
have relevant clinical effect) in an open -label extension, Part 3, initially for 3years
(unless exempted for the reasons listed inSection 4.4).  In addition, all subjects entering 
Part 3 at centers already  involved in a WN25203 PET substudy  of brain amy loid imaging 
will be offered to take part in the PET substudy , independent of their previous 
participation during double -blind treatment.  To ensure the minimum number of 
participants in the PET substudy  during Part 3, additional centers may be included. 
APET scan previousl y done for the Study  WN25203 within 12 months prior to first dose 
in Part 3 does not need to be repeated. 
During Part 3, approved symptomatic treatments for AD will be permitted at the 
discretion of the Principal I nvestigator.
1.2.4 Rationale for Prolonging Open -Label Extension (Part 3)
Asof 13 February 2018, a total of 384 patients have been enrolled in the OLE 
studies (WN25203 and WN28745) with no new identified safety findings.  
Because AD is characterized by progressive decline, it will be important to 
further characterize the long -term safety of gantenerumab beyond the initial 
3years.  Given that the safety profile of gantenerumab in the OLE studies 
remains similar compared with the double -blind studies, the duration of both 
OLE studies will be increased.  Treatment duration in Part 3 of this study 
(WN25203) will be extended until the end of July 2020, at which time 
anticipated results from other relevant monoclonal antibody treatments will be 
available.  The Sponsor will then evaluate the appropriateness of providing 
patients continued gantenerumab anti-amyloid treatment.
1.3 Overall Benefit-Risk A ssessment
As described in Section 1.1.1, one of the leading explanations for the cause of AD is the 
accumulation of Aβ in the brain.  In addition it has been shown that by the time a 
diagnosis of AD can be made due to the development of dementia, brain Aβ has alread y 
reached maximal or near maximal amounts [10, 11, 
12].  It has therefore been 
hypothesized that treatments directed at reducing Aβ may be more effective, or perhaps 
may only be effective, if begun early in the course of AD and specifically  before the 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
36/Protocol WN25203 , Version Honset of dementia.  As such, the purpose of this study  is to determine whether 
gantenerumab, which has been shown to reduce brain Aβ in AD patients by PET scan, 
can benefit subjects when treatment is initiated in the pre -dementia or prodromal stage of 
AD. 
Section 1.3.1 describes how it is now possible to make a reliable diagnosis of prodromal 
AD by using the recent advances in knowledge and laboratory  techniques regarding 
biomarkers in AD.
Section 1.3.2, describes the reduction in brain amyloid with gantenerumab, which 
hopefully  will be the underly ing basis for any  benefit of gantenerumab.
Finally  in Section 1.3.3 the various measures taken throughout the protocol to minimize 
risks of MRI  events are discussed.
The benefit -risk for Part 2 (the optional extension) is in Section 1.3.6.
Section 1.3.7 depicts the benefit -risk for the open -label extension (Part 3).
1.3.1 Selecting Prodromal A D Subjects for Study WN25203
The selection criteria for Study  WN25203 are designed to select subjects with prodromal 
or pre -dementia AD, which are MCI  subjects who have a very high likelihood of having 
AD pathology .  The ability  to accuratel y identify such subjects has been made possible 
by advances in AD biomarkers.  Consensus is developing in the field about how these 
individuals can be identified.  A group of internationally  renowned experts proposed an 
updated diagnostic criteria for (a) AD dementia, (b) MCI due to AD, and (c) for 
preclinical AD [34].  The criteria for MCI due to AD contains a description of 
“prodromal Alzheimer’s Dementia” which requires the kind of cognitive decline 
specified in this study  as well as a positive biomarker for the molecular neuropathology 
of AD such as low CSF A
β1-42.  These criteria were based on studies such as the one by 
Hansson et al. [8] where individuals with MCI (and controls) were followed for 
46years.  CSF biomarkers assessed at baseline (see Figure 3below) show low CSF
Aβ1
-42in MCI subjects who convert to clinical AD dementia (MCI -AD) as opposed to 
MCI  patients who progress to a different type of dementia (MCI -Other), or remain stable 
over the course of the observation (Stable MCI).
Figure 3 CSF Biomarkers at baseline in MCI subjects (taken from [8])
VaD = vascular dementia, DLB = Dementia with Lewy bodies, FTD = frontotemporal dementia, SD = 
semantic dementia, TBI = brain injury -induced dementia

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
37/Protocol WN25203 , Version HThe study  further more shows that individuals with pathological CSF at baseline (here 
defined as low CSF Aβ1-42and high CSF T-tau) have a high likelihood to convert to 
dementia of the Alzheimer’s t ype (see Figure 4below) during the follow -up period.
Figure 4 Kaplan -Meier Estimates of the Rate of Progression to Alzheimer's 
Disease in Patients with MCI Who Have Either Normal CSF or 
Pathological CSF at Baseline
Note: Numbers at risk are the number of patients with MCI at each time point who had not developed any 
type of dementia and for whom clinical follow -up w as still ongoing.  Cutoff values for pathological CSF 
were >350 ng/L for T -tau and <530 ng/L for Aβ42 [note: exact cut -off values are assay dependent].
Low CSF Aβ1-42is associated with high plaque load on amyloid PET [11], with a 
suggestion that the changes in the CSF mark er preceding PET positivity  [12].  Using the 
selection criteria requiring a low CSF Aβ1
-42, an annual conversion rate to dementia of 
approximately  20% may  be expected [ 14].  As indicated in Section 1.2, w ithin the ADNI, 
CSF Aβ1
-42 was identified as the most sensitive marker for AD detection using an 
independent autopsy  confirmed AD cohort (96.4% sensitivity , 95.2% negative predictive 
value, 78.6% specificity , and 81.8% positive predictive value) [9].  With longer 
follow -
up, the incidence of a correctly  identified AD-like biomarker profile at baseline is 
expected to increase as more patients convert to dementia.  Moreover, as a follow -up of 
their original publication, Hansson and colleagues reported that at the study -defined 
cutoff , the sensitivity  and specificit y of Aβ42 to predict development of AD dementia 
within 10 years of clinical follow -up were 90% and 76%, respectively  [
36]. 
Based on the applied clinical and biomarker criteria [34], the population in this study 
consists with a high degree of certainty  of individuals with AD in the prodromal phase 
who would inevitably  progress to dementia in the years to come and for whom in the 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
38/Protocol WN25203 , Version Hprodromal phase there is no approved medication.  The screening MRI will furthermore 
help exclude other neurodegenerative diseases (exclusion criterion 1, e.g., frontotemporal 
dementia) as well as extensive cerebrovascular disease (exclusion criterion 8) that could 
explain cognitive decline.  However, 
since no criteria will provide absolute certainty  of 
diagnosis, Section 4.6states that“…the subject must be withdrawn from the study  if it 
becomes clear that the subject's cognitive impairment is not due to AD.”  It is expected 
that this decision may be made at any time during the course of the study  and that it will 
be based on the invest igator’s clinical judgment.
If gantenerumab works as expected and if halting amyloid deposition and/or removal of 
amyloid plaque are processes relevant to slowing disease progression, individuals in the 
prodromal phase of the disease might possibly benefit more than patients who have 
developed AD dementia alread y, since the intervention occurs relativel y earlier in the 
disease process when presumably  less damage to neurons has occurred.
1.3.1.1 Adjustment of CSF Aβ1-42 Cutoff
Rationale for the original CSF Aβ42 cutoff
For Study  WN25203, Roche chose to use low CSF Aβ42, an indicator of amyloid 
pathology , along with appropriate clinical and imaging criteria, to identify  subjects for 
treatment with gantenerumab.  As the study  population is very similar to that studi ed by 
the ADNI, WN25203  CSF Aβ42 inclusion criterion was based on the ADNI -defined 
cutoff (192 pg/mL measured by Luminex xMAP assay  and based on pre-mortem CSF 
samples obtained from patients with autops y-diagnosed AD and age-matched controls ) 
[9].  Measur ements of CSF Aβ42 levels for inclusion into Study  WN25203 are performed 
at a central laboratory  using a different validated assay  (Innotest ELISA).
  To bridge 
between the two assay  platforms [35], Roche used a correlation between the Innotest 
ELISA and Luminex to derive the threshold level of 500 pg/mL included in the original 
study  protocol.
Rationale for the new CSF Aβ42 cutoff
Using ADNI CSF data, De Meyer and colleagues [37 ] applied a mixture modeling 
approach to identify  two distinct AD biomarker signatures, one related to AD (low CSF 
Aβ42) and the other to the non-AD group (high CSF Aβ42) (Figure 5, panel A below)
consistent with the current understanding that some of these individuals have MCI due to 
AD but others will remain stable, revert to normal, or develop dementias of other types.  
Remarkabl y, the cutoff of 188 pg/mL  selected in the mixture model based on CSF Aβ42 
concentration only and in the absence of any clinical data was almost identical to the 
value of 192 pg/mL determined by Shaw et al. using autopsy confirmed clinical 
diagnoses.  Such bimodal type distribution was also confirmed in a European study  of 
MCI  patients with up to 10 years clinical follow -up [36] where an unbiased “natural” 
cutoff was determined using the same mixture model classification (Figure 5, panel B).  
In this study , at this natural cutoff, CSF Aβ42 was able to predict future development of 
AD dementia with a sensitivity  of 90% and 76% s pecificit y.  
The 
above clustering method was applied to screening data from all subjects screened for 
Study  WN25203 who had CSF Aβ42 measured (269 samples up to December 21, 2011).  
Gantenerumab (RO4909832) —F.Hoffmann -La Roche Ltd
39/Protocol WN25203 , Version HAsimilar bimodal distribution as in ADNI  and the European MCI  cohort (Figure 5, 
panel C) was observed with a natural cutoff between the two populations of 599pg/mL, 
instead of 500 pg/mL , currentl y specified in protocol WN25203.
Figure 5 A. Cerebrospinal Fluid –derived A 42 Mixture Model Applied to 
Individuals with Amnestic MCI from the ADNI Study
Note:  Results are shown as histograms of observed biomarker levels overlaid with the 2 mixture 
distributions (adapted from [37]).  B. Model based clustering in European MCI study [ 36]. 
C.Model based clustering of CSF A 42 in WN25203
The robustness of the cutoff estimate of 599 pg/mL was evaluated by performing the 
model -based clustering approach using distinct subsets of the data set of WN25203 CSF 
screening samples, and also using snapshots of this data set at several different time 
points.  Both analyses provided consistent estimates of the cutoff, which did not vary 
substantially  from the cutoff value estimated based on the entire data set.  In addition to 
the above modeling approach, Roche has obtained from its central lab an independent 
dataset consisting of CSF Aβ42 levels from patients diagnosed with AD (n=43) and 
cognitivel y normal age-matched controls (n=43).  The patients with AD met the 
Diagnostic and Statistical Manual of Mental Disorders (DSM), vIII-revised criteria of 
dementia (1987) and the criteria of probable AD defined by NINCDS -ADRDA [15], and 
were also followed clinically  in order to increase the clinical diagnostic accuracy  [38].  
At the originally  defined cutoff of 500 pg/mL  sensitivity  and specificit y were 91% and 
81%, compared to 100% and 75% at the adjuste d cutoff of 600pg/ml.  As the estimated 
assay performance at the adjusted cutoff is in line with the autopsy  (gold standard) ADNI 
dataset (96% sensitivity  and 77% specificity ) [9], it appears that the proposed adjustment 
of the WN25203 CSF inclusion crite rion will not change the population that was planned 
to be enrolled in Study  WN25203.  Thus a “natural” cutoff identified in the Study  
WN25203 screened population (600 pg/ml) will be used to select patients for treatment 
with gantenerumab. 
1.3.2 Reduction in Brain A β by Gantenerumab
The potential benefit of gantenerumab can be anticipated from its mechanism of action 
which is to reduce brain amyloid.  This was shown in the NN19866 MAD study  in AD 
MCI n=137 aMCI  n=267A. B. C.
aMCI  n=196
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
40/Protocol WN25203 , Version Hpatients where amyloid PET imaging was performed.  Figure 6below shows the mean 
change in PET tracer activity  (11C- Pittsburgh Compound B [11C-PIB] which indicates 
the amount of brain amyloid) for a composite cortical brain region of interest (including 
bilateral frontal, sensorimotor, lateral temporal, parietal, anterior cingulate, and posterior 
cingulate cortex).
Figure 6 Median Amyloid PET Percent Change from Baseline:  Compo site, 
6 Months (ITT Population)
Since prodromal AD is considered part of the continuum of AD the amyloid removing 
effect of gantenerumab in patients with mild to moderate AD is expected to be relevant to 
the prodromal AD population in this new study .  This type of positive biomarker data is 
probably  among the strongest that could be expected in a short -term trial of a 
disease modify ing drug candidate and it is hoped that amyloid removal will provide 
benefit to individuals with prodromal AD.
The WN25203 PET substudy , which enrolled 114 participants, confirmed the findings 
from NN19866 MAD study  (the reduction of brain amyloid by gantenerumab) using 
Florbetapir 18F (or AV-45), a novel 18F-labeled PET ligand for imaging fibrillar Aβ.  
Atime-dependent reduction was observed with 225 mg gantenerumab in PET composite 
cortical SUVR with all the reference regions used.  With the mean cerebellar grey cortex 
as the reference, after 2 years of treatment mean percent change from baseline in PET 
SUVR was −1.11, 0.19 and −5.37 in the placebo -, gantenerumab 105 mg-and 
gantenerumab 225 mg -groups, respectivel y (Figure 7).  Following 3 years (156 weeks) of 
treatment, the difference was more pronounced with a 9.1% decrease 
in the 
gantenerumab 225 mg group.pet_bar_med_comp_6m_i Amyloid PET Percent Change from BL: Composite, 6 months
18SEP2008 20:22Output : $PROD/cdp11751/i19866f/reports/pet_bar_med_comp_6m_i.cgmProgram : $PROD/cdp11751/pet_bar_med_comp.sasTreatment Group PLACEBO RO4909832 200 mg
RO4909832 60 mgMedian
-10-9-8-7-6-5-4-3-2-1012345678910
Test Name COMPCTX
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
41/Protocol WN25203 , Version HPK analyses corroborated that the reduction in PET SUVR was drug 
concentration -dependent (i.e., subjects with higher plasma gantenerumab concentration 
had higher reduction in PET SUVR).  Figure 8shows PET SUVR percent changes from 
baseline after 2 years of treatment based on the drug exposure category  with cerebellar 
grey cortex as the reference .  No sig nificant changes were present in the placebo -and the 
low concentration (1.9–5 µg/mL ) gantenerumab groups; in contrast, higher gantenerumab 
concentration groups (5–10 µg/mL  and 10–20.72 µg/mL) display ed PET SUVR 
reductions of up to 5% and 10%, respectively.
 
 This apparent inconsistency  may 
be due to a difference between target population (moderate AD population in 
Study NN19866 and prodromal AD population enriched with “slow progressors” in 
Study WN25203) and to differences in the ligands used in study  amyloid load in the brain 
(11C-PIB and Florbetapir 18F).  An additional voxel -wise exploratory  analysis was also 
performed looking at region specific treatment effects after 1 year of study  treatment, 
using cerebellar grey matter as a reference region.  An extensive anatomical network 
covering precuneus, ventral striatum, anterior, middle and posterior cingulate, insular, 
medial, and lateral prefrontal regions showed significant treatment -related SUVR 
reductions as compared with placebo, in both 105 and 225mg gantenerumab treatment 
groups (Figure 9).  At the peak voxel in precuneus, the most significant region in the 
voxel
-wise analy ses, an SUVR reduction of 15% from baseline and of 18% relative to 
placebo was observed in the 225mg group.  In the 105mg gantenerumab group an 8% 
and an 11% reduction relative to baseline and placebo, respectivel y, were detected.
Figure 7
Mean Percent Changes from Baseline in Composite Amyloid PET 
SUVR after 2 years of Treatment (ITT Population)

Gantenerumab (RO4909832) —F.Hoffmann -La Roche Ltd
42/Protocol WN25203 , Version HFigure 8 Time Course PET SUVR during 2 Years of Treatment by 
Gantenerumab Serum Concentration Category
Purple bold line median; shaded 50% observatio ns; red dotted line 5th and 95th percentile

Gantenerumab (RO4909832) —F.Hoffmann -La Roche Ltd
43/Protocol WN25203 , Version HFigure 9 Voxel -Wise Changes in PET SUVR After 1 Year of Treatment with 
Gantenerumab
Results from the PRIME study  showed dose-dependent PET composite SUVR reduction 
with aducanumab [42].  PK analy sis demonstrated linear exposure across the 
aducanumab doses tested (1, 3, 6, and 10 mg/kg by IV infusion) after 26 weeks of 
treatment.  Based on PK -PD assessment, significant covariates for am yloid removal were 
aducanumab exposures and baseli ne PET SUVR [44].  PET SUVR showed no changes or 
very minimal changes at Weeks 26 and 54 in the placebo and 1 mg/kg treatment arms, 
respectivel y; whereas, dose-dependent, statistically  significant reductions were observed 
with 3 mg/kg (mean absolute change from baseline of -0.087, p<0.01), 6 mg/kg (-0.143, 
p<0.001) and 10 mg/kg (-0.205, p<0.001) treatment arms at 26 weeks as well as in the 
3mg/kg (-0.139, p<0.001) and 10 mg/kg (-0.266, p<0.001) treatment arms at 54weeks.  
These reductions were also associ ated with clinical effects on both the MMSE and 
CDR -SOB with overall slowing of cognitive decline compared to placebo reaching 
statistical significance with the highest dose after 1 year.  The difference from placebo in 
CDR -SOB after 1 year of treatment was -0.33, -0.71, and -1.44 (p<0.05) with 1, 3, and 
10mg/kg respectivel y.

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
44/Protocol WN25203 , Version HOverall, reduction in PET SUVR corresponding to the observed clinical effect after 
1year of treatment with 10 mg/kg aducanumab, was approximately  20%.  Compared to a 
mean PET amyloid reduction of approximately  5% achieved by 225 mg gantenerumab 
over 2 years, higher doses of gantenerumab will be needed to achieve the plasma 
concentration associated with clinically  effective ~20% PET SUVR reduction. 
A gantenerumab PK-PET model of amylo id reduction (details provided in 
) has been confirmed by PET data from the open -label Studies 
WN25203 and WN28745.  As of 31August 2017, 40patients treated with 
9001200 mg gantenerumab for ≥6months had an OLE Week 52 PET- amyloid 
scan.  Patients were divided into three groups for analyses purposes, on the basis 
of the study and on the double -blind treatment prior to switching to open -label 
gantenerumab and dose increase:  patients in Study WN28745 treated with 
placebo durin g double -blind part (non -pre-treated), patients in Study WN28745 
pre-treated (active arm during double -blind part, received gantenerumab 
225 mg), and patients in Study WN25203 (off treatment for an approximate 
median of 78 weeks).  Across the three group s, there was a 7% 16% reduction in 
PET SUV Rfrom baseline, which was two to threefold greater than the reduction 
observed in the Study WN25203 double -blind PET substudy with 225 mg 
gantenerumab after 2years of treatment (see Figure 7and Figure 10). 
Inaddition , approximately one third of patients had results below the 
quantitative amyloid positivity threshold after 1year of treatment with 
open -label gantenerumab ,including a titration period and 69months at higher 
doses (900 mg). Taken together, these results strongly confirm the 
gantenerumab mechanism of action and support selection ofatarget dose in 
alignment with the PK -PET efficacy model ( see ). 

Gantenerumab (RO4909832) —F.Hoffmann -La Roche Ltd
45/Protocol WN25203 , Version HFigure 10 Reduction of Brain Amyloid PET SUV Rin P atients 
Exposed to at Least 900 mg for 69Months in Studies 
WN25203 (SR) and WN28745 (MR) Open -Label Extension 
Studies
MR-NPMarguerite RoAD (Study WN28745) non -pretreated, N 14; 
MR-PMarguerite RoAD (Study WN28745) pretreated, N 17; PET positron 
emission tomography; SD standard deviation.
1.3.3 MRI Findings
As described in Section 1.1.2.1 , MRI  findings, ARIE-E, and microbleeds were seen at 
200mg IV Q4W in the NN19866 MAD study , which was conducted in mild/moderate 
AD patients.  The risk of ARI A-E appeared to be ApoE4 carrier status dependent.  
None of the patients required any treatment for the MRI  findings.  All ARIA-E resolved 
spontaneously  when treatment was discontinued.
Based on the results of the NN19866 MAD study  and on knowledge about ARIAs 
available at the time of WN25203 study  design, selection of the doses was focused on 
safet y.  As the ApoE 4 carrier status appears to be a risk factor for the development of 
MRI  findings, the low dose of 105 mg SC was evaluated in individuals homozy gous for 
ApoE 4.  On the basis of total exposure (plasma AUC), this dose is comparable to the 
MAD dose of 60mg IV, which was not associated with MRI  findings.  For individuals 
who are heteroz ygous for ApoE 4 or non -carriers for ApoE 4, doses of 105 and 225 mg 
SC were evaluated.  The high dose of 225 mg SC is (based on plasma concentrations) 
equivalent to approximately  137 mg IV, well below the 200-mg IV dose where promptly 
reversible ARIA -E events were detected in the heteroz ygous ApoE 4 population.  
 
 Also, additional protocol measures were put in place to mitigate any  

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
46/Protocol WN25203 , Version Hrisk due to ARIAs, including monitoring by regularly  scheduled, centrally  read MRIs;
intensified MRI monitoring in the case of ARIA events; and, as applicable, dose 
modifications, temporary  interruption, or permanent treatment discontinuation.  All 
relevant new MRI  findings were brought to the attention of the MRI-C (during Part1 
those were all new cases of ARIA -E, ARIA -H meeting criteria for dose modification or 
discontinuation, non-ARIA findings requested to be reviewed by the central reading
center or sponsor, and MRI  findings with associated sy mptoms).
In Study  WN25203, out of 797 sub jects who received blinded study  treatment, 52 (6.5%) 
subjects had ARIA -E events, 2 (0.8%) subjects in the placebo group, 18 (6.6%) subjects 
in gantenerumab 105 mg group, and 32 (12.3%) subjects in gantenerumab 225 mg group.  
Over two-thirds (approximately 71%) of the ARIA -E cases occurred during the first 
6months of treatment (corresponding to 5 gantenerumab administrations):  1  (0.4%), 
13(4.8%) and 23 (8.8%), in the placebo -, gantenerumab 105 mg-and gantenerumab 
225mg groups, respectively .  Approximat ely 75% of ARIA -E cases occurred in 
APOE 4 carriers.  Most of the events were asymptomatic (~90%), non-serious, resolved 
without consequences, and of mild severity  by MRI  Barkhof scoring that uses a scale 
from 0 (no edema) to 60 (whole brain edema) [45]. In Study WN25203, the median 
ARIA
-E score was 3 (rated as low); only 10% of ARIA -E events were scored as >10.  
ARIA-E did not commonly  recur in subjects who restarted treatment at half of the 
original dose.  The findings confirmed that the risk factors for developing ARIA -E are a 
higher gantenerumab dose and the presence of ApoE 4 allele ( Figure 11).
One hundred fifteen (14.4%) subjects had ARIA -H findings during double -blinded 
treatment phase, 29 (10.9%) subjects in the placebo group, 52 (19.2%) subjects in 
gantenerumab 105 mg group, and 34 (13.1%) subjects in gantenerumab 225 mg group.  
Most of ARIA-H findings were without associated symptoms and non-serious.  The time 
dynamic of ARIA -H followed the pattern of ARIA -E. 
Figure 11 ARIA Adverse Events by APOE 
ε4Genotypes
04 14 24
Placebo
(N=79)105 mg
(N=57)225 mg
(N=100)Placebo
(N=134)105 mg
(N=111)225 mg
(N=160)Placebo
(N=53)105 mg
(N=103)
ARIA -E 2
(2.5%)1
(1.8%)10
(10.0%) 06
(5.4%)22
(13.8%) 011
(10.7%)
ARIA -H 5
(6.3%)8
(14.0%)9
(9.0%)15
(11.2%)19
(17.1%)25
15.6%)9
(17%)25
(24.3%)
Bapineuzumab is also a monoclonal antibody  with an affinity  for amyloid.  Similar MRI 
findings have been reported in a Phase 2 and Phase 3 studies [16, 46].  The majority  of 
ARIA-E cases (69%) occurred after the first or second infusion (13 weeks apart) and 
were transient.  An increased risk to develop ARIA-E findings was also found to be 
dependent on the dose and on the number of ApoE ε4 alleles [2].  The increased risk for 
ARIA
-H were found to be assoc iated with APOE ε4 allele frequency, pre-existing 
ARIA-H, treatment with bapineuzumab, and use of antithrombotic agents [47].  
Homozy gosit y for APOE ε4 exhibited the greatest risk.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
47/Protocol WN25203 , Version HIn the PRIME study , incidence of ARIA -E with aducanumab was also dose-and ApoE 
ε4-status –dependent.  It was 5%, 5%, 43%, and 55% for 1, 3, 6, and 10 mg/kg 
aducanumab, respectively , versus 0% for placebo for ApoE ε4 carriers, and 0%, 9%, 
11%, and 17% versus 0% among ApoE ε4 non- carriers.  Most ARIA -E events (92%) 
were observed within the first 5 doses.  MRI findings resolved typicall y between 4and 
12weeks.
The exact mechanisms giving rise to ARIA remain to be fully elucidated; the frequent 
co-occurrence of ARIA -E and ARIA -H as observed with bapineuzumab suggests a 
common pathoph ysiological mechanism that may be related to transient increases in 
vascular permeability  [2, 33].  Over the course of AD, vascular amyloid deposition may 
disrupt vascular integrity  and impair perivascular pathway s, leading to development of 
cerebral amyloid angiopathy , with age and APOE ε4 genoty pe being main contributors to 
these changes.  After initiation of an anti-
Atherap y, vessels with pre-existing amyloid 
vascular pathology  may be transiently  more susceptible to vascular extravasation events 
as beta amyloid is removed from the vessel wall.  Also, excess amyloid accumulating in 
blood vessels as it is removed from amyloid plaques could also give rise to a transit 
increase in vascular beta amyloid, contributing to extravasation [17, 18].  Depending on 
the location of the vessel (intraparenchy mal or meningeal), leakage of proteinaceous fluid 
could give rise to an increased signal detected on FLAIR images as ARIA -E in the brain 
parench yma (vasogenic edema) and leptomeningeal spaces (sulcal effusions); leakage of 
red cells would result in ARIA -H [33].  An anti-Atherap y that maintains effectivel y 
vascular beta amyloid clearance would allow recovery  of vascular structural integrit y, 
and with time, the risk of such extravasation events is expected to decreas e [2].
In summary , ARIA -E events in Study  WN25203 were manageable, reversible, and 
mostly  mild with the majority  occurring early  in treatment (with the highest frequency 
between 3 and 6 months).  To date, substantial information is available about MRI 
findings and their relationship of exposure to anti-aggregated Aantibodies; a PK-PD 
model could be developed allowing a more accurate prediction of ARIA -E incidence 
expected with higher dose gantenerumab treatment, taking into account drug 
concentrations, time of ARIA-E occurrence since the first dose, and APOE 4 genoty pe.  
The model was originally  developed for bapineuzumab showing time-dependence of 
ARIA-E [48].  Please see for additional information on 
modeling of safet y outcomes.
To date, data from the OLE studies indicate that the safety profile of 
gantenerumab when administered in doses up to 1200 mg is comparable to the 
safety profile of gantenerumab in earlier studies.  As of 13February 2018, 
incidence of ARIA -E findings has been as expected (26% and 30.1% in Studies 
WN25203 and WN28745, respectively), with the majority of events being 
non-symptomatic and well controlled by protocol defined management rules.  
Ina few cases, patients developed symptoms, sometimes of mild intensity 
(e.g., headache) and sometimes serious (e.g., confusion or seizures/epilepsy).  
Overall, epilepsy did not occur more frequently than expected in the AD 
population; however, it cannot be excluded that the presence of the ARIA -E 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
48/Protocol WN25203 , Version Hcontributed to or triggered the onset of the symptoms.  Refer to the 
Gantenerumab I B for additional information about ARIAs. 
1.3.5 Risk to Subjects without AD Pathology
As an engineered monoclonal antibody , gantenerumab has an extremely  high selectivit y 
and specificity  for aggregated amyloid-and therefore gantenerumab is not expected to 
have any biological effect in subjects who do not have aggregated amyloid-.  However 
as subjects must have a lowlevel of CSF amyloid-at entry  and this accuratel y selects 
for subjects with elevated aggre gated brain amyloid, it is likely  that very few subjects 
would be enrolled who do not have cerebral amyloid pathology  and those who do not 
have amyloid pathology should not be at risk for MRI  findings.  Nevertheless and as 
outlined above, the study  protocol applies a safety  monitoring scheme that is considered 
to sufficientl y protect all study  participants as if they were at similar risk for MRI 
findings like AD patients.
1.3.6 Part 2 (Optional Extension Phase)
The hy pothesized mechanism of action of gantenerumab is the removal of and prevention 
of accumulation of brain amyloid.  Because this process is believed to continue 
throughout the course of AD, if gantenerumab has a beneficial effect on the course of 
prodromal AD, it is reasonable to expect that continuing therap y beyond 2 years may 
provide additional benefit.  Regarding the time course of known adverse effects with 
gantenerumab, based on experience with bapineuzumab, it is likely  that the risk of ARIA 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
49/Protocol WN25203 , Version Hdecreases substantiall y after approximately  6 months oftreatment.  The other known risk 
factor is injection site reactions.  These, however, have generall y been mild and have not 
led to treatment discontinuation.
In Part 2, symptomatic treatments for AD will be allowed.  These medications (such as 
donepezil and memantine) are unlikel y to alter the safet y profile of gantenerumab and 
vice versa because the adverse event characteristics are not overlapping and the 
pharmacological targets are different.  Dosing in Part 2 of the study  was terminated on 
19December 2014.
1.3.7 Part 3 (Open -Label Extension)
Since clinical efficacy  may  be related to both the degree of PET SUVR reduction and the 
timeframe over which it occurs, it is considered important to allow subjects to safel y 
access the target dose of 1200 mg ganteneruma b SC Q4W as quickly  as possible, taking 
into account APOE 4 status.   
 
with ARIA-E findings seen after 
two to four doses as described inSection 1.1.2.1.  With the implementation of the dosing 
regimen with gradual up-titration, subjects should be able to reach the target dose of 
1200 mg safely  within 10 months for APOE 4 carriers who 
were on placebo or on 
105mg gantenerumab during double -blind treatment, and within 6 months for APOE 4 
carriers previousl y receiving 225 mg and for subjects who are non-carriers (see Sections 
3.1.5.1 and 3.1.5.2).  With such a titration schedule, the incidence of ARIA -E is expected 
to be <25%, compared to the predicted incidence of 61% in APOE 4 carrier subjects 
over 2years in the case that the target dose would be administered from the start without 
the up-titration regimen.  The implemented protocol measures (which include dose 
adjustment and temporary  interruption) aim to minimize the risk 
of MRI  findings, 
allowing the subjects to reach the target dose in a flexible and safe manner. 
The PK-PD model predicts that PET SUVR (i.e., brain amyloid load) reduction will be 
~15% after 1 year of treatment with the implemented gradual up-titration schedule and 
~20% after 2 years.  Thus, the proposed dosing regimen attempts an optimal balance 
between safet y and efficacy.
All subjects enrolled in Part 3 will receive active treatment and will be allowed to take 
symptomatic therapy .
Part3 will only includ
e patients who had participated in the study , either Part 1 or Part2 
prior to the futility  analysis, and had at least 1 follow -up/drop- out visit after double -blind 
treatment (placebo or 105 or 225 mg gantenerumab SC Q4W).

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
50/Protocol WN25203 , Version H1.3.8 Overall Benefit Risk Summation
The following items support the Sponsor’s assessment that the overall risk-benefit for 
both the double -blind treatment phase (Parts 1 and 2) and the open -label extension 
(Part 3) of this study  is favorable:
(i) Recent progress in understanding the continuum from prodromal AD to AD 
dementia providing the strong rationale to investigate Aβ directed therapies at the 
very early stage of the disease 
(ii) The proven effect of gantenerumab on amy loid plaques and, thus, the potential 
benefit for gantenerumab to slow the onset or progression of AD with doses 
higher than those studied during double -blind treatment phase 
(iii) The various measures taken to reduce the risk of MRI  findings (including gradual 
up-titration in Part 3) and , if these MRI findings should develop, to rapidly  
identify  and effectivel y manage them 
(iv)
The likelihood that ARIAs are substantiall y less common after approximately  
6months of treatment.  During this time period, subjects are exposed to lower 
doses and gr adually  exposed to higher gantenerumab concentrations (see also 
).
(v) The lack of overlap of safety characteristics between gante nerumab and 
symptomatic AD treatments (allowed in Part 2 and Part 3 of this study )
2. OBJECTIVES OF PART 1(THE FIRST 2 YEA RS OF THE S
TUDY)
2.1 Primary  Objective
To evaluate the effect of 2doses of gantenerumab versus placebo given as SC injections 
on the chang e in the CDR -SOB, a global measure of cognition and functional ability .
2.2 Secondary  Objectives
To evaluate efficacy , safety , and tolerability  of gantenerumab versus placebo given as SC 
injections using the following: 
2.2.1 Cognition
Assessed with the 1) ADAS -Cog 2) MMSE, 3) the CANTAB and 4) the FCSRT -IR.
2.2.2 Global
Assessed with the CDR global score.
2.2.3 Functioning
Assessed with the FAQ.
2.2.4 Neuropsy chiatric Functioning
Assessed with the Neuropsy chiatric Inventory  Questionnaire (NPI -Q).
2.2.5 Dementia A ssessment
To determine the onset of dementia.  This will be done at each of the visits when all the 
cognitive and functional scales are done (screening and Weeks 24, 52, 76, and 104) .

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
51/Protocol WN25203 , Version H2.2.6 Safety  and Tolerability
Assessed by MRI, physical and neurological examinations, vital signs, blood and urine 
safet y tests, ECGs, geriatric depression scale (GDS), Columbia -Suicide Severity  Rating 
Scale (C -SSRS), and adverse event monitoring.
2.2.7 Brain MRI
Hippocampal volume, whole brain volume, ventricular enlargement, and possibly  other 
volumetric measures will be assessed in an effort to detect and quantify  drug effects on 
disease progression.  Further exploratory  analyses may be conducted as methods become 
available, in an effort to detect and quantify  drug effects on disease progression.
2.2.8 Cerebros pinal Fluid Biomarkers
The effect of gantenerumab on CSF biomarkers A1-42, T- tau, and P -tau will be 
assessed to detect and quantify  drug effects on underly ing disease pathology . 
2.2.9 Pharmacokinetics 
Plasma and CSF concentrations of gantenerumab will be quan tified to explore the 
relationships between pharmacokinetics and other responses. 
2.2.10 Anti-Drug Antibodies 
The development of anti-gantenerumab antibodies (also referred to as anti-drug 
antibodies, ADAs, or human antihuman antibodies, HAHAs) will be assessed ,and if 
detected, explored for their association with the PK, PD, efficacy , and safety  parameters 
of gantenerumab.
2.3 Exploratory  Objectives 
2.3.1 Plasma Biomarkers
To evaluate the effect of study  treatment on peripheral biomarkers of amyloid deposition 
and/or cl earance, markers of neurodegeneration, inflammation, and other markers thought 
to be involved in the pathogenesis of AD. 
2.3.2 Clinical Genoty ping
The effect of ApoE genoty pe and fragmented crystalizable gamma receptor (FcR) 
genot ype on PK/PD/efficacy /safety  parameters of gantenerumab will be assessed. 
Given the association of ApoE 4 allele and the occurrence of MRI  findings seen with 
gantenerumab in the MAD study  as well as reported for bapineuzumab, ApoE 4 status 
will be used for randomizing into study  treatment groups (see Section 3.1.4) and also for 
assignment to the titration schemes in Part 3 (see Section 3.1.5).
The Fcreceptor will also be genot yped as it may play a role in response to IgG 
treatments.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
52/Protocol WN25203 , Version H2.3.3 Roche Clinical Repository
Exploratory  biomarkers will be ass essed in consenting subjects.
The Roche Clinical Repository  (RCR) is a centrally  administered facility  for the 
long-term storage of human biological specimens.  Specimens stored in the RCR will be 
used to:
 Study  the association of biomarkers with efficacy and/ or adverse events 
associated with medicinal products; and/or
 Increase our knowledge and understanding of disease biology ; and/or
 Develop biomarker or diagnostic assay s; establish the performance characteristics 
of these assay s. 
The following sample types will be assessed in consenting subjects:
RCR DNA: may be used to explore the associations of variants of genes implicated in 
susceptibility  and pathogenesis of AD, such as Clusterin and PICALM, and therap y 
response.
RCR RNA: RNA samples may be tested using techniques such as high-density  
microarray  profiling and/or quantitative RT-PCR to study  the expression profile of genes 
known to be involved in AD, and any other differentially  expressed genes relative to 
treatment or dose response. 
RCR plasma: may be used for exploratory  biomarker analysis, including but not limited 
to markers of oxidative stress, neurodegeneration, inflammation or other processes 
involved in AD pathology.  
RCR CSF: samples remaining from the mandatory  analysis will be stored as RCR 
samples for future exploratory  analysis and to support the development of biomarker and 
diagnostic assay s.
2.4 Objecti ves of Part 2 (Optional Extension) 
The main objectives of the study  extension are to assess the long-term safet y of 
gantenerumab as well as effects on biomarkers beyond 2 years of treatment.  In addition, 
cognition and related measures will be assessed in Part 2; however, due to the anticipated 
high rate of attrition over the several years of the study , these will be exploratory 
outcome mea sures.
The following outcome measures will be assessed at select visits during Part 2, as shown 
in Table 3and Table 4.
2.4.1 Cognition
Assessed with the 1) ADAS -Cog,2) MMSE, and 3) the FCSRT
-IR.
2.4.2 Global
Assessed with the 1) CDR global score 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
53/Protocol WN25203 , Version H2.4.3 Functioning
Assessed with the FAQ.
2.4.4 Neuropsy chiatric Functioning
Assessed with the NPI -Q.
2.4.5 Dementia A ssessment
To determine the onset of dementia.  This will be done at visits when all the cognitive 
and functional scales are done (Weeks 128, 156, 180, and 208).
2.4.6 Safety  and Tolerability
Assesse d by MRI, physical and neurological examinations, vital signs, blood and urine 
safet y tests, ECGs, GDS, C -SSRS and adverse event monitoring.
2.4.7 Brain MRI
Hippocampal volume, whole brain volume, ventricular enlargement, and possibly  other 
volumetric measures ( Weeks 152, 208, and 256 [the final visit]). 
2.4.8 Cerebrospinal Fluid Biomarkers
The effect of gantenerumab on CSF biomarkers A1-42, T- tau, and P -tau will be 
assessed to detect and quantify  drug effects on underly ing disease pathology .
2.5 Objecti ves of Part 3 (Open -Label Extension)
The main objective of the open -label extension is to assess the short -term and long-term 
safet y and tolerability  of gantenerumab (RO4909832) given at doses up to 1200 mg SC 
Q4W (see Section 2.5.1). 
The secondary  objectives include the following:  
1.
To evaluate the effect of 1200 mg gantenerumab SC Q4W over time on imaging 
biomarkers (PD)
2. To evaluate the effect of 1200 mg gantenerumab SC Q4W over time on clinical 
outcomes (cognition and function) compared to baseline and to start of Part 3 and 
3. To explore pharmacokinetics and ADAs with higher gantenerumab doses in target 
patient population.
2.5.1 Safety  and Tolerability
To evaluate the safet y and tolerability  of gantenerumab as assessed b y MRI, ph ysical 
and neurological examinations, vital signs, blood safet y tests, ECGs, Columbia -
Suicide Severity  Rating Scale (C -SSRS), and adverse event monitor ing
2.5.2 Brain MRI Volumetry
To evaluate the effect of gantenerumab over time on hippocampal volume, whole 
brain volume, ventricular enlargement, and possibly  other volumetric measures of the 
brain compared to baseline and to the start of Part 3 .  This objecti
ve will be 
assessed during the initial 3 years of Part 3.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
54/Protocol WN25203 , Version H2.5.3 Brain A myloid Load by PET Imaging
To assess changes in amy loid load over time using Florbetapir 18F (AV -45; 
Amy vid) compared to screening (if available), and to the start of Part 3.  PET scans 
performed within 12 months prior to the first study  drug administration in Part 3 will 
be used for the baseline of Part 3.  This objective will be evaluated during the 
initial 3 years of Part 3 in a subset of consenting patients participating in the PET 
subst udy. 
2.5.4 Cognition
To evaluate the effect of gantenerumab over time compared with baseline and 
with the start of Part 3as assessed by the ADAS -Cog and the FCSRT- IRduring 
the initial 3 years of Part 3, and by MMSE until the end of Part 3
2.5.5
Global Measures of Cognition and Function
To evaluate the effect of gantenerumab over time as assessed b y the CDR -SOB and 
CDR global score, compared to baseline and to the start of Part 3 .  This objective 
will be evaluated during the initial 3 years of Part 3.
2.5.6 Functioning
To evaluate the effect of gantenerumab over time as assessed b y the FAQ, compared 
to baseline and to the start of Part 3 .  This objective will be evaluated during the 
initial 3 years of Part 3.
2.5.7 Dementia A ssessment
To determine the presence of and time to the onset of dementia, according to the 
investigator’s judgment .  This objective will be evaluated during the initial 
3years of Part 3.
2.5.8 Pharmacokinetics
Plasma concentrations of gantenerumab will be quantified to explore the relationships 
between pharmacokinetics and responses. 
2.5.9 Anti-Drug Antibodies
The development of anti-gantenerumab ADAs will be assessed and, if detected, 
explored for their association with the PK, PD, efficacy , and safet y parameters of 
gantenerumab.
3. STUDY DESIGN
3.1 Overview  of Stud y Design and Dosing Regimen
This is a Phase 3, multicenter, randomized, double -blind, placebo -controlled, 
parallel -group study , followed by open-label extensio n with active study  drug treatment.  
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
55/Protocol WN25203 , Version HIn Part 1 subjects will be selected who meet criteria of memory  impairment and have 
reduced CSF A 1-42levels.  These requirements will select subjects with a high likelihood 
of prodromal AD who are in the pre-dementia phase of Alzheimer's disease.  SC study 
treatment will be given Q4W for 26 administrations so the total treatment duration is 
104weeks or approximately  2 years.  
Subjects who complete Part 1 of the study  through the Week 104 visit may  continue in to 
the optional Part 2 where they will continue to receive blinded treatment Q4W for up to 
2additional y ears. 
Subjects who complete the double -blind treatment period (Part 1 or both Parts 1 and 2), 
as well as subjects who prematurel y discontinue double -blind treatment at any time 
during the study , will be asked to return for the follow up visits 4 and 12 weeks after the 
last dose of double -blind s tudy treatment, and for an optional visit 1 y ear (52 weeks) after 
the last dose of double -blind study  treatment.
All subjects who were eligible for and enrolled into Study WN25203 and had at least 
1follow -up/drop- out visit after double -blind treatment (placebo or 105 or 225 mg 
gantenerumab SC Q4W) will be offered participation in an open -label extension (Part 3) 
during which they will be treated with higher gantenerumab doses (up to 1200mg 
gantenerumab SC) 
Q4W initially for an additional 3 years, unless exempted for the 
criteria listed in Section 4.4. All subjects who complete 3years of open -label 
treatment will be given the option to continue receiving gantenerumab until July 
2020 (up to 19 additional months).
Subjects will undergo brain MRI  exams for monitoring safety  and response to study
treatment.  Subjects will also undergo common tests of safety  as well as tests of cognition 
and other clinical scales commonly  used when monitoring subjects likely  to develop 
dementia.
3.1.1 Use of Sy mptomatic Treatments for A D in Part 1
Approved agents for the symptomatic treatment of AD are AChEIs and memantine.  
These agents are not to be taken for 2 months prior to signing of the Informed Consent 
Form (ICF) and are not permitted at entry  to or during Part 1 of the study  through the 
Week 104 or Drop -
Out 1 visit.  This is the case even for subjects who develop dementia 
of the Alzheimer's type during Part 1 of the study .  These agents are not approved for 
prodromal/pre -dementia AD (clinicall y MCI) and several studies of multi- year durations 
have failed to show they  delay  the onset of dementia, which tends to suggest their effects ,
once dementia is first dia gnosed ,are likel y to be minimal [ 19].
Though it has been well established that there is a cholinergic deficiency  in the brains of 
patients with advanced AD, it is controversial whether there is significant cholinergic 
deficiency  in MCI or early  AD.  Two recent imaging studies with different tracers have 
not shown a reduction in nicotinic receptors in MCI  (MMSE 26.8 SD 2.3) or early AD 
(MMSE 22.5 SD 2.5).  These articles discuss and reference other studies that suggest that 
cholinergic deficits are not a prominent feature of MCI  or early Alzheimer's disease 
[20, 21].  In addition ,a recent postmortem study  showed no decrease in cholinergic 
projections to the cortex in MCI  subjects (MMSE range 2228).  However, there was a 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
56/Protocol WN25203 , Version Hdecrease in the mild -to-moderate AD group (MMSE range 14 25), which correlated with 
impairment on the MMSE, Global Cognitive Score, and frontal lobe functioning [22]. 
Though AChEIs are, for 
most subjects, likely to provide little or no benefit during the 
period of this study , an additional reason for not allowing them to be added on prior to 
completion of the first follow -up visit is that this will interfere with evaluating whether 
gantenerumab has an effect on disease progression.  As an example of this, if 
gantenerumab does slow the progression of prodromal AD, a disproportionately  greater 
number of placebo subjects are likely to receive an AChEI and even though the agent 
may have little or no effect on cognition in MCI or early ADmany of these subjects are 
likely  to improve mainly due to a "placebo response" which will diminish any treatment 
difference between placebo and gantenerumab.  Such biased estimates of treatment 
difference cannot properly  be addressed by any statistical analy sis methods.  A  recent 
publication of a 48-week study  of one of these agents (donepezil) in MCI  (MMSE of 
2428) showed a prominent placebo effect but did not show benefit ofdonepezil based 
on the primary  endpoint [23].  The study  reported a small but significant benefit of less 
than 1 point on the ADAS -Cog in the last observation carried forward (LOCF) analysis.  
However, as pointed out in a subsequent letter to the editor, this may be an artifact of 
significantl y more donepezil subjects stopping treatment earl y, and the L OCF scores used 
in the analy sis are likely  to be better than thescores would have been had they stayed in 
the study  for 48 weeks [24].  Overall about 42% of the donepezil group discontinued 
treatment early compared to 29% for placebo and of these, 
discontinuations due to 
adverse events were 18% for donepezil and 8% for placebo.  As commented in the 
article, MCI subjects may be less tolerant of these agents than patients with AD.  This 
would be an additional rationale for excluding these agents at trial entry  or as added on 
during the trial as they  would likely  increase the incidence of adverse events and dropouts 
and may require adjustment of the symptomatic treatment which will further complicate 
the evalu ation of effects of the study  treatment on disease progression.
3.1.2 Use of Sy mptomatic Treatments for A D in Part 2
Subjects who continue into Part 2 of the study may start approved symptomatic AD 
treatments after the Week 104 assessments have been complet ed at the discretion of the 
Principal I nvestigator. 
3.1.3 Use of Sy mptomatic Treatments for A D in Part 3
Use of any  approved s ymptomatic treatments for AD is allowed in Part 3 at the discretion 
of the Principal Investigator.
3.1.4 Rationale for Dose Selection Parts 1 and 2
Based on the results of the MAD study , the doses to be evaluated will depend on the 
ApoE genot ype of the subject in order to minimize the possibility  of MRI findings.
3.1.4.1 Dosing in Subjects WhoAre 04 and 1 4
At 200 mg IV in the MAD study , of the 3 patients who were 04, the only MRI finding 
was 1 microbleed (first seen at treatment follow -up and not seen at subsequent MRI) and 
of the 11 who were 14, 3 had MRI  findings of which 1 was probabl y a small ischemic 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
57/Protocol WN25203 , Version Harea and 2 were MRI findings suggesting “inflammation or vasogenic edema” (which in 
these cases were as ymptomatic and resolved rapidly  after treatment was suspended).
Given (i) the asymptomatic nature of these MRI  findings together with the prompt 
reversibility  of the FLAIR findings and the fact that the single microbleed was seen 
during the follow -up period (off treatment and within expected background incidence of 
microbleeds in this population), plus (ii) the absence of MRI  findings in the 60 mg MAD 
dose cohort which included six 04 and six 14, plus (iii) the MRI monitoring schedule 
implemented in this study, SC doses equivalent to approximately  130 mg IV and 60mg 
IV (based on plasma gantenerumab AUC) will be administered every  28 day s to subjects 
with genot ypes 04 and 1 4.
 
, the doses of 105 mg and 225 mg have been selected.  Results from the 
SC bioavailability  study (Section 1.1.2.2) demonstrated that based on AUC comparison, 
these SC doses of 105 mg and 
225 mg would translate into , 
respectivel y.  Therefore, subjects who are 04 or 14 will receive placebo, 105 mg 
( ) or 225 mg ( ).  
3.1.4.2 Dosing in Subjects WhoAre 24
Subjects who are 2 4 will receive either placebo or 105 mg.  I n the MAD, no MRI  effects 
were seen in the 3 subjects who were 24 at 60 mgIV.  However because both subjects 
who were 24 at 200 mg had prominent findings it has been decided to be more cautious 
with this group and to apply  only the lower dose of 105 mg SC.
Also 
supporting dose selection for this study  are the PET data availabl e from the MAD 
study  as mentioned in Section 1.1.2.1, suggesting an amyloid-removing effect of 
gantenerumab over the period of up to 6months at doses of 60 and 200 mg IV with the 
effect 
at the higher dose appearing larger.  It is uncertain whether brain amyloid removal 
will result in clinical efficacy ; however, the MAD data, together with the known 
preclinical profile of gantenerumab, s uggest that the doses used in this Phase 3 study  may 
lead to the desired am yloid-removing effect.
3.1.5 Rationale for Dose Selection for the Open -Label Extension 
(Part 3)
As described earlier in Sections 1.2.3, 1.3.3, and 1.3.7, PK-PD (PK -PET) models for 
anti-aggregated Ahave been developed to extrapolate clinically  effective gantenerumab 
doses and to predict dosing regimens with up-titration to reduce the incidence of MRI 
findings.  Based on the results of the PRI ME study, statistically  significant clinical effects 
of aducanumab were present at 10 mg/kg IV Q4W, associated with ~20% reduction in 
composite amyloid PET SUVR after 2years.  The equivalent gantenerumab dose to 
achieve this SUVR reduction was predicted as 1200 mg SC Q4W.  Additional 
information on population PK-PET response analy sis of gantenerumab and aducanumab 
can be found in .
Safety  outcomes at doses higher than the 225-mg dose (the highest gantenerumab dose 
tested in Phase 3) were projected from the results of the double -blind treatment period of 
Study  WN25203 and from the PRIME study , using a bapineuzumab -based model [48], 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
58/Protocol WN25203 , Version Htaking into consideration known risk factors for ARIA-E: drug concentrations, time since 
the first dose, and APOE 4 allele status.  Gradual exposure to gantenerumab is predicted 
to be linked with an acceptable incidence of ARIA -E, mostly  occurring during the first 
months of treatment.  The starting dose of gantenerumab and the titration schedule will 
be adapted to the presence of APOE 4 allele and to the dose of gantenerumab received 
during Par ts 1 and 2 ( Table 5and Table 6).  
3.1.5.1 Dosing in A POE 4 carriers (1 4 and 2 4 genotypes) prev iously 
on placebo, 105 mg gantenerumab, and 225 mg gantenerumab 
meeting criteria for dose reduction due to A RIAs:
Doses 1, 2, and 3:  105 mg SC
Doses 4, 5, and 6:  225 mg SC
Doses 7 and 8:  450 mg SC
Doses 9 and 10:  900 mg SC
Dose 11 onwards:  1200 mg SC
The above titration schedule will allow subjects to reach the target dose of 1200 mg 
gantenerumab within 10 months and is predicted to result in an ARIA-E incidence close 
to 25% in subjects carry ing APOE 4 allele, compared to 61% expecting to occur witho ut 
up-titration by  starting with 1200 mg gantenerumab.
3.1.5.2 Dosing in A POE 4 non -carriers (0 4 genotype) and in A POE 
4 carriers receiving 225 mg gantenerumab until the end of 
double -blind treatment (1 4 genoty pe):
Doses 1 and 2:  225 mg SC
Doses 3 and 4:  450 mg SC
Doses 5 and 6:  900 mg SC 
Dose 7 onwards:  1200 mg SC
The above titration schedule will allow the subject to reach the target dose of 1200 mg 
gantenerumab within 6 months. 
3.2 End of Study
The end of the study  will be considered to be the date of the last visit (including the last 
scheduled follow -up visit according to the study  protocol) of the last subject in the study .
3.3 Number of Subjects / A ssignment to Treatment Groups in 
Part 1
The planned total number of subjects is approximately  770, 256 on placebo and 257 on 
each of the twogantenerumab doses.  Based on the ADNI data the approximate genoty pe 
distribution is expected to be 33% 04, 50% 14, and 17% 24 (with respective N’s of: 
257, 
385, and 128).  Subjects with ApoE genotypes 04 or 14 will be randomized to 
gantenerumab 105 mg, 225 mg, or placebo.  Subjects with ApoE genotype 24 will be 
assigned to gantenerumab 105 mg or placebo.  Within each of the three ApoE genot ype 
groups (04, 
14, or 24) subjects will be assigned to either gantene rumab or placebo in 
2:1 ratio.  Additional information is given in Section 6.4.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
59/Protocol WN25203 , Version H3.4 Centers
Approximately  150200 centers will participate in the study .
4. STUDY POPULA TION
Under no circumstances were subjects enrolled in this study  (in Parts 1 and 2) permitted 
to be re-randomized to this study  and enrolled for a second course of double -blind 
treatment.  Subjects who were eligible for and enrol led into Study  WN25203 and had at 
least 1 follow -up/drop- out visit after double -blind treatment (placebo or 105 or 225mg 
gantenerumab SC Q4W) will be offered participation in an open- label extension (Part 3).
4.1 Overview  
The population will consist of subje cts with prodromal AD who were not receiving 
memantine or cholinesterase inhibitors and have not been treated with these agents for at 
least 2 months prior to signing the ICF for Part 1.
4.2 Inclusion Criteria 
A subject may  be included if the answer to all of the following statements is “y es.”
1. Written consent signed by the subject (co -signed by  the subject’s next of kin or 
study  partner, if required by  the local regulations/guidelines/Ethics Committee 
[EC]/I nstitutional Review Board [I RB])
2. Age: 5085 at the time of signing the ICF
3. Males and females. Females must be either:
Of non-childbearing potential (more than 2 years after the cessation of 
menses or surgically  sterile by means of hysterectom y, bilateral 
oophorectom y, or tubal ligation).  Additional blood tests will be done if 
required by the local regulations/guidelines/EC/I RB for further 
confirmation of non -childbearing potential or –
If she is of childbearing potential, she must:
Have a negative urine pregnancy  test at screening and a negative urine 
pregnancy  test at baseline.
Agree to use two methods of contraception from the screening visit until 
16 weeks after study  drug discontinuation.  Of the two contraceptive 
methods, one must be from Group 1, and one must be from Group 2, 
defined as follows:  Gr oup 1:  Oral, implantable, trans- dermal or injectable 
hormonal contraceptives, intrauterine devices, or partner’s sterilization 
(vasectom y).  If a hormonal contraceptive will be chosen from this group, 
it must have been taken for at least 1 month prior to randomization.  
Group 2:  Condoms, diaphragm or cervical cap, all in combination with 
spermicide.  Abstention and rhythm methods are not acceptable methods 
of contraception.
4. Has a study  partner, who in the investigator's judgment has frequent and sufficient 
contact with the subject so as to be able to provide accurate information as to the 
subject's cognitive and functional abilities, who agrees to provide information at 
clinic visits which require partner input for scale completion, and who signs the 
necessary  consent form if applicable.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
60/Protocol WN25203 , Version H5. Fluent in the language of the tests used at the study site
6. Mental retardation has been excluded by the investigator.  This may be based on, 
for example, sufficient education or work experience
7. Willing to complete all aspects of the study  (including MRI, lumbar puncture 
[LP], and genoty ping) and capable of doing so either alone or with the help of the 
study  partner
8. Have not received within the past 2 months and are not currentl y being treated 
with approved marketed medications for AD and the study  physician does not 
anticipate an y treatment with one during the stud y 
9. If not already  aware, willing to have their ApoE genotype status withheld until the 
study  is unblinded unless required by the relevant health authorit y or EC/I RB .  
Ifinforming the subject of their ApoE status is required, the informed consent 
may be reviewed and re -signed before treatment begins.
10. Visual and auditory  acuity  sufficient to perform the cognitive tests (eye glasses 
and hearing aids are permitt ed.)
11. Agree not to donate blood or blood products for transfusion for the duration of the 
study  and for 1 y ear after final dose
Cognition -related and test-based inclusion criteria indicating the subject has 
prodromal AD
12. Study  partner has noticed a recent gradual decrease in the subject's memory 
(e.g., over the prior 12 months), which the subject may  or may  not be aware of.
13. Abnormal memory  function at screening or 1 month prior to screening based on 
the FCSRT -IR of 
ofree recall <17, or 
ototal recall <40, or 
o[free recall <20 and total recall <42]. 
14. Screening MMSE score of 24 or above.
15. Screening global CDR of 0.5 with a memory box score of 0.5 or 1.
16. Aside from memory  impairment, general cognition and functional performance 
are largely  preserved such that a diagnosis of AD with dementia cannot currentl y 
be made.
17. Modified Hachinski Ischemia Scale score of 4
18. CSF A1-42level 600 ng/L as measured by the central laboratory .  Individuals 
who do not meet this criterion may  not be re -screened for this study .
4.3 Exclusion Criteria
A subject will be excluded if the answer to an y of the following statements is “yes.” 
CNS Disorders
1. Other prior or current neurologic or medical disorder which may currently  or 
during the course of the study  impair cognition or psychiat ric functioning 
including but not limited to: head trauma, seizure disorder, neurodegenerative 
disease, hydrocephalus, cerebral / spinal hematoma, inflammatory  disease, CNS 
infection (e.g., encephalitis or meningitis), neoplasm, toxic exposure, metabolic 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
61/Protocol WN25203 , Version Hdisorder (including hypoxic or hypoglycemic episodes), or endocrine disorder.  If 
one of these disorders is suggested by the central reading of the baseline MRI , the 
subject may be included after consensus agreement between the investigator and 
the study  di
rector that the subject is still considered to have prodromal AD.
2. A history  of stroke
3. A documented history  of transient ischemic attack within the last 12 months
4. History  of schizophrenia, schizoaffective disorder, or bipolar disorder
5. Currently  meets criter ia for major depression 
6. Any other psychiatric condition/disorder which could significantly  interfere with 
the subject’s cooperative participation (e.g., prominent anxiety , agitation, or 
behavioral problems)
7. Current evidence or history  of substance abuse d isorder (DSM- IV) within 2 y ears, 
except, nicotine use is allowed. 
Imaging -Related Criteria
8. As assessed by the central reader, MRI evidence of a) more than one lacunar 
infarct, b) territorial infarct or macroscopic hemorrhage, or c) any deep white 
matter lesion corresponding to an overall Fazekas score of 3 which requires at 
least 1 confluent hyperintense lesion on the FLAIR sequence which is 20 mm or 
greater in an y dimension
9. The combined number of ARIA -H (microbleeds and areas of leptomeningeal 
hemosiderosis) on MRI  is more than 2 on a 1.5T machine or more than 3 on a 3T 
machine based on the review done b y the central reader.
10. Presence of pacemakers, aneury sm clips, artificial heart valves, ear implants, 
foreign metal objects in the eyes, skin or body or any other circumstance which 
would contraindicate an MRI  scan or significantly  impair MRI image quality 
based on review b y the central reader.
Cardiovascular Disorders
11. History  of atrial fibrillation except if only one episode which resolved more than 
three years ago and for which treatment is no longer indicated
12. Within the last 2 years, unstable or clinically  significant cardiovascular disease 
(e.g., myocardial infarction, angina pectoris, New York Heart Association Class II 
or more cardiac failure)
13. Average QT interval corrected with Fridericia’s equation (QTcF) above 470 msec 
based on a set of three good quality  ECGs, or clinically  relevant abnormalities on 
screening ECG based on centralized reading (e.g., multifascicular block; left 
bundle branch block, AV block II) 
14. Uncontrolled hypertension (i.e., blood pressure generall y >160 systolic or 
>95mmHg diastolic)
Hepatic/Renal Disorders
15. Screening AST or AL T 2 or total bilirubin 1.5 times the upper limit of normal 
(ULN) which is still above these limits if retested due to a slightly  elevated initial 
result
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
62/Protocol WN25203 , Version H16. Screening creatinine clearance <30 mL/min as calculated by the central lab using 
the Cockcroft -Gault formula, which remains <30 mL /min if retested 
Infections/Immune Disorders
17. History  of HIV infection, history  of Hepatitis B infection within the past year, 
history  of Hepatitis C infection which has not been adequately  treated or history 
of spirochete infection of the CNS, (e.g., s yphilis, ly me, or borreliosis)
18. Autoimmune disease which is debilitating or potentially  debilitating (e.g., Lupus, 
multiple sclerosis).  Rheumatoid arthritis may be allowed if, in the opinion of the 
investigator, it will not 
put the subject at increased risk or interfere with the 
interpretation of the study . 
19. Immunocompromised systemicall y due to continuing effects of immune 
suppressing medication
Metabolic/Endocrine Disorders
20. Screening thyroid function tests are abnormal such that a new treatment or an 
adjustment of current treatment is required.  The subject may be rescreened if 
there is no improvement in cognition after 3 months of adequate treatment.
21. Folic acid or B12 levels (current or within the past 6 months) that are sufficiently 
low such that deficiency may be contributing to cognitive impairment.  In such 
cases the subject may be rescreened if there is no improvement in cognition after 
6 months of appropriate treatment.
22. Screening hemoglobin A1C (HbA1C) >8% (retesting is permitted if slightly 
elevated) or poorl y controlled insulin -dependent diabetes (including 
hypoglycemic episodes).  The subject may be rescreened after 3 months to allow 
optimization of diabetic control.  
23. Body mass index 36
Other
24. Deformit y of the lumbosacral spine which would contraindicate a lumbar 
puncture
25. Screening prothrombin time (PT) is abnormal and remains abnormal when 
retested.
26. History  of cancer except if considered likely to be cured or in the case of prostate 
cancer there has been no significant progression over the last 2 years.
27. Any other medical condition not previously  mentioned that could be expected to 
progress, recur, or change to such an extent that it could bias the assessment of the 
clinical or mental status of the subject to a significant degree or put the subject at 
special risk or an y pre -planned surgery , other than minor procedures.
28. C linically  significantly  abnormal screening blood, urine, or CSF which remain 
abnormal on retest
29. Currently  or within the last 1 month participated in a non-pharmacological trial 
with a key  objective of improving cognition
30. Residence in a skilled nursing facility such as a convalescent home or long-term 
care facility  
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
63/Protocol WN25203 , Version HMedications
31. Ever participated in a study  of gantenerumab
32. Ever participated in a study  of a vaccine or other long-acting biological agent 
which was being evaluated to prevent or postpone cognitiv e decline
33. Received any other investigational treatment within 3 months of screening or 
5half-lives, whichever is longer.
34. Received within 2 months of screening a cholinesterase inhibitor ,  memantine, or 
Souvenaid
35. Within 1 month of screening:
a) Started taking ginkgo biloba, lecithin, vitamin B12, or any other agent or 
supplement intended to improve cognition or reduce cognitive decline
b) Received medication for systemic immunosuppression including 
corticosteroids
c) Received medication used to treat Parkinsonian symptoms or any other 
neurodegenerative disorder even if it is being taken for a 
non-neurodegenerative disorder such as restless legs disorder
d) Received medication that may currently  be contributing to cognitive 
impairment (e.g., clonidine, alphameth yldopa
)
e) Received an antipsy chotic or a neuroleptic medication except as brief 
treatment for a non -psychiatric indication (e.g., emesis)
f) Received medication used to treat a mood or anxiety  disorders except if it 
is a selective serotonin reuptake inhibitor (SSRI ),selective norepinephrine 
reuptake inhibitor (SNRI ), selective serotonin /norepinephrine reuptake 
inhibitor (SSNRI ), bupropion, buspirone, mirtazapine, or trazadone and is 
given as maintenance treatment 
g) Received anti-hemostasis medication (e.g., warfarin) except low-dose 
aspirin (dose depends on local practice but preferably  100 mg or less)
h) Received medication with anticholinergic activity  that may impair 
cognition or attention (e.g., centrally  acting antihistamines or 
anti-spasmodics) except if used only intermittently  (generall y no more 
than twice per week) and there has been no use within the 4 days before 
the screening cognitive testing
i) Received anticonvulsant medication except if for an approved pain 
indication
j) Received narcotic analgesics except if typically on 4 or fewer days per 
month for a self-limited pain indication (e.g., migraine) or if used for 
cough or diarrhea (e.g., codeine) and there has been no use within the 
4days before the screening cognitive testing  
k) Received sedative, hypnotic, or benzodiazepine medication except if used 
only intermittentl
y (generally no more than twice per week).  For example, 
use of a short -acting benzodiazepine -like medication (e.g., zolpidem) or 
trazadone for sleep and lorazepam for occasional mild anxiety  are 
allowed.  These medications may not have been taken within the 4 days 
before the screening cognitive testing    
Gantenerumab (RO4909832)—F. Hoffmann-La Roche Ltd 
64/Protocol WN25203, Version H 36. For the medication exceptions listed just above, any change in the prescribed 
regimen within the last month.  
4.4 Eligibility for the Open-Label Ex tension (Part 3) 
Subjects who received double-bli nd treatment during either Part  1 or Part 2 prior to the 
futility analysis, and had at least one follow-up/drop-out visit will be eligible to enter Part 3.  For reasons related to subject safe ty, subjects who meet any of the following 
criteria will not be el igible for Part 3:  
 Prematurely discontinued from Parts 1 and 2 for safety reasons affecting participation 
in the study (e.g., MRI findings meeting cr iteria for treatment discontinuation in 
Parts 1 and 2) 
  
 
 Received another investigational medicati on after the end of double-blind treatment 
 Participation in Part 3 deemed inappropria te by investigator or Sponsor (eg, any 
serious medical condition or abnormality in c linical laboratory tests that precludes the 
patient’s safe participation in  the open-label extension). 
 
4.5 Concomitant Medication and Treatment 
Adding a new medication or changing the dose of a medication after signing the informed 
consent form should only occur for the treatment of an adverse event.  Exceptions to this 
include:  1) preventive medication such as prophylactic use of an  anti-infective or 
vaccination 2) medication for a pre-existing condition which has not worsened, or 
3) temporary use or withholding of medication to help carry out cer tain study procedures 
(e.g., LP, MRI or PET scan). 
Adding a new vitamin regimen or dietary supplement during double-blind treatment 
(Parts 1 and 2) is discouraged.  Any medica tions that are used intermittently that may 
affect cognition such as a narcotic analgesics , hypnotics, or anxioly tics should be avoided 
as much as possible prior to the scheduled as sessments of cognition.  If such a medication 
is required, sufficient time must have passed (preferably 4 or mo re days) so that the effect 
of the medication will not interfere with the assessment.   Anxiolytics may be given prior 
to an MRI, PET scan, or LP; however, cognition testing should not be done until sufficient time has passed for the effects to have diminished. 
If the subject requires treatment with a me dication listed in the exclusion criteria, a 
medication listed as an exception above shoul d be used if possible and appropriate 
(i.e., for depression an SSRI and not a tricyclic).  If the subj ect requires treatment that is 
not listed as an exception, the subject may need to be withdrawn from the trial 
(e.g., warfarin as an anticoagulant, anti-P arkinson medication, antipsychotic medication 
or continuous treatment with narcotics).  In  these cases, the invest igator should inform 
and consult with the Sponsor. Of special note, if a subject is to be started on a cholinesterase inhibitor, memantine, or 
Souvenaid during Part 1 of the stud y prior to completion of the visit  at Week 104, the 
subject will need to be withdrawn from the study.  These medications should be withheld 
until after the Week 104 or first drop-out (DO1) is completed.  However, for subjects 

Gantenerumab (RO4909832)—F. Hoffmann-La Roche Ltd 
65/Protocol WN25203, Version H entering Part 2 of the study, these medications may be started after the Week 104 
assessments have been completed if judged a ppropriate by the Principal Investigator.  
These medications will be permitted at any time in Part 3. 
4.6 Criteria for Premature Withdrawal 
In addition to withdrawals de scribed above for concomitant medication, the subject must 
be withdrawn from the study if it becomes clear that the subject's cognitive impairment is 
not due to AD.  Subjects do not  have to be withdrawn from  the study if they develop 
dementia.  However, they do need to be withdrawn if prohibited AD medications will 
then be started prior to completion of the Week 104 or first drop-out (DO1) visit. 
Subjects have the right to withdraw from  the study at any time for any reason.  
In the case that the subject decides to pr ematurely discontinue study treatment [“refuses 
treatment”], he/she should be asked if he/she  can still be contacted for further information 
concerning their reasons for discontinuing an d will be asked to return at 4 weeks, 
12 weeks, and, optionally, 1 year (52 weeks) from the time of thei r last dose of study 
drug in Parts 1 and 2 (see Table 2, Table 3, an d Table 4), and 4 weeks after the end of 
treatment in Part 3 (see Table 8  and Table 9).  The outcome of that discussion should be 
documented in the medical records.  If lost  to follow-up, the investigator should contact 
the subject or a responsible relative by te lephone followed by registered mail or through a 
personal visit to establish as completely as possible the reason for the withdrawal.  
A complete final evaluation at the time of the subject’s withdrawal s hould be made with 
an explanation of why the subjec t is withdrawing from the study. 
Subjects should be informed of circumstan ces under which their participation may be 
terminated by the investigator without the subject’s consent.  The investigator may 
withdraw subjects from the study in the event of  intercurrent illness, adverse events, lack 
of compliance with the study and/or study procedures (e.g., dosing instructions; missing 
more than three consecutive doses, or more th an six study visits in a calendar year for no 
other reason than compliance), or any reason wher e it is felt by the investigator that it is 
in the best interest of the subject to be te rminated from the study.  Any administrative or 
other reasons for withdrawal must  be explained to the subject. 
If the reason for removal of a subject from the study is an Adverse Event, the principal 
specific event will be recorded on the AE eCRF.  The subject should be followed until the Adverse Event has re solved, if possible. 
An excessive rate of withdrawals can re nder the study non-interpretable; therefore, 
unnecessary withdrawal of subj ects should be avoided.  Should a subject decide to 
withdraw, all efforts will be made to complete and report the observations prior to withdrawal as thor oughly as possible. 
4.6.1 Withdrawal from Study Drug 
Study treatment must be discontinued for protocol-specific rules implemented for subject 
safety.  The pre-specified criteria for withdrawal fr om the study drug include the 
following: 
 Pregnancy (see Section 7.2.3) 
Gantenerumab (RO4909832)—F. Hoffmann-La Roche Ltd 
66/Protocol WN25203, Version H  MRI findings (see Section 5.1.6.1 for Part 3) 
 
In addition, study treatment may be also modified or discontinued based on MRI-C 
recommendations and/or iDMC recommendati ons (during double-bind treatment period), 
as deemed necessary (Section 10.1) 
4.6.2 Withdrawal of Subjects from  the Roche Clinical Repository 
(RCR)  
Subjects who gave consent to provide RCR spec imens have the right to withdraw their 
specimen from the RCR at any time for any r eason.  If a subject wishes to withdraw 
his/her consent to the testing of his/her specimen(s), the i nvestigator must inform the 
Roche monitor in writing of the subject’s  wishes using the RCR Subject Withdrawal 
Form.  A  subject’s withdrawal from the main trial does not, by it self, constitute 
withdrawal of the specimen from the RCR.  Likewise, a subject’s withdrawal from the 
RCR does not constitute a withdr awal from the main trial. 
4.7 Replacement Policy [Ensuring Adequate Numbers of 
Evaluable Subjects] 
4.7.1 For Subjects 
Subjects prematurely discontinued from the study will not be replaced.  
4.7.2 For Centers 
A center may be replaced for the following administrative reasons: 
 Excessively slow recruitment. 
 Poor protocol adherence. 
 Non-GCP compliance or any significant au dit findings 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
67/Protocol WN25203 , Version H5. SCHEDULE OF ASSESSMENTS AND PROCEDURES
Table 1 Schedule of A ssessments –First Year
Visit by week  # Screen Baseline 1 4 8 12 16 20 24 28 32 36 40 44 48 52 53
Dose Number (8 wk s) 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Demographics12X
Medical/surgical history X
Physical Exam X X
Neurological Exam X X
Modified Hachinsk i X
Clinical Genotyping X
RCR Plasma and RNA X6X
RCR DNA X6
Vital Signs X P X P P P P P P P P P P P P P X
ECG (triple if underlined) X P X P P P P X
Blood and Urine Labs X10P X X X X X X10
Urine Pregnancy Test5X P P P P P P P P P P P P P P
PK  plasma P X P P P X
ADA samples P X P P P
Plasm a Biomark ers P P P
CDR X P- 1 wk P P
FAQ, NPI -Q, GDS X P- 1 wk P P
MMSE X P- 1 wk P P P P
Dementia Assessment X P P
ADAS -Cog X P- 1 wk P P P P
FCSRT -IR X4P-1 wk P P
CANTAB X P- 1 wk P P
C-SSRS P-1wk X X X X X X X X X X X X X
LP/CSF, plasma PK and 
matching serum  sample3 X210/20d2
RCR CSF X 10/20d2
MRI X210/20d * 10/20d * 10/20d * 10/20d * 10/20d *
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
68/Protocol WN25203 , Version HTable 2 Schedule of A ssessments –Second Year
Visit by week  # 56 60 64 68 72 76 80 84 88 92 96 100 101 FU1/1047FU2/112 FU3/152 Unsch.1FU1/DO1 FU2/DO2 FU3/DO312
Dose Number 15 16 17 18 19 20 21 22 23 24 25 26
Physical Exam X X X X X
Neurological Exam X X X X X
RCR Plasma and RNA X6X6
Vital Signs P P P P P P P P P P P P X X X X X X X X
ECG (triple if underlined) P P P X X X X
Blood and Urine Labs X X X X10X X X X10X X
Urine Pregnancy Test5P P P P P P P P P P P P X X X
PK  plasma P P X X X X
ADA samples P P X X X
Plasm a Biomark ers P P X X X
CDR P P P X X X X X
FAQ, NPI -Q, GDS P X X11X X X11
MMSE P P P X X X
Dementia Assessment P X X X
ADAS -Cog P P P X X X
FCSRT -IR P P X X X
CANTAB P X X X
C-SSRS X X X X X X X X X X X X X X X X X
LP/CSF,  plasma PK and 
matching serum sample3 10/20d2X 10/20d2
RCR CSF 10/20d210/20d2
MRI 10/20d * 10/20d * 10/20d2X8X 10/20d2X8
P indicates Prior to Injections: P-1 wk is within 1 week prior the 1st dose; P is prior to the injections on the day of dosing.
ECG readings underlined above to be done in triplicate for subjects enrolled prior to prot ocol amendment D.  Subjects enrolled after approval of amendment D will have triplicate 
ECG done only at Screen.  All ECGs are sent for central reading.
DO1, DO2 and DO3 are drop-out visits; FU1, FU2, and FU3 are 4, 12, and 52 weeks after last dose of stud y treatment.
LP/CSF and MRI: the times are days after the visit (e.g., 10/20d is 10 -20 days.  Attempt to schedule MRI closer to 10 days than 20 days as the result must be received prior to the 
next dose).
RCR CSF:  after aliquoting the required samples, an y remaining CSF fluid from consenting subjects will be saved for RCR sample.
Visit window:  +/- 7 days for dosing days; +/ -3 days for visits that are 1 week post -dose (see Section 5.1.2 ).
* The MRI result as determined by the central reader must be known before a subsequent dose can be given.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
69/Protocol WN25203 , Version HTable 2Schedule of A ssessments –Second Year (Cont.)
1.Any procedure or assessment marked may be done at an unscheduled visit as required.
2.LP performed in the morning (8 am 12 pm ); MRI should not be done during the 3 days follow ing an LP.  The LPs at screening and Week 104 (FU1/104, 
FU1/DO 1 or 104 Ext) are mandatory.  The LPs at 1 year and during th e extension part of the study are optional.  The final LP in the extension (FU1/208 or 
ext208/DO1) is highly encouraged. 
3.LP/CSF for biomarkers and PK assays, plasma PK and matching serum samples: at screen, Wk 52 Wk FU1/104 (or FU1/DO 1 or Wk 104 Ext), Wk 156 and 
Wk FU1/208 (or ExtFU1/DO 1).  See Section 5.2.14.2 .
4.FCSRT -IR performed up to 1 month prior to screening can be use d to satis fy inclusion criteria.
5.Wom en who are of childbearing potential must have a urine pregnancy test done at the site prior to each dose.
6.RCR plasma and RNA samples should be taken at the same time as the blood samples taken during the LP visit.
7.Subjects conti nuing directly into the Extension, should follow Week 104 Ext schedule in Table 3.  FU2/112 and FU3/152 visit in Table 2will not be 
performed.
8.The final MRI should be done approximately 4 weeks before the final follow -up visit to allow  revie w before the final visit.
9.At scr eening, demographic data collected w ill include years of education.
10.During the screening period, Week 53, the Week 101 or DO1 and, Week 204, or Ext DO1 only, HbA1C, folic acid and, B12, T4, fre e T4, and thyroid 
stimulating hormone levels will also be ass essed.
11.At FU, DO3, Ext FU3 or Ext DO3, only FAQ will be administered.
12.Optional follow -up/drop -out visit .
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
70/Protocol WN25203 , Version HTable 3 Schedule of A ssessments –Extension Year 1
Visit by week # 104 Ext 108 112 116 120 124 128 132 136 140 144 148 152
Dose Number 27 28 29 30 31 32 33 34 35 36 37 38 39
Physical Exam P
Neurological Exam P
RCR Plasma and RNA X6
Vital Signs P P P P P P P P P P P P P
ECG P P
Blood and Urine Labs X X
Urine Pregnancy Test5P P P P P P P P P P P P P
PK  plasma P P
ADA samples P P
Plasma Biomarkers
CDR P P P P
FAQ, NPI -Q, GDS P P
MMSE P P P P
Dementia Assessment P P
ADAS -Cog P P P P
FCSRT-IR P P P
CANTAB P
C-SSRS X X X X X X X X X X X X X
LP/CSF, plasma PK and 
matching serum  sam ple3 10/20d2
RCR CSF 10/20d2
MRI 10/20d * 10/20d * 10/20d
Also refer to footnotes Table 2.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
71/Protocol WN25203 , Version HTable 4 Schedule of A ssessments – Extension Year 2 
Visit by week # 156 160 164 168 172 176 180 184 188 192 196 200 204FU1/
208FU2/
216FU3/
256Unsch.1ExtFU1/
DO1ExtFU2/ 
DO2ExtFU3/ 
DO312
Dose Numbe r 40 41 42 43 44 45 46 47 48 49 50 51 52
Physical E xam P P X X X X X
Neurologic al Exam P P X X X X X
RCR Plasma and RNA X6X6X6
Vital Signs P P P P P P P P P P P P P X X X X X X X
ECG P P P X X X
Blood and Urine Labs X X X10X X X X10X X
Urine Preg nancy Test5P P P P P P P P P P P P P X X X
PK  plasma P P P X X X
ADA sample s P P P X X X
Plasma Bio markers X X X
CDR P P P P X X X X X
FAQ, NPI -Q, GDS P P X X11X X X11
MMSE P P P P X X X
Dementia A ssessment P P X X X
ADAS -Cog P P P P X X X
FCSRT-IR P P X X X
C-SSRS X X X X X X X X X X X X X X X X X X
LP/CSF, pl asma PK and 
matching serum  sam ple310/20d210/20d2X 10/20d2
RCR CSF 10/20d210/20d210/20d2
MRI * 10/20d * 10/20d2X8X 10/20d2X8
Also refer to footnotes in Table 2.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
72/Protocol WN25203 , Version HTable 5 Schedule of A ssessments –Open -Label Extension Year 1 -for A poE 4 carriers previously  on:  1) Placebo, 
2) 105 mg Gantenerumab and 3) 225 mg Gantenerumab meeting Criteria for Dose Reduction due to A RIAs
Visit by week #OLE Pre -baseline 
(8weeks)Day 1 (OLE 
Baseline)4 8 12 16 20 24 28 32 33 36 40 44 48 52
Dose Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Dose (mg) 105 105 105 225 225 225 450 450 900 900 1200 1200 1200 1200
Physical Exam P P P
Neurological Exam P P P
Vital Signs P P P P P P P P P P P P P P
ECG P P
Blood Labs P X
Urine Pregnancy Test4P P P P P P P P P P P P P P
PK  plasma P P X P P
ADA samples P P P
CDR P-1wk P P
FAQ P-1wk P P
MMSE P-1wk P P
Dementia Assessment P-1wk P P
ADAS -Cog P-1wk P P
FCSRT-IR P-1wk P P
C-SSRS P-1wk X X
MRI X X2* X2* X2* X2* X2*
Refer to Table 8footnotes .
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
73/Protocol WN25203 , Version HTable 6 Schedule of A ssessments –Open -Label Extension Year 1- for:  1) A poE 4 non- carriers and 2) A poE 4 
Carriers receiving 225 mg Gantenerumab until the End of Double -blind Treatment
Visit by week #OLE Pre -
baseline (8 
weeks)Day 1 
(OLE 
Baseline) 4 8 12 16 17 20 24 28 32 36 40 44 48 52
Dose Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Dose (mg) 225 225 450 450 900 900 1200 1200 1200 1200 1200 1200 1200 1200
Physical Exam P P P
Neurological Exam P P P
Vital Signs P P P P P P P P P P P P P P
ECG P P
Blood Labs P X
Urine Pregnancy Test4P P P P P P P P P P P P P P
PK  plasma P P X P P
ADA samples P P P
CDR P-1wk P P
FAQ P-1wk P P
MMSE P-1wk P P
Dementia Assessment P-1wk P P
ADAS -Cog P-1wk P P
FCSRT-IR P-1wk P P
C-SSRS P-1wk X X
MRI X X2* X2* X2* X2* X2*
Refer to Table 8footnotes .
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
74/Protocol WN25203 , Version HTable 7 Schedule of A ssessments –Open -Label Extension Year 2 for all Participants
Visit by week # 56 60 64 68 72 76 80 84 88 92 96 100 101 104
Dose Number 15 16 17 18 19 20 21 22 23 24 25 26 27
Physical Exam P
Neurological Exam P
Vital Signs P P P P P P P P P P P P P
ECG P
Blood  Labs X
Urine Pregnancy Test4P P P P P P P P P P P P P
PK  plasma P P X P
ADA samples P P
CDR P P
FAQ P P
MMSE P P
Dementia Assessment P P
ADAS -Cog P P
FCSRT-IR P P
C-SSRS X X
MRI X2* X2*
Refer to Table 8footnotes .
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
75/Protocol WN25203 , Version HTable 8 Schedule of A ssessments –Open -Label Extension Year 3 for all Participants
Visit by week # 108 112 116 120 124 128 132 136 140 144 148 152OLE156/
FU/DO5Unsch.1
Dose Number 28 29 30 31 32 33 34 35 36 37 38 39
Physical Exam X X
Neurological Exam X X
Vital Signs P P P P P P P P P P P P X X
ECG X X
Blood  Labs X X
Urine Pregnancy Test4 P P P P P P P P P P P P X X
PK  plasma P X X
ADA samples P X X
CDR P X X
FAQ P X X
MMSE P X X
Dementia Assessment P X X
ADAS -Cog P X X
FCSRT-IR P X X
C-SSRS X X X
MRI X2 * X2,3 * X
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
76/Protocol WN25203 , Version HTable 8Schedule of A ssessments –Open- Label Extension Year 3 for all Participants (Cont.)
Note: Visit window:   +/ -7 days for dosing days; +/ -3 days for visits that are 1 w eek post -dose.
OLEOpen -Label Extension ; Pprior to study drug administration: P -1 wk is within 1 week prior the first dose .
Eligibility for Part 3 should be confirmed during OLE pre -baseline , and MRI should be performed within 8 weeks and the results available before 
the first dosing visit in t he OLE.  Additional assessments can be performed as per the i nvestigator’s judgment.
MRI scans must be performed w ithin a maximum of 20 days (ideally 10 20days) after dose administration and results made available and reviewed before the 
next scheduled dose. 
* The MRI result as determined by the central reader must be known before a subsequent dose can be given.
1Any procedure or assessment may be performed at an unscheduled visit as required. 
2Subjects will be asked if they experience CNS adverse events up to 1 w eek before each MRI is performed .
3The results of the final MRI should be available before the final follow -up visit to allow  review before the final visit (after the last dose for patients not 
continuing in Part 3 extension after 3 years) .
4Wom en who are of childbearing potential must have a urine pregnancy test done at the site prior to each dose.
5Follow -up/drop-out visit to be performed 4weeks after the last dose during the initial 152 weeks of treatment.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
77/Protocol WN25203 , Version HTable 9 Schedule of Assessments – Open -Label Extension Years 4 and 5 for Participants Continuing 
Part 3 until July 2020
Visit by week # 156 160176 180 184204 208212Onwards 
(Upto 236)OLE/FU/DO 
5Unsch. 1
Dose Number 40 4145 46 4752 5354Onwards 
(Upto 60)
Physical Exam P P X X
Neurological Exam P P X X
Vital Signs P P P P P P X X
ECG P P X X
Blood  Labs P P X X
Urine Pregnancy Test4 P P P P P P X X
PK  plasma P P X X
ADA samples P P X X
CDR P
FAQ P
MMSE P P P X X
Dementia Assessment P
ADAS -Cog P
FCSRT -IR P
C-SSRS P P P X X
MRI * L2,3 * L2,3 * L2, 3 * X
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
78/Protocol WN25203 , Version HTable 9Schedule of Assessments – Open -Label Extension Years 4 and 5 for Participants Continuing Part 3 
until July 2020 (Cont.)
Note: Visit window:   +/ -7 days for dosing days.
Lan MRI after the Last dose within the indicated interval;  OLE Open -Label Extension; P prior to study drug administration and prior to 
the injections on the day of dosing.
The schedule of assessment outlines the maximum number of week visits and doses until July 2020 and serves as guidance.  The duration of 
Part 3 extension wi ll vary for each subject dependent on when the subject begins the OLE.
MRI scans are scheduled at approximately 6 -month intervals and is mandatory after the last study drug administration.  The time between the 
previous scan and the final study scan should not exceed 8 months.
An MRI must be performed within 20 days (ideally 10 20days) after dose administration and results made available and reviewed before the 
next scheduled dose.
* The MRI result as determined by the central reader must be known before a subsequent dosing visit and should be available before the OLE 
follow -up/drop -out visit to allow review before the final visit.
1Any procedure or assessment may be performed at an unscheduled visit as required. 
2Subjects will be asked if they experienc e CNS adverse events up to 1 week before each MRI is performed.
3The results of the final MRI (after the last dose) should be available before the final follow -up visit to allow review before the final visit.
4.Women who are of childbearing potential must have a urine pregnancy test done at the site prior to each dose.
5OLE follow -up/drop -out visit to be performed 4 weeks after the last dose in Years 4or5 of Part 3.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
79/Protocol WN25203 , Version H5.1 General Instructions by  Study  Phase
All subjects must sign and date the most current IRB/IEC -approved written informed 
consent before any study  specific assessments or procedures are performed.  Recording 
of adverse events begins after the informed consent form is signed.   
In general, results of study  assessments should be shared with the subject only if the 
result may require that some action related to safety  be taken.  For example an abnormal 
MRI  which means an unscheduled MRI will be done.  This is to minimize any 
expectation bias.
See also Section 4.5on concomitant medication use during the study .
5.1.1 Assessors for Clinical Scales and Order of A ssessments
As much as feasible, the CDR should be administered for a single subject by the same 
assessor throughout the study  and that assessor should not perform the MMSE or 
ADAS -Cog.  However, if in exceptional circumstances only this assessor is available to 
perform these other scales, then the CDR must be performed first.  The CDR assessor 
must be involved in the dementia assessment (Section 5.2.8). 
The remaining assessments may be done by other site staff as long as they have been 
qualified, trained, and where necessary  certified to perform the scale.  As much as 
possible for an y one scale, the same assessor should be used throughout the study .
When done at the same visit, other than screening (see below) the order of the following  
cognitive assessments should be:  CDR first (the entire scale in full), FCSRT before the 
ADAS -cog, ADAS -cog before the MMSE, and then CANTAB.  The order should be 
FCSRT, ADAS -Cog, and then MMSE at visits where these are the only assessments.  
Asthey are informant based and not subject -based questionnaires, there is no restriction 
on the order of the FAQ and NPI-Q.  As a general rule, the test sequence should remain 
the same for agiven subject as at baseline and testing should occur around the same time 
of day  at each visit.
5.1.2 Screening Period
The screening period is up to 8 weeks.  The screening assessments are shown in the 
Schedule of Assessments in Table 1.  
It is recommended that the first screening tests done are the CDR, FCSRT -IR, and 
MMSE in any order.  If the subject doesn't qualify on the basis of these tests the subject 
may be re-screened again after at least 3 months have passed if recruitment for the study 
is still on -going (see inclusion criteria 13, 14, and 15).
As noted in exclusion criteria 20, 21, and 22, subjects may be re-screened after 
appropriate treatment if they were originall y excluded for abnormal thyroid, B12, or 
HbA1C results.
Subjects can 
be re-screened if the protocol is amended such that they would satisfy  the 
amended criteria and if recruitment for the study  is still on-going.  In this case, all 
screening assessments must be repeated other than the LP/CSF testing if done previousl y 
for this study . 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
80/Protocol WN25203 , Version HSubjects can be re-screened if there is a substantial change in the subject’s condition 
(e.g., a disallowed medication was stopped) and if recruitment for the study  is still 
ongoing.
Other laboratory  tests which would exclude the subject may be repeated once 
(asunscheduled labs) if it is suspected that the abnormal result is transient and likely  to 
be normal at repeat.   
The remaining screening tests except the lumbar puncture and MRI (and PET scan if a 
PET substudy  subject) should be done within 12 weeks of signing the informed consent 
(to allow adequate time for the remaining tests).  As soon as all these results are available 
and none exclude the subject from the trial, the CSF collection and MRI scan should be 
done.  If the subject has had a brain MRI within the last 6 months as part of the 
evaluation of cognitive impairment, and if the scan did not have any  obvious findings that 
would 
exclude the subject from the study , the CSF results can be obtained before the 
screening MRI is done and the screening MRI should then be done only after it is known 
that the CSF results satisfy the selection criteria.  If no recent scan is available, then the 
MRI  should be done first and the lumbar puncture done after it is known the MRI 
satisfies the selection criteria unless, in the opinion of the Investigator there is sufficient 
reason that the LP should be done prior to the MRI.
It may take several days to receive the results of the MRI or CSF, and on occasion the 
originall y scheduled MRI or CSF collect ion day may need to be postponed and in the 
case of the MRI, it may need to be repeated.  Therefore the scheduling of these tests 
needs to be done carefully  and should begin as soon as possible.
For subjects in the PET substudy , all other screening results including those on MRI and 
CSF will need to be available before the PET.  In these cases the MRI appointment and 
LP should be scheduled to occur no more than 3 weeks after the beginning of the 
screening period.  This is to allow sufficient time for the PET scan to be done and 
evaluated before the end of the screening period.  In rare cases where an MRI  needs to be 
repeated or any other unexpected delay  due to logistical or technical reasons, this may 
necessitate extending the screening period by  a few day s.  Extending the screening period 
beyond 8 weeks should be in exceptional circumstances only and careful scheduling 
should remain a priorit y.
A Subject Eligibility  Checklist documenting the investigator’s assessment of each 
screened subject with regard to the protocol’s inclusion and exclusion criteria is to be 
completed b y the investigator.
A screen failure log must be maintained b y the investigator.
5.1.3 Treatment Period during Part 1 of the Study (Including Day  of 
First Dose)
See Section 6.4regarding treatment assignment.
All baseline assessments must be done before the first dose of study  medication is given.  
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
81/Protocol WN25203 , Version HSubject s will receive up to26SC drug administrations over the course of 2 yearsin 
Part1 of the study  with a 4-week interval between each dose.  On each dosing day, after 
all assessments indicated in the schedule of assessments to be done prior to dosing are 
completed, 
the gantenerumab or matching placebo will be administered SC at room 
temperature.  For the first 4 doses, subjects should be observed for a minimum of 2 hours 
after dosing.  For doses 5 and beyond, the subject may leave the study  center soon after 
the injectio ns if the subject appears to be tolerating the injections.  Rescue 
medications/equipment to treat anaph ylactic/anaphy lactoid reactions must be available at 
the site.  Subjects and study  partners will be alerted to watch for signs of 
anaph ylactic/anaph ylactoid reactions and to contact the study  center as soon as possible if 
any such signs are noted.
The schedule (Table 1, Table 2) shows visits after baseline by the number of weeks since 
the first dose.  It also shows when assessments should be done relative to the time of the 
injections.  Visits at which the subject receives study  medication may take place within 
7days of the exact date.  Visits that occur one week after a dose may take place 
3days of the exact date.  However all visits should be scheduled as close as po ssible to 
the exact day.  It is preferred that 
all assessments for a visit be done on the same day,but 
if necessary , assessments may be done over more than one day.  Preferably , all clinical 
scales and CANTAB should be performed on the same day .
The investigator may  choose to repeat the informed consent process if the subject has had 
appreciable cognitive decline during the stud y.
5.1.3.1 Procedures for New MRI Findings in Part 1 of the Study
In addition to any local reading as per local procedures and requirement s, all MRIs will 
be reviewed by an expert central reader within approximately  1 w eek of receipt, and a 
report provided to the site.  For the purposes of overall study  relevant decisions and 
recommendations including patient eligibility  as well as for analysis, results from the 
central expert read will be used.  Any time the central reader identifies a new MRI 
finding, the study  center medical staff and the sponsor will be rapidly  notified.  For 
relevant new MRI findings (as defined in the MRI -C Charter), the Sponsor will rapidly 
notify  the MRI -C, who will then be actively  involved in the review and can furthermore 
make recommendations that can deviate from the protocol guidelines, as deemed 
necessary . The iDMC will also be informed about relevant new MRI findings (see 
Section 10).
As described below, MRI  findings will be classified into one of three types:  
ARIA
-Edema (ARIA -E), ARIA -Hemosiderin (ARIA- H), and non -ARIA.  If an MRI scan 
shows any  new finding, the follow ing action should be taken: 
1.The site will contact the subject and study  partner as soon as possible to determine if 
there are an y symptoms that may  be related to the MRI  finding.  If the subject has 
developed or develops s ymptoms, the subject should be se en before the next 
scheduled visit, and the symptoms should be reported in the electronic case report 
form (eCRF) (see Section 7.1.4, MRI Observations).
2.A 4-week follow -up MRI will be done. 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
82/Protocol WN25203 , Version HPrior to the follow -up MRI,  the site should immediatel y inform the Sponsor if there are 
any new or worsening s ymptoms that may  be related to the MRI  findings.  
5.1.3.1.1 New A RIA-E Findings in Part 1 of the Study
If the MRI shows new ARIA-E findings, the investigator will take action as described 
above.  Treatment will be withheld and thesubject will continue to attend the scheduled 
visits and will have a follow -up MRI approximately  4 weeks after the prior MRI .  MRIs 
will then be done approximately  every 48 weeks (done as “unscheduled” if not 
associated with the current visit schedule) until the ARIA -E finding has resolved or has 
clearl y decreased and stabilized (as per the central read) at which point treatment may be 
restarted at half the original dose level.  Treatment will still end at the time the 
final dose 
was originally  scheduled to occur. 
If treatment is restarted, the MRI  schedule returns to the frequency  done at entry  into the 
study .  That is, “reset” MRI s will be done after the second, fourth, sixth, ninth, etc., dose 
after dosing resumes.  However, because an MRI is required after the Week 104 visit, in 
some cases a “reset” MRI  is not required after the Week 96 or Week 104 visits.  If a 
second ARIA -E finding occurs, treatment will be permanentl y discontinued.  
If possible, an LP (additional to those alread y specified) should be done near the time of 
identification of an ARIA -E finding to aid in understanding the mechanism of these 
findings.
5.1.3.1.2 New A RIA-H Findings (Microbleeds or A reas of 
Leptomeningeal Hemosiderosis) in Part 1 of the Study
Approximately  20% of MCI  subjects will have one or more microbleeds on a standard 
1.5Tesla T2* MRI  [25].  Because microbleeds may develop spontaneously in prodromal 
AD subjects, it is reasonable to allow for the 
occurrence of occasional microbleeds 
without altering the treatment regimen.  The following describes the management of 
dosing in cases of new ARI A-H.
1) If the cumulative number of new ARIA-H within the last 12 months is more than 
4, treatment must be immediately  discontinued.  This is the case no matter what 
the dosing was over the prior 12-month period (e.g., full dose, half dose, dose 
held).
If the above is not met, dosing will be changed according to the following:
2) If on a full dose and the cumulative number of new ARIA -H within the last 
12months is more than 2, the dose will be halve d.
3) If on a half dose, treatment will be discontinued if the cumulative number of new 
ARIA
-H is more than 2 within the shorter of the last 12 months or since the dose 
was halved.
These limits apply  for both 1.5T and 3T magnets.
After any new ARIA -H findings (microbleed or new area of leptomeningeal 
hemosiderosis), dosing can continue as long as the criteria for dose discontinuation is not 
met.  However, the dose due after the 4 week follow -up MRI  should not be given until 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
83/Protocol WN25203 , Version Hthe MRI  result is known.  If criteri a for dose alteration due to ARIA-H was not met, then 
no further action is needed after the 4 week follow -up MRI  unless suggested by the 
MRI -C.
5.1.3.1.3 New Non -ARIA MRI Findings in Part 1 of the Study
In the case of new non-ARIA MRI findings (e.g., cases of ischem ia, cerebral infarction, 
or other lesions) the MRI -C may propose further actions, if deemed appropriate 
(e.g., dose modification, additional MRI sequences, or recommendations for additional 
testing for diagnostic purposes).
5.1.4 Part 2 -Extension Period for Co ntinued Double
-Blind 
Treatment
Subjects who complete Part 1 of the study , up to and including the Week 104 visit, may 
continue to receive double -blind study  medication during the optional Part 2 of the study  
after signing informed consent for the additiona l treatment.  
Subject s may receive up to 26additional SC administrations of their originall y 
randomized study  drug over the course of 2 years with a 4-week interval between each 
dose.  On each dosing day, after all assessments indicated in the schedule of assessments 
to be done prior to dosing are completed, the gantenerumab or matching placebo will be 
administered SC at room temperature. 
The schedule Table 3and Table 4) shows visits during Part 2 of the study  by the number 
of weeks since the first dose.  It also shows when assessments should be done relative to 
the time of the injections.  Visits at which the subject receives study  medication may  take 
place within 7 days of the exact date.  However, all visits should be scheduled as close 
as possible to the exact day. It is preferred that 
all assessments for a visit be done on the 
same day,but if necessary , assessments may be done over more than 1 day.  Preferabl y, 
all clinical scales should be performed on the same day .
As noted in Section 5.1.4.3 below, dosing at certain visits during the extension may not 
require the subject to come to the study  center.
The investigator may  choose to repeat the i nformed consent process if the subject has had 
appreciable cognitive decline during the stud y.
5.1.4.1 Procedures to Follow for Subjects who reach the Week 104 
Visit prior to A pproval of A mendment D
If a subject completes the Week 104 visit prior to approval of protocol amendment D, the 
subject may still continue in the optional Part 2 of the study  once approval is received.
If Week 104 has been completed, and approval of amendment D is received prior to 
Week 112, the subject can be assessed and dosed as for the appropriate week (Week 108 
or 112) in Table 3.  In this case, the original visit schedule relative to baseline will be 
maintained as if the subject had not missed a dose and/or visit, as the case applies.  
If amendment D approval is not received by  the time the subject completes the follow -up 
Week 112 visit in the main study , the subject may still receive extended treatment once 
approval is received.   In this case, the original visit schedule relative to baseline will be 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
84/Protocol WN25203 , Version Hmaintained as if they had not missed a dose and/or visit, as the case applies.  However, 
the assessments for Week 104Ext must be performed with the exceptions of RCR plasm a 
and RNA, LP/CSF (with plasma PK and matching serum sample), RCR CSF, CANTAB, 
and MRI  (which were already  performed at Week 104/FU1 visit.
5.1.4.2 Procedures to Follow for Subjects who reach the Week 104 or 
112 Visit without having made a Decision to Continue in Part 2 
of the Study
If the amendment has been approved and the decision to continue double -blind treatment 
is not taken at Week 104, the schedule in Table 1should be followed.  If the decision is 
not made by the time of the Week 112 visit, the subject should have the final visit and 
must be discontinued from the study .  
5.1.4.3 Dosing during Part 2 of the Study
For sites and subjects where this is practical, visits that require only dosing, vital signs 
and C-SSRS assessments may be done at the subject’s residence conducted by 
appropriate site staff. 
5.1.4.4 Procedures for new MRI findings in Part 2 of the Study
The procedures are the same as for Part 1 except for the following:
The MRI -C is not required to review new MRI  findings that are typical of ARIA.  The 
MRI -C will review findings where any  of the following appl y:
• The finding is not a t ypical ARIA finding (e.g., ischemic lesion)
• The subject has one or more new CNS adverse events which the investigator 
assesses as possibly  related to the MRI  finding 
• Review by the Committee is requested by the central reading center, investigator, 
Sponsor, or iDMC 
5.1.5 Treatment -Free Follow -up
Subjects are considered to be on treatment until 4 weeks after the last dose.  All subjects
(including premature withdr awals) will be followed for 12 weeks and, optionally , 1year 
(52 weeks) after the last dose.  These assessments (see Table 2and Table 4- FU1/DO1, 
FU2/DO2, and FU3/DO3 visits) should also be done if possible in case a subject 
prematurel y withdraws consent for the study  or is withdrawn early for other reasons.  
FU3/DO3 visit 
is optional for subjects who do not continue in the open -label extension 
and not needed for those entering Part 3, as all relevant assessments will be performed 
during Part 3 prebaseline and baseline (Table 5and Table 6).  For subjects continuing in 
Part3, treatment –free follow - up is estimated to last approximately  between 12 and 
18months, depending on the approval of study  protocol WN25203G by local Competent 
Authorities (CAs).  During this period, unscheduled assessments may be performed at 
any time.
5.1.6 Part 3 –the Open -Label Extension
Subjects who received double -blind treatment and 
had at least one follow -up/drop-out 
visit will be eligible to enter Part 3 after signing an informed consent for the additional 
treatment with higher doses of gantenerumab.  Subjects who meet any of the criteria 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
85/Protocol WN25203 , Version Houtlined in Section 4.4will not be eligible for Part 3.  Eligibility  for Part 3 should be 
confirmed within 8 weeks prior to the first dose administered (see Table 5andTable 6). 
APOE ε4 status will be communicated to subjec ts, and appropriate counseling will be 
offered.
Subjects may receive up to 39 SC administrations over the course of the 3-year 
open -label extension with a 4-week interval between each dose.  All subjects who 
complete 3years of open -label treatment will begiven the option of extending 
open -label treatment beyond the initial 3years until July 2020  and may receive 
up to 21additional administrations every 4weeks during Years 4 and 5 (up to a 
maximum of an additional 19months).  The final number of SC administrations 
will depend on when a subject enter sPart 3 and receives the first dose of 
open -label gantenerumab.
On each dosing day, after all scheduled assessments to be done prior to dosing are 
completed, gantenerumab will be administered SC at room temperature. For the 
first 
4doses, subjects should be observed for a minimum of 2hours after dosing.  For 
doses 5 and beyond, subjects should be observed for a minimum of 1hour after 
dosing (if the subject appears to be tolerating the injections).  Rescue 
medications and equipment to treat anaphylactic and anaphylactoid reactions 
must be available at the site or at the dosing location for home nursing visits.  
Subjects and study partners will be alerted to watch for signs of 
anaphylactic/anaphylactoid reactions and to contact the study center as soon as 
possible if any such signs are noted.
The schedule of assessments in Part 3 (Table 5, Table 6, Table 7, Table 8, and Table 9) 
display s when assessments should be done relative to the time o
f gantenerumab 
administration.  I t includes separate schedules for Year 1 for APOE 4 carriers previously 
on placebo and 105 mg gantenerumab (Table 5) and for APOE 4 carriers previously  on 
225mg gantenerumab and for the non-carriers (Table 6).  All visits should be scheduled 
relative to the first dosing visit (“Day  1-baseline”) in the open -label extension, as close 
as possible to the exact day.  As in the Parts 1 and 2, all visits on which the subject 
receives study  medication may take place within 7 days of the scheduled date.  It is 
preferred that all assessments for a visit are performed on the same day, but if necessary , 
assessments may be done over more than 1 day.  Preferab ly, all clinical scales should be 
performed on the same day.  For the PK analysis, it is important to capture date and time 
of dosing and PK sampling correctl y.  InPart 3 for certain d osing visits, the subject 
may not be required to return to the study center.  Atselect sites and specified 
visits, study drug administration and limited safety assessments may be 
performed by home nursing staff.
The investigator may  choose to repeat the informed consent process if the subject has had 
appreciable cognitive de cline during the stud y.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
86/Protocol WN25203 , Version H5.1.6.1 Procedures for new MRI findings in Part 3 of the Study
MRI  scans in Part 3 will  be performed according to the schedule of assessments, prior to 
each increase in gantenerumab dose (Table 5and Table 6) and then at regular intervals 
thereafter (Table 7,Table 8, and Table 9).  
All MRI scans will be read and reported by the central MRI  reader in alignment with the 
processes from Parts 1 and 2 of the trial.  When the central reader identifies a new MRI 
finding, the study  center medical staff and the Sponsor will be notified, and in the case of 
relevant new MRI  findings (as defined in the MRI -C Charter), the Sponsor, in turn, 
notifies the MRI -C concurrentl y.  The MRI -C is activel y involved in review and has the 
remit to make recommendations that may deviate from the protocol guidelines, as 
deemed necessary .  
MRI  findings are classified as ARIA -E, ARIA -H, and non-ARIA.  Information about 
potential symptoms will be collected prospectively  (i.e., the site will contact the subjects 
up to 1 week before each MRI  to ask if they  experience CNS adverse events, as described 
in Section 7.1.4
).  
Management of MRI findings are presented in sections below. 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
87/Protocol WN25203 , Version H5.1.6.1.3 New Non -ARIA MRI Findings
The MRI -C may be alerted in cases of new non-ARIA MRI findings (e.g., cases of
hematoma, large cerebral infarction, or other lesions), if the central reader or sponsor 
requests the committee to review the MRI.
5.2 Assessments and Procedures
5.2.1 CDR
The CDR is used to characterize six domains of cognitive and functional performance 
applicabl e to Alzheimer disease and related dementias:  Memory , Orientation, Judgment 
& Problem Solving, Community  Affairs, Home & Hobbies, and Personal Care.  The 
necessary  information to make each rating is obtained through a semi -structured 
interview of the subject and a reliable informant or collateral source (e.g., famil y 
member).  D etails of the CDR can be found at the website:  
http://www.biostat.wustl.edu/~adrc/cdrpgm/index.html.  The scale will not be 
administered beyond the initial 3 years of Part 3.
5.2.2 Funct ional A ctivities Questionnaire (FA Q)
The FAQ [26] is an informant -based assessment which presents a forced choice of 
4levels of functioning for 10 activities of daily living (ADL).  The scale will not be 
administered beyond the initial 3 years of Part 3.
5.2.3 MMSE
The MMSE consists of a set of standardized questions to assess a subject’s mental status 
and identifies the individual’s general level of impairment [27 ].  The questions target 
5areas; orientation, short term memory  retention, attention, short term recall and 
language.   The MMSE is the only scale that will be collected beyond the initial 
3years of Part 3.
5.2.4 Neuropsy chiatric Inventory  (NPI- Q)
The NPI-Q [28] was developed to assess a wide range of behaviors encountered in 
dementia patients, to provide a means of distinguishing severit y of behavioral changes, 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
88/Protocol WN25203 , Version Hand to facilitate rapid behavioral assessment through the use of screening questions.  It is 
an informant -based instrument in which 10 behavioral domains are evaluated on a 3- point 
scale (mild, modera te, and severe).  The caregiver distress portion of the scale will not be 
used in this study .  The scale will not be administered during Part 3.
5.2.5 Alzheimer Disease A ssessment Scale -Cognition (A DAS-Cog)
The modified version will be used which has 13 items.  The modified items are: addition 
of delay ed word recall and number cancellation and use of only one trial for word 
recognition.  This is the version used in the ADNI protocol (http://www.adni -
info.org/Scientists/ADNIGrant/ADNIProtocol.aspx).  Equivalent alternate forms of the 
word recall and word recognition and number cancellation subtests will be used in 
successive test administrations.   The scale will not be administered beyond the 
initial 3 years of Part 3.
5.2.6 Free and Cued Selective Reminding Test (FCSRT-IR)
The version of FCSRT -IR to be used will use written words and immediate recall after 
each card with four words is completed [29].  The FCSRT -IR is a measure of memor y 
under conditions that control attention and cognitive processing in order to obtain 
an 
assessment of memory unconfounded by normal age related changes in cognition.  
FCSRT -IR performance has been associated with preclinical and early  dementia in 
several longitudinal epidemiological studies [30].  The scale will not be administered 
beyond t he initial 3 years of Part 3.
5.2.7 Cambridge Neuropsychological Test A utomated Battery
The CANTAB is a computerized assessment battery  consisting of tests for 
neurops ychological function.  D etails of CANTAB can be found at: 
www.cantab.com/camcog/default.asp.  The tests selected for 
this study  are listed in 
8.1.2.1 and additional information on the CANTAB can be found in Appendix 2.  The 
scale is administered during the first 2 y ears of double -
blind treatment only.
5.2.8 Dementia A ssessment
This is to assess if the subject has progressed to a diagnosis of dementia.  It should 
involve the assessor who completes the CDR and is done during the visit after reviewing 
the results of all scales done at that visit.  It is done even if the subject was judged to have 
dementia at a prior assessment.  In most cases, to meet criteria for dementia, worsening 
from baseline shoul d be seen on one or more domains of the CDR, the FAQ and on 
cognition (as assessed by ADAS, MMSE, and during the first 2 years of treatment by 
CANTAB).  If dementia is judged to be present, an additional determination will be made 
as to whether it is consi dered to be dementia of the Alzheimer's type.  Dementia 
assessment will not be performed beyond the initial 3 years of Part 3.
5.2.9 Modified Hachinski Ischemia Scale
This is a simple clinical tool currently  used for helping to differentiate different types of 
dementia (primary degenerative, vascular or multi -infarct, mixed ty pe).
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
89/Protocol WN25203 , Version H5.2.10 MRI
The MRI should be performed using a 1.5 Tesla magnet.  In exceptional circumstances if 
a 1.5T magnet is not available in reasonable proximity  to the study  center, a 3 T magnet 
may be used.  
MRI  will be conducted for subject screening, for safety  monitoring and to determine 
potential treatment effects on brain volume according to the Schedule of Assessments.
The screening MRI will be used to help in determining whether the exclusio n criteria are 
met (e.g., number of microbleeds, presence of mass lesions, etc.).  MRI will be used 
during the course of this study  to help assess safety  such as the occurrence of microbleeds 
or signs potentiall y indicative of inflammation or vasogenic edema.  Additional 
unscheduled MRIs may be utilized to better understand relevant CNS -related AEs (such 
as increased confusion) or to follow a sign which emerged at a scheduled scan; contrast 
agent may be used in such a case of follow -up if administration of contrast agent is 
considered safe for the subject according to local standards.  MRIs done at screening, 
after the 12th and 26th dose in Part 1 of the study , and after the 39th and 52nd dose in 
Part 2, will be used for volumetric analysis.  In Part 3, MRI sperformed before the first 
dose, after 13th, 26th, and 39th dose will be used for volumetric analysis.  The following 
MRI  sequences will be acquired every  time an MRI  is scheduled:
 3D T1 - weighted gradient echo scans
 T2* - weighted gradient echo scans
 T2-weighted spin echo scans
 T2 - weighted Fluid attenuated inversion recovery  (FLAI R) scans
 Diffusion weighted scans, if available
The MRI  will take approximately  30 minutes to complete.
MRI  should not be done unless at least 3 days have passed since a lumbar puncture.  
Further instructions regarding the MRI can be found in the separate MRI Manual.  Scans 
will be reviewed by a central MRI  Core Lab and it will be the assessment of the data as 
done by  the central reader that will be used in the anal ysis.
5.2.10.1 Healthy  Volunteer MRI Scans for Site Qualification
MRI  acquisition of phantoms provides some information regarding how the proposed 
sequences are standardized at a site as well as the resultant qualit y of scans.  However, 
this data is often not suitable enough to provide clarity  on important aspects of the image 
quality  for quantitative analysis of brain atrophy .  Such issues include tissue contrast, 
susceptibility  artifacts, and the effects of motion on the quality  of scans.  Thus as part of 
site qualificat ion, 1 or 2 volunteers at each site should be recruited and scanned using the 
same machine and the same sequences to be used for the study  before any subject is 
scanned in this study .  These volunteers must not have any contraindications for MRI 
scanning (evaluation as per local procedures at the imaging site), and they will not be 
enrolled in the study  nor undergo any other assessments as part of the trial.  If volunteer 
scans are acquired, then they will be reviewed for suitable image quality  and used for
qualitative comparison with scans acquired after certain events as follows:  Upon a major 
upgrade to the site’s scanner, 4 months without any subject scans occurring at a site, or 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
90/Protocol WN25203 , Version Hany other event deemed significant enough to affect image qualit y, additional scans with 
the same volunteer should be acquire d.  This procedure will help ensure consistency  in 
scanning qualit y over the duration of the study .  Two volunteers are ideal in case one 
volunteer is no longer readily  available for test scanning.
5.2.11 Pharmacokinetic [PK] Sampling
5.2.11.1 Plasma Gantenerumab
Blood samples will be collected to evaluate the pharmacokinetics of gantenerumab in 
plasma as noted in the Schedule of Assessments Table 1, Table 2, Table 3, and Table 4in 
Parts 1 and 2.
Samples from patients receiving placebo will not be assessed in the first instance, but 
retained for subsequent analy sis if appropriate.
In Part 3, the PK sampling schedule follows the separate titration schedules for the 
APOE 4 carriers and non -carriers during the first year (Table 5and Table 6).  Collection 
of plasma samples for pharmacokinetics during Years 2 and 3 of Part 3 
for all 
participants is outlined in Table 7and Table 8, respectivel y.  The PK sampling 
schedule during Years 4 and 5 is outlined in Table 9.
Unused sample material may  also be used for the purposes of current gantenerumab assay  
improvement. 
5.2.11.2 CSF Gantenerumab (Parts 1 and 2)
An aliquot of CSF collected by lumbar puncture as detail ed in section 5.2.14.2   (Table 1, 
Table 2, Table 3, and Table 4) will be allocated for the measurement of gantenerumab 
concentration.
Samples from patients receiving placebo will not be assessed in the first instance, but 
retained for subsequent analy sis if appropriate.
Unused sample material may  also be used for the purposes of current gantenerumab assay  
improvement.
5.2.12 Anti-Drug Antibody Sampling
Blood samples will be collected to assess the possible development of ADAs in all 
subjects as noted in the Schedule of Assessments Table 1, Table 2, Table 3, and Table 4.  
The procedures for the collection, handling and shipping of PK and ADA samples are 
specified in the Sample Handling and Logistics Manual supplied to the site by the 
Sponsor.  The total volume ofblood taken for PK and ADA assessments will be 
approximately  85 mL in Part 1 of the study  and approximately  12 mL each year that the 
subject continues in Part 2.
In Part 1 of th e study , analy sis of samples will be limited initially  to those collected at the 
Baseline (pre-dose), Dose 6 (Week 20) and Follow -
up (Week 112) occasions. For 
subjects participating in Part 2, sample analysis will be limited initially to Baseline 
Gantenerumab (RO4909832)—F. Hoffmann-La Roche Ltd 
91/Protocol WN25203, Version H (pre-dose), Dose 6 (Week 20), Dose 29 (Week 112), Dose 43 (Week 168), Dose 52 
(Week 204) and FU2 (Week 216).  
For subjects participating in Part 3, blood sa mples for ADA will be collected during the 
first year as indicated in Table 5 for the APOE 4 carriers and Table 6 for the non-APOE 
4 carriers.  Collection of blood samples for ADA during Years 2 and 3 of Part 3 for all 
participants is outlined in Ta ble 7 and Table 8, respectively.  Collection of blood 
samples for ADA during Years 4 and 5 of Pa rt 3 for all participants is outlined 
in Table 9.  The analysis of the remaining samples for Parts 1, 2, and 3 of the study  may 
be requested for some individuals as appropriate, dependent  on the initial results. 
Unused sample material may also be us ed for the purposes of current ADA assay 
improvement. 
5.2.13 Clinical Genotyping 
During screening, a mandatory 3 mL whole blood sample will be taken for DNA 
extraction from every subject who has consented to participate in th e study.  All subjects 
will be evaluated for ApoE 4 status and Fc  receptor genotype.  Subjects will be 
assigned to study treatment based on ApoE 4 status.  Fc  receptor genotype may play a 
role in PK and PD variabil ity of antibody-based therapeu tics and predict response/non 
response.  ApoE  4 status and Fc  receptor genotype information will not be shared with 
the Investigator or the subj ect until the study is unblinded un less required by the relevant 
health authority or EC/IRB.  Data arising from  these analyses will be subject to the same 
confidentiality as the rest of the study.  The procedures for the collection, handling and 
shipping of Clinical Genotyping samples ar e specified in the Laboratory Manual.  
The APOE ε4 genotype information will be communicated to subjects continuing in the 
open-label extension (Part 3), and appr opriate counseling will be offered. 
5.2.14 CSF and Plasma Biomarker  Sampling (Parts 1 and 2) 
Samples will be collected from all subjects and will be used for research purposes to 
identify dynamic biomarkers that may be pr edictive of response to treatment with 
gantenerumab (in terms of dose, safety and tolerability) and will he lp to better understand 
the pathogenesis, course and outcome of Alzheimer’s Disease and related diseases. 
5.2.14.1  Plasma Biomarkers Sampling 
Approximately 5 mL blood sample for biomarker  analysis will be collected according to 
the Schedule of Assessments Table 1, Table 2, Table 3, and Table 4.  A total of 
4560 mL of plasma will be collected throughou t the course of the study (30–35 mL in 
Part 1 and an additional 15 mL in Part 2).  These samples will be used for analysis of 
markers of amyloid deposition and clearance (e.g., A β1-40 and Aβ1-42, potentially 
-amyloid pyroglutamate).  The procedures  for collection, handling and shipping of 
plasma biomarker samples are specified in the Sample Handling and Logistics Manual. 
5.2.14.2  CSF Sampling 
CSF samples will be collected according to the Schedule of Assessments Table 1, Table 2, Table 3, and Table 4.  The lumbar pun cture will be performed by an individual 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
92/Protocol WN25203 , Version Hwho meets all local requirements and is proficient in the procedure.  Post lumbar 
puncture care will be done in accordance with local practice.  
CSF sampling will be done in the morning (between 8 AM and noon) to minimize 
potential diurnal variation of CSF parameters [ 31].  CSF and, in addition, matching blood 
samples (serum and plasma) will be taken at screening and Weeks 52, 104 (FU1 or 
104Ext), 156, 208/FU1, 
and/or drop-out visits (as applicable).  Serum samples may be 
used if required to determine parameters that allow the assessment of the blood -brain 
barrier status and/or inflammatory  processes in the brain, such as CSF/serum album in 
ratio, CSF/serum IgG and IgM indices, and oligoclonal bands.  Plasma samples will be 
collected for pharmacokinetics.  Procedures for the processing of the CSF samples can be 
found in the Sample Handling and Logistics Manual. 
Approximately  12 mL of CSF will be collected at each timepoint.  The sample will be 
aliquoted on -site and used for:
 Local lab testing for cell count (ery throcy tes and leukocy tes with differential)
 Measuring the CSF gantenerumab levels (see Section 5.2.11.2), and biomarker 
analysis including A 
42, T-tau and P -tau, tentatively  A40, and markers of 
inflammation.  This sample may  also be used to support the devel opment of 
biomarker assay s for patient selection/stratification (i.e., A tau, P -tau). 
Normal ranges for CSF cell counts will be sent to the sponsor by  the site for data entry . 
Unused CSF sample (up to 6 mL) will be kept for future Biomarker Research if the 
subject gives consent to RCR (see RCR CSF, below).  The procedures for handling and 
shipping of CSF samples for biomarker analy ses are specified in the Sample Collection, 
Handling and Logistics Manual.
5.2.15 Roche Clinical Repository Specimen(s)
Specimens for dynamic (non-inherited) biomarker discovery  and validation will be 
collected from consenting subjects in Parts 1 and 2. 
These specimens will be used for research purposes to identify  dynamic biomarkers that 
are predictive of response to gantenerumab treatment (in terms of dose, safet y, and 
tolerability ) and will help to better understand the pathogenesis, course and outcome of 
Alzheimer’s Disease and related diseases.  They may also be used to support the 
development of biomarker and diagnostic assay s. 
Three types of specimens will be collected: RCR CSF (samples remaining from the CSF 
analysis described in Section 5.2.14.2 above) RCR plasma, and RCR RNA. 
Analy sis of plasma and CSF samples may include determination of markers of amyloid 
deposition and/or clearance, oxidative stress, neurodegeneration, inflammation, and other 
processes implicated in the pathogenesis of AD.  RNA samples may be tested using 
techniques such as high-density  microarray  profiling and/or quantitative RT-PCR to 
study  the expression profile of genes known to be involved in AD, and any other 
differentiall y expressed genes relative to treatment or dose response . 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
93/Protocol WN25203 , Version HSpecimens for dynamic biomarker discovery  will be single coded like any other clinical 
sample (labeled and tracked using the subject’s study  identification number 
(seeSection 17).
Specimens for genetic (inherited) biomark
er discovery  and validation will also be 
collected from consenting subjects (RCR DNA).  Theses samples may be used to explore 
the associations of variants of genes implicated in susceptibility  and pathogenesis of AD, 
such as Clusterin and PICAL M, and thera py response or adverse events.
The pharmacogenetic information gathered through the analy sis of specimens in the RCR 
is hoped to improve subject outcome by predicting which subjects are more likely  to 
respond to specific drug therapies, predicting which subjects are susceptible to 
developing adverse side effects and/or predicting which subjects are likely to progress to 
more severe disease states.  Such genetic samples collected for anal ysis of heritable DNA 
variations will be double coded: a new independen t code will be added to the first code to 
increase confidentialit y and data protection (see Section 17). 
The results of specimen analysis from the RCR will facilitate the rational design of new 
pharmaceutical agents and the development of diagnostic tests, which may allow for 
individualized drug therapy  for subjects in the future.
All RCR specimens will be destro yed no later than 15years after the final lock of the 
respective clinical database unless regulatory  authorities require that specimens be 
maintained for a longer period.  The specimens in the RCR will be made available for 
future biomarker research towards further understan ding of treatment with gantenerumab, 
of Alzheimer’s Disease, related diseases and adverse events and for the development of 
potential associated diagnostic assay s.  The implementation and use of the RCR 
specimens is governed by the Roche Clinical Repositor y policy  to 
ensure the appropriate 
use of the RCR specimens.
5.2.15.1 Specimen Ty pes [the follow ing list is not exhaustive]
Plasma assay s
Blood (one approximately  6.0 mL sample in EDTA) for plasma isolation will be obtained 
at various time points as shown in Table 1, Table 2, Table 3, and Table 4.  For sampling 
procedures, storage conditions and shipment instructions see study  Sample Handling and 
Logistics Manual.
Blood Sample for RNA Expression Profiling
Blood for RNA isolation (two 2.5 mL  samples collected in PAXgene vacutainers) will be 
collected from consenting patients at various time points according to the Schedule of 
Assessments Table 1, Table 2, Table 3, and Table 4.  Date of consent and specimen 
collection should be recorded on the associated RCR page of the eCRF.  For sampling 
procedures, storage conditions and shipment instructions see study  Sample Handling and 
Logistics Manual. 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
94/Protocol WN25203 , Version HBlood sample for genetic anal ysis (RCR DNA)
Blood (approximately  6 mL in K3 EDTA) for DNA isolation will be collected as shown 
inTable 1.  If, however, the RCR genetic blood sample is not collected during the 
scheduled visit, it may be collected at any time (after randomization) during the conduct 
of the clinical stud y.  See study  Sample Handling and Logistics Manual for more details.
5.2.16 Safety
5.2.16.1 Physical Examination
A general physical examination will be carried out at the time points listed in the 
Schedule of Assessments (for Part 3, please refer to Table 5, Table 6, Table 7, Table 8, 
and Table 9).  Weight and height measurements will be done as part of the screening 
physical exam.
5.2.16.2 Neurological Examination
A neurological examination will be performed at time points listed in the Schedule of 
Assessments (for Part 3, please refer to Table 5, Table 6, Table 7, Table 8, and 
Table 9).
5.2.16.3 GDS
The Geriatric Depression Scale (short form) [32] is aself-report scale designed to 
identify  symptoms of depression in the elderly .  The scale consists of 15 questions which 
are answered yes or no on the basis of how the subject felt over the past week.  Total 
scores of 05 are considered normal and scores of 615 are considered depressed.  The 
scale will not be administered in Part 3.
5.2.16.4 Vital Signs
Vital signs (systolic and diastolic blood pressure and pulse rate) will be measured after 
the subjects have been in a supine position for at least 5 minutes at time points listed in 
the Schedule of Assessments (for Part 3, please refer to Table 5, Table 6, Table 7, 
Table 8, and Table 9).
5.2.16.5 ECG
After 5 minutes in a supine position, 12-lead ECG single read will be performed at the 
time points indicated in the Schedule of Assessments (for Part 3, please refer to Table 5, 
Table 6, Table 7, Table 8,and Table 9).  Triplicate ECGs will be recorded at certain 
visits a
s indicated in the Schedule of Assessments during Parts 1 and 2 only.  Triplicates 
should be done 25 minutes apart (i.e., 3 readings within 10minutes).  All ECGs will be 
recorded/digitized using a validated device.  All ECGs will be read by the central reader.  
The investigator or designee must review the outputs to ensure there are no clear alerts 
for quality  or clinical issues and then sign, and date the outputs.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
95/Protocol WN25203 , Version H5.2.16.6 Laboratory  Assessments
Blood Chemistry :AST/SGOT, ALT/SGPT, alkaline phosphatase, total protein, total 
bilirubin, serum albumin, creatine phosphokinase, sodium, potassium, calcium, 
BUN/urea and serum creatinine (and creatinine clearance calculated by central lab).  
During the screening period, Week 53, Week 101 or DO1 in Part 1, Week 204, or 
ExtDO1 in Part 2, and at all visits with scheduled blood chemistry  in Part 3, HbA1C, 
folic acid, B12, thyroxine (T4), free T4, and thyroid-stimulating hormone levels will also 
be assessed. 
Hematology : hemoglobin, hematocrit, red blood cell (with morphology ), white blood 
cell, platelet, basophil, eosinophil, lymphocy te, monocy te, neutrophil, and WBC –other 
total counts.
Coagulation : prothrombin time (PT)
Urine for Drugs of Abuse:  at screening only, urine samples will be analy zed for the 
presence of the following drugs: amphetamine, benzodiazepines, cannabinoids, opiates, 
cocaine, barbiturates, and methadone.  Results will be used to verify  subject eligibility  
pertaining to drug abuse.
Urinaly sis: performed during Parts 1 and 2 onl y at the site by dipstick for blood, protein, 
glucose and pH.  Microscopic examination will be performed by the central lab if blood 
and/or protein results are posi tive or strong positive.
Urinaly sis for Pregnancy : urine pregnancy  testing will be performed at the site for 
women of childbearing potential, and at the site for any other female participants if 
required by local regulations.  Women who are of child- bearin g potential must have a 
pregnancy  test conducted at the site prior to each dose.
The total volume of blood taken for laboratory  assessments will be approximately  130 to 
215mL over the course of Part 1 of the study  and an additional 3040 mL during each 
year of Part 2.  During Part 3, the total volume of blood taken at scheduled visits will be 
approximately  111 mLduring the initial 3years, and up 40mL during Years 4 
and 5.
The procedures for the collection, handling and shipping of laboratory  samples are
specified in the manual provided b y the central laboratory.
5.2.16.7 Columbia- Suicide Severity Rating Scale (C -SSRS)
The C-SSRS (http://www.cssrs.columbia.edu) is an assessment tool used to assess the 
lifetime suicidality  of a subject (C-SSRS baseline) as well as any new instances of 
suicidality  (C-SSRS since last visit).  The structured interview prompts recollection of 
suicidal ideation, including the intensity  of the ideation, behavior and attempts with 
actual/potential lethality .  The C-SSRS baseline will be collected at baseline and the 
C-SSRS since last visit will be collected at subsequent visits during Parts 1 and 2. 
The C-SSRS will be done at visits indicated in the Schedule of Assessments (for Part3, 
please refer to Table 5, Table 6, Table 7, Table 8, and Table 9).  It will be completed by 
the clinician after interviewing the subject and also the study  partner when in attendance 
at the visit. 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
96/Protocol WN25203 , Version H6. INVESTIGA TIONA L MEDICINA L PRODUCT
6.1 Formulation, Packaging and Labeling
A  antibody -producing cell line was established  
by fermentation of a recombinant  cell line and subsequent purification of 
the antibody .   
 
 
 
  
The study  drug must be stored according to the details on the product label.  RO4909832 
Drug Product should be stored at 28°C and protected from light.   Study  drug packaging 
will be overseen by the Roche clinical trial supplies department and will bear labeling 
with identification required by  law, the protocol number, drug identification, and dosage.
The packaging and labeling of the study  medication will be in accordance with Roche 
standard and local regulations.
Upon arrival of investigational products at the site, site personnel should check them for 
damage and verify  proper identity , quantit y, integrity  of seals and temperature conditions, 
and report any deviations or product complaints to the monitor upon discovery.
6.2 Dose and Schedule of IMP
For details on dosing schedule see Sections 5.1.2, 5.1.4, and 5.1.6.
6.2.1 Dose Modifications, Interruptions, and Delay s
Strict adherence to the planned 
dose regimen is required.  However, a single missed dose 
may not automaticall y result in study  withdrawal. If cognitive assessments were to have 
been done at a missed visit, these may  be rescheduled to the next visit.
For details on dose modification due to MRI  findings see Section 5.1.3.1.
6.3 Preparation and A dministration of the IMP
6.3.1 Preparation and A dministration of the IMP in Parts 1 and 2
Prior to administration, each vial of test drug or placebo needs to be reconstituted with 
Water for Injection using a sterile needle and syringe.    
DO NOT SHAKE AND DO NOT FREEZE VIAL CONTENTS.
 
  Vials will contain either gantenerumab or placebo depending on the dose to be 
delivered.  
 
If reconstitution of the product has taken place in controlled and aseptic conditions 
(including the use of a laminar flow hood), 
the solution can be stored for up to 24 hours 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
97/Protocol WN25203 , Version Hat 2°C8°C and 6 hours at ambient temperature.  Otherwise, the product should beused 
immediately  (within 2 hours) after reconstitution.
The study  medication will be administered as  SC injections in the abdominal area.  The 
SC injections are to be administered slowly   
 
Exposure of the study  medication to direct sunlight in the vial or syringe should be 
avoided.
Parenteral Drug Products should be inspected visually  for particulates prior to 
administration.  Partially  used vials should NOT be re- used.
Other parenterally administered medications should not be mixed with the study  drug. 
Personnel involved in reconstitution of and filling syringes with study  medication must 
not be involved with subject care in the study  nor communicate any observations made 
during the study  drug preparation to any personnel involved in the care of the subject.  
Personnel who reconstitute and/or fill syringes may also give the injections but must 
observe the rules above for those involved in study  drug preparation.
6.3.2 Preparation and A dministration of the IMP in Part 3
Gantenerumab will be available in 2 drug product formulations during Part 3:  
, containing 105 or 225 mg gantenerumab 
ready for SC administration
.
Gantenerumab doses of 105 and 225 mg will be administered SC   
 
  The 1200- mg gantenerumab dose will be administered SC  
  
 
All formulations should be stored at 2C–8°C and protected from light.  The liquid 
formulation in 
 can be stored for up to 6 hours at ambient temperature.  If withdrawal 
from the vial (for the liquid formulation in vial) has taken place in controlled and aseptic 
conditions (including the use of a laminar flow hood), the solution can be stored for up to 
24 hour s at 2C–8°C and 4hours at ambient temperature once prepared; otherwise, the 
product should be used immediately  after withdrawal from the vial.  All drug product 
solutions should be brought to room temperature prior to administration to minimize 
discomfor t during the injection.
6.4 Randomization, Blinding, and Unblinding
Randomization will be performed centrall y using an interactive system (IxRS).  After 
being screened, those subjects who meet all eligibility  criteria will be randomly  assigned, 
within each ApoE 4 genoty pegroup (i.e., 04, 14, 24), to one of three treatment 
groups (gantenerumab 105 mg, gantenerumab 225 mg, or placebo ).  The ratio will be 

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
98/Protocol WN25203 , Version H2active to 1 placebo.  Within the 24 genoty pe all subjects receiving gantenerumab will 
receive 105 mg. Based on the ADNI data, it is expected that for the 04 and 14 
genot ypes receiving gantenerumab, approximately  40% will receive 105 mg and 60% 
will receive 225 mg. 
 Except in circumstances where a health authority , EC or IRB 
requires the subject be told of his/her ApoE genot ype, the individual patient ApoE 
genot ype results will be blinded to the subjects, investigators, and the Sponsor, and will 
be supplied directly  to the IxRS vendor by the testing lab so that the information can be 
incorporated at the t ime of randomization.
Randomization to treatment allocation will also be stratified by geographical region of 
the study  center. 
Subjects participating in the PET substudy  will also be allocated to a study  treatment as 
described above to achieve the ratio 2 active to 1 placebo.
The study  is conducted in a double -blind manner in order to minimize potential bias from 
investigators and subjects.  Except as described in Section 10, the Sponsor will be blinded 
to the study  treatments (randomized and actually  given).  Treatment allocation for 
patients who continue in the optional Part 2 of the study  will continue to be 
double - blinded. 
The Master Randomization or Master Medication list will not be available at the study 
center, to the Roche monitors, project Statisticians or to the project team at Roche.  
Unblinding should not occur except in the case of emergency  situations where knowledge 
of the study  drug assigned would impact subject treatment.  The Investigator should make 
every  effort to contact Roche before unblinding a patient’s treatment assignment, but 
must contact Roche within 1 working day  of the event.  Any  request from the investigator 
for information about the treatment administered to study  subjects for another purpose 
must be discussed with Roche.
When required, unblinding will be performed by  means of an Interactive Voice Response 
System (IVRS) or an equivalent method. 
As per regulatory  reporting requirement, Roche will unblind the identity of the study 
medication for all unexpected serious adverse events that are considered by the 
Investigator to be related to study  drug.   Details of subjects who are unbl inded during the 
study  will be included in the Clinical Study  Report (CSR).
The password -protected and/or encry pted electronic Master Randomization or Master 
Medication List is kept by  Clinical Supply  in their secure sy stem and is only  accessible to 
the Ra ndomization L ist Managers.  No open key  to the code will be available at the study  
center, to the Roche monitors, project statisticians, or to the project team at Roche.
Unblinding for MRI -C, iDMC, and PK/PD analysis groups (which are independent from 
the project team) will be performed according to Roche standard procedures.
During the open label Part 3, gantenerumab treatment will be allocated by IxRS based on 
the titration schedule assigned for the APOE 4 carriers (i.e., 14 and 24) and 
non-carriers (0 4).
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
99/Protocol WN25203 , Version H6.5 Accountability  of IMP and A ssessment of Compliance
6.5.1 Accountability of IMP
The Investigator is responsible for the control of drugs under investigation.  Adequate 
records for the receipt (e.g., Drug Receipt Record) and disposition (e.g., Drug Dispensing
Log) of the study  drug must be maintained.  Accountability  will be assessed by  maintaining 
adequate drug dispensing and return records. 
Accurate records must be kept for each study  drug provided by the sponsor.  These 
records must contain the following: 
 Documentation of drug shipments received from the Sponsor (date received and 
quantity )
 Disposition of unused study  drug not dispensed to subject
A Drug Dispensing Log must be kept current and should contain the following  
information:
 The identification o f the subject to whom the study  medication was dispensed
 The date[s], quantity  of the study  medication dispensed tothe subject
All records and drug supplies must be available for inspection by the Monitor at every  
monitoring visit.
When the study  is completed, the Investigator will return all empt y, partially  used, and 
unused containers of study  drug to Roche unless site has received alternate authorization 
from Roche.  The completed Drug Dispensing Log and Drug Return Record(s) will be 
returned to Roche unless alternate destruction has been authorized by Roche or required 
by local or institutional regulations (Section 6.5.2).  The Investigator's copy  of the Drug 
Return Record(s) must accuratel y document the return of all study  drug supplies to 
Roche.
6.5.2 Assessment of Compliance
Subject compliance will be assessed by maintaining adequate study  drug dispensing 
records.  The Investigator is responsible for ensuring that dosing is administered in 
compliance with the protocol.  Delegation of this task must be clearly  documented and 
approved b y the Investigator.
6.6 Destruction of the IMP/Comparator
Local or institutional regulations may require imm
ediate destruction of used 
investigational medicinal product (IMP) for safety  reasons.  In these cases, it may be 
acceptable for investigational site staff to destroy dispensed IMP before a monitoring 
inspection provided that source document verification i s performed on the remaining 
inventory  and reconciled against the documentation of quantity  shipped, dispensed, 
returned and destroy ed.  Written authorization must be obtained from the Sponsor at 
study  start up before destruction.
If there are any issues with the drug it should be returned to the appropriate Roche 
clinical trial supplies department for long -term storage and not destroy ed.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
100/Protocol WN25203 , Version HWritten documentation of destruction must contain the following:
 Identity  (batch numbers or participant identification numbers) of IMP and 
comparator destro yed
 Quantity  of IMP destro yed
 Date of destruction
 Method of destruction
 Name and signature of responsible person who destroy ed investigational products.
7. SAFETY INSTRUCTIONS A ND GUIDA NCE
7.1 Adverse Events (AEs)
7.1.1 Clinical Adverse Events
According to the International Conference of Harmonization (ICH), an AE is any 
untoward medical occurrence in a subject or clinical investigation subject administered a 
pharmaceutical product ,regardless ofcausal attribution .  An AE can therefore be any 
of the following:
Any unfavorable and unintended sign [including an abnormal laboratory  finding], 
symptom, or disease temporally  associated with the use of a medicinal 
[investigational] product, whether or not considered related to the medici nal 
[investigational] product.  
Any new disease or exacerbation of an existing disease ( a worsening in the 
character, frequency, or severity of a known condition)
Recurrence of an intermittent medical condition (e.g., headache) not present 
at baseline
Any deterioration in a laboratory value or other clinical test (e.g., ECG, 
X-ray) that is associated with symptoms or leads to a change in study 
treatment or concomitant treatment or discontinuation from study drug
Adverse events that are related to a protoco l-mandated intervention, 
including those that occur prior to assignment of study treatment 
(e.g., screening invasive procedures such as biopsies)
A consistent methodology of non -directive questioning should be adopted for 
eliciting adverse event informati on at all patient evaluation timepoints.  
Examples of non -directive questions include the following:
"How have you felt since your last clinic visit?"
"Have you had any new or changed health problems since you were last 
here?"
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
101/Protocol WN25203 , Version H7.1.1.1 Intensity  
All clinical AEs encountered during the clinical study  will be reported on the AE eCRF.  
Intensit y of AEs will be graded on a three -point scale [mild, moderate, severe] and 
reported in detail on the AE eCRF.
Mild Discomfort noticed, but no disruption of normal daily 
activity .
Moderate Discomfort sufficient to reduce or affect normal daily 
activity .
Severe Incapacitating with inability to work or to perform normal 
daily activity .
Note:  Regardless of severity, some events may also meet seriousness criteria.  
Refer to definition of a serious adverse event (see Section 7.1.1.3 ).
7.1.1.2 Drug Adverse Event Relationship (Assessment of Causality of 
Adverse Events)
Relationship of the AE to the treatment should alway s be assessed by the investigator. 
Investigators or their designees should use their knowledge of the patient, the 
circumstances surrounding the event, and an evaluation of any potential 
alternative causes to determine whether or not an adverse event is considered 
related to the study drug, indicating “yes” or “no” accordingly.
To ensure consistency  of causality  assessments, investigators should apply  thefollow ing 
general guidelines:
Temporal relationship of event onset to the initiation of study drug
Course of the event, considering especially the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (where 
applicable)
Known association of the event with the study drug or with similar 
treatments
Known association of the event with the disease under study
Presence of risk factors in the patient or use of concomitant medications 
known to increase the occurrence of the event
Pres ence of non -treatment -related factors that are known to be associated 
with the occurrence of the event
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
102/Protocol WN25203 , Version HCausal Attribution Guidance
Is the AE/SAE suspected to be caused by the investigational product based on facts, 
evidence, science -based rationales, and clinical judgment?
Yes There is a plausible temporal relationship between the onset of the 
adverse event and administration of the study drug, and the adverse 
event cannot be readily explained by the patient's clinical state, 
intercurrent illness, or con comitant therapies; and/or the adverse event 
follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the study 
drug or dose reduction and, if applicable, reappears upon re challenge.   
No An adverse event will be considered related, unless it fulfills the 
criteria specified below.   
Evidence exists that the adverse event has an etiology other than the 
study drug (e.g., preexisting medical condition, underlying disease, 
intercurrent illness, or concomitant medication); and/or the adverse 
event has no plausible temporal relationship to administration of the 
study drug (e.g., cancer diagnosed 2 days after first dose of study 
drug).
7.1.1.3 Serious A dverse Events [Immediately  Reportable to Sponsor ]
A Serious Adverse Event is any AE that at any dose fulfils at least one of the following 
criteria:
 is fatal; [results in death; NOTE: death is an outcome, not an event] 
 is Life-Threatening [NOTE: the term "Life- Threatening" refers to an event in 
which the subject was at immediate risk of death at the time of the event; it does 
not refer to an event which could h ypotheticall y have caused a death had it been 
more severe]
 requires in- patient hospitalization or prolongation of existing hospitalization
 results in persistent or significant disability /incapacity (i.e., the adverse event 
results in substantial disruption of the patient's ability to conduct normal 
life functions)
 is a congenital anomal y/birth defect born to a mother exposed to study drug
 is medically  significant in the investigator’s judgment (e.g., may jeopardize 
the patient or may require intervention to prevent one or other of the outcomes 
listed above )
The terms "severe" and "serious" are not synonymous.  Severity refers to the 
inten sity of an adverse event (e.g., rated as mild, moderate, or severe, see 
Section 7.1.1.1 ); the event itself may be of relatively minor medical significance 
(such as severe headache without any further findings). Severity and seriousness 
need to be independently assessed for each adverse event recorded on the eCRF.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
103/Protocol WN25203 , Version HThe study  will comply  with all local regulatory requirements and adhere to the full 
requirements of the ICH Guideline for Clinical Safety  Data Management, Definitions and 
Standards for Expedited Reporting, Topic E2.
Any adverse event that results in hospitalization (i.e., inpatient admission to a 
hospital) or prolonged hospitalization should be documented and reported as a 
serious adverse event (per the definition of serious adverse event in this section), 
except as outli ned below.
An event that leads to hospitalization under the following circumstances should 
not be reported as an adverse event or a serious adverse event:
 Hospitalization for respite care
 Hospitalization for a pre -existing condition, provided that the fol lowing criteri on
ismet:
The hospitalization was planned prior to the study  or was scheduled during the 
study  when elective surgery  became necessary  because of the expected normal 
progression of a disease present at baseline
 The study subject has not suffered an adverse event
In centers where it is standard practice to hospitalize a subject for an LP for observation, 
this hospitalization itself would not be considered a serious adverse event.  If the 
hospitalization is extended due to an adverse event , this would be considered an SAE.
7.1.1.4 Adverse Events of Special Interest (Immediately Reportable 
to the Sponsor)
Adverse events of special interest are required to be reported by the investigator 
to the Sponsor immediately (i.e., no more than 24hours after learning of the 
event; see Section 7.2.2 for reporting instructions).  Adverse events of special 
interest for this study are as follow s:
 Cases of potential drug -induced liver injury that include an elevated ALT 
or AST in combination with either an elevated bilirubin or clinical 
jaundice, as def ined by Hy's Law (see Section 7.1.2 )
 Suspected transmission of an infectious agent by the study drug, as
defined below
Any organism, virus, or infectious particle (e.g., prion protein 
transmitting transmissible spongiform encephalopathy), pathogenic or 
non-pathogenic, is considered an infectious agent.  A transmission of 
an infectious agent may be suspected from clinical symptoms or 
laboratory findings that indicate an inf ection in a patient exposed to a 
medicinal product.  This term applies only when a contamination of 
the study drug is suspected.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
104/Protocol WN25203 , Version H7.1.2 Laboratory  Test Abnormalities
Laboratory  test results will appear on electronically  produced laboratory  reports 
submitted dire ctly from the central laboratory . 
Any laboratory  result abnormality  fulfilling the criteria for a serious adverse event should 
be reported as such on the AE eCRF.  An y treatment -emergent abnormal laboratory  result 
which is clinicall y significant, i.e., meeting one or more of the following conditions, 
should be recorded as a single event on the AE eCRF:
 Accompanied b y clinical sy mptoms
 Leading to a change in study  medication [e.g., dose modification, interruption or 
permanent discontinuation]
 Requiring a ch ange in concomitant therapy  [e.g., addition of, interruption of, 
discontinuation of, or any  other change in a concomitant medication, therapy  or 
treatment].
 Results in a medical intervention (e.g., potassium supplementation for 
hypokalemia) 
 Is clinically significant in the investigator's judgment
This applies toany protocol and non-protocol specified safety  and efficacy  laboratory 
result from tests performed after signing of the informed consent, which falls outside the 
laboratory  reference range and mee ts the clinical significance criteria.
It is the investigator's responsibility to review all laboratory findings.  Medical 
and scientific judgment should be exercised in deciding whether an isolated 
laboratory abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or 
syndrome (e.g., alkaline phosphatase and bilirubin 5 ULN associated with 
cholestasis), only the diagnosis (i.e., cholestasis) should be recorded on the 
Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or 
syndrome, the abnormality itself should be recorded on the Adverse Event eCRF, 
along with a descriptor indicating whether the test result is above or below the 
normal range (e.g., "elevated potassium," as opposed to "abnormal potassium").  
If the laboratory abnormality can be characterized by a precise clinica l term per 
standard definitions, the clinical term should be recorded as the adverse event.  
For example, an elevated serum potassium level of 7.0 mEq/L should be recorded 
as "hyperkalemia." 
The finding of an elevated ALT or AST (>3ULN) in combination with either an 
elevated total bilirubin (>2ULN) or clinical jaundice in the absence of cholestasis or 
other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury
(as defined by Hy's Law) .  Therefore, Investigators must report as an adverse event of 
special interest (Section 7.1.1.4) if the occurrence of either of the following:
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
105/Protocol WN25203 , Version H Treatment -emergent ALT or AST >3 ULN in combination with total bilirubin 
>2ULN
 Treatment -emergent ALT or AST >3 ULN in combination with clinical 
jaundice.
If a patient develops moderate to severe neutropenia (ANC 1000/mm3) in the absence 
of an identified cause, investigators should consider temporary  discontinuation of the 
study  drug.  Neutrophil counts should be monitored according to the local guidelines.  
Reintroduction of study  drug could be done only after the investigator discusses the case 
with the Sponsor 's Medical Monitor.
7.1.2.1 Follow -up of A bnormal Laboratory  Test Values
In the event of medically  significant unexplained abnormal laboratory  test values, the 
tests should be repeated and followed up until they have returned to the normal range 
and/or an adequate explanation of the abnormalit y is found.  
Observations of the same clinically significant laboratory abnormality from visit 
to visit should only be recorded once on the Adverse Event eCRF.
7.1.3 Abnormal Vital Sign Values
Not every vital sign abnormality quali fies as an adverse event.  A vital sign 
result must be reported as an adverse event if it meets any of the following 
criteria:
 Is accompanied by clinical symptoms
 Results in a change in study treatment (e.g., dosage modification, 
treatment interruption, or treatment discontinuation) 
 Results in a medical intervention or a change in concomitant therapy
 Is clinically significant in the investigator's judgment 
It is the investigator's responsibility to review all vital sign findings.  Medical 
and scientific judgment should be exercised in deciding whether an isolated vital 
sign abnormality should be classified as an adverse event.
If a clinically significant vital sign abnormality is a sign of a disease or 
syndrome (e.g., high blood pressure), only the diagno sis (i.e., hypertension) 
should be recorded on the Adverse Event eCRF.
Observations of the same clinically significant vital sign abnormality from visit 
to visit should only be recorded once on the Adverse Event eCRF.
7.1.4 MRI Observations
Any treatment -emergent MRI  observations, ARIA-E, and ARIA -H, as well as other 
clinically  relevant findings that are clinically significant (i.e., meeting one or more  
of the following conditions) should be recorded as a single event on the AE eCRF:
 Accompan ied by clinical symptoms
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
106/Protocol WN25203 , Version H Leading to a change in study medication (e.g., dose modification, 
interruption or permanent discontinuation )
 Requiring a change in concomitant therapy (e.g., addition of, interruption 
of, discontinuation of, or any other change in a concomitant medication, 
therapy or treatment)
 Results in a medical intervention
 Is clinically significant in the investigator’s judgment
All such MRI  observations will also be compiled in a separate MRI report.  Inaddition, 
adverse events considered tobe symptoms of ARIA will be marked as such in the eCRF.  
These events will be summarized separatel y in the CSR.  Tofurther elucidate potential 
clinical implications of ARIA findings, patients will be asked within 1 week before each 
MRI , by non-directive, unbiased questioning, if they experience CNS adverse events.  
The adverse events collected in this prospective fashion will be distinct from other 
adverse events and summarized separatel y in the clinical study  report.  Additional data on 
associated s ymptoms (as defined on the eCRF) and safet y MRI scans will be collected for 
these adverse events.
7.1.5 Adverse Events Associated with an Overdose or Error in Drug 
Administration
An overdose is the accidental or intentional use of a drug in an amount higher 
than thedose being studied.  An overdose or incorrect administration of any 
drug including study treatment is not itself an adverse event, but it may result 
in an adverse event.  All adverse events associated with an overdose or incorrect 
administration of study drug should be recorded on the Adverse Event eCRF.  
Ifthe associated adverse event fulfills serious criteria, the event should be 
reported to the Sponsor immediately (i.e., no more than 24hours after learning 
of the event; see Section 7.1.1.3 ).
Any study drug overdose or incorrect administration of study drug should be 
noted on the Study Drug Administration eCRF.
7.1.6 Deaths
All deaths that occur during the protocol -specified adverse event reporting period 
(see Section 7.1.1 ), regardless of relationship to study drug, must be recorded on 
the Adverse Event eCRF and immediately reported to the Sponsor (see 
Section 7.2.2).  This includes death attributed to progression of AD. 
Death should be considered an outcome and not a distinct event.  The event or 
condition that caused or contributed to the fatal outcome should be recorded as 
the single medical concept on the Adverse Event eCRF.  Generally, only one such 
event should be reported.  If the cause of death is unknown and cannot be 
ascertained at the time of reporting, "unexplained death" should b e recorded on 
the Adverse Event eCRF.  If the cause of death later becomes available (e.g., after 
autopsy), "unexplained death" should be replaced by the established cause of 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
107/Protocol WN25203 , Version Hdeath.  The term "sudden death" should not be used unless combined with the 
presu med cause of death (e.g., "sudden cardiac death").
If the death is attributed to progression of AD, "Alzheimer’s disease
progression" should be recorded on the Adverse Event eCRF.
7.2 Handling of Safety  Parameters
7.2.1 Reporting of A dverse Events
Collection of adverse events begins at the time the informed consent is signed and 
continues throughout the study , including the follow -up period.  All AEs will be recorded 
in detail on the source documents and on the AE eCRF for subjects who are randomized 
to study  treatment.
7.2.2 Reporting of Serious A dverse Events and Adverse Events of 
Special Interest [Immediately  Reportable]
For reports of serious adverse events and adverse events of special interest, 
investigators should record all case details that can be gathered imme diately  
(i.e., within 24hours) on the Adverse Event eCRF and submit the report via the 
electronic data capture (EDC) system.  A  r eport will be generated and sent to 
Roche Safety Risk Management by the EDC system.
In the event that the EDC system is unavailable, a paper Serious Adverse Event 
Reporting Form and fax cover sheet should be completed and faxed to Roche 
Safety Risk Management or its designee immediately (i.e., no more than 24 hours 
after learning of the event).  Once the EDC system is available, all information 
will need to be entered and submitted via the EDC system.
After informed consent has been obtained , but prior to initiation of study  medication, 
only SAEs caused by a  protocol -mandated intervention will be collected (e.g., SAEs 
related to MRIs or invasive procedures such as lumbar punctures).   After initiation of 
study drug, alladverse events, regardless of relationship to study drug, will be 
reported until the last visit .  After this period, the investigator should report any 
serious adver se events that are believed to be related to study drug treatment.
Related Serious Adverse Events MUST be collected and reported regardless of the time 
elapsed from the last study drug administration, eve n if the study  has been closed.
Unrelated Serious Adverse Events must be collected during the study  until the last 
study visit.
If the study  is closed but a SAE occurs within required reporting period, the SAE 
worksheet is used to report the event to the sponsor.
This study  adheres to the definition and reporting requirements of ICH Guideline for 
Clinical Safety  Data Management, Definitions and Standards for Expedited Reporting, 
Topic E2.  Complete information can be found in Appendix 1.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
108/Protocol WN25203 , Version H7.2.3 Reporting of Pregnancy
A female subject must be instructed to immediately  inform the Investigator if she 
becomes pregnant during the study .  She will then be discontinued from study 
medica tion.  The Investigator should report all pregnancies within 24 hours to the 
Sponsor.  The Investigator should counsel the subject; discuss the risks of continuing 
with the pregnancy  and the possible effects on the fetus.  Monitoring of the subject 
should continue until conclusion of the pregnancy .  Pregnancies that occur up to 
16weeks after the last dose of study  medication must also be reported to the Investigator.
The site must report the pregnancy  on the Pregnancy  Report eCRF for randomized 
subjects.  If the study  is closed but pregnancy  occurs within required reporting period, the 
Pregnancy  Report worksheet is used to report the event to the sponsor.
Any spontaneous abortion should be classified as a serious adverse event 
(because the Sponsor considers spontaneous abortions to be medically significant 
events), recorded on the Adverse Event eCRF, and reported to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event).
Any congenital anomaly/birth defect in a child born to a fema le patient should be 
classified as a serious adverse event, recorded on the Adverse Event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24hours after learning 
of the event).
7.2.4 Reporting Requirements for Medical Device Complaints
The inve stigator must report all medical device complaints (e.g., devices for 
study drug administration) to the Sponsor.  The investigator should document as 
much information as possible on the IMP Deviation Form, including the product 
batch number, and forward the form to the Sponsor immediately (i.e., no more 
than 24hours after learning of the event) (refer to the pharmacy manual for 
further details).  If the medical device results in an adverse event to the study 
patient, the event must be reported on the Adver se Event eCRF and submitted 
through the EDC system.  If the event is serious, the Adverse Event eCRF must 
be completed immediately (i.e., no more than 24hours after learning of the 
event).
7.2.5 Expedited Reporting to Health Authorities, Investigators, 
Institutional Review Boards, and Ethics Committees
Any treatment -emergent SAE deemed related to gantenerumab will be reported 
as a suspected unexpected serious adverse reaction (SUSAR) and will be reported 
to investigat ors at each site and associated Institutional Review Boards
(IRBs)/ Ethics Committees (ECs) .
The Sponsor will promptly evaluate all serious adverse events and adverse events 
of special interest against cumulative product experience to identify and 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
109/Protocol WN25203 , Version Hexpeditio usly communicate possible new safety findings to investigators, IRBs, 
ECs, and applicable health authorities based on applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor 
will assess the expectedness of th e events using the Gantenerumab IB.
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
Gantenerumab IB.
Reporting requirements will also be based on the investigator’s assessment of 
causality and seriousness, with allowance for upgrading by the Sponsor as 
needed.
7.2.6 Recording A dverse Events on the eCRF
Investigators should use correct medical terminology /concepts when recording AEs or 
SAEs on the AE eCRF.  Avoid colloquialisms and abbreviations.
Only  one medical concept should be recorded in the event field on the AE eCRF.
In general, adverse events that are secondary to other events (e.g., cascade events 
or clinical sequelae) should be identified by their primary cause, with the 
exception of severe or serious secondary events.  A medically significant 
secondary adverse event that is separated in time from the initiating event 
should be recorded as an independent event on the Adverse Event eCRF.  For 
exampl e:
 If vomiting results in mild dehydration with no additional treatment in a 
healthy adult, only vomiting should be reported on the eCRF.
 If vomiting results in severe dehydration, both events should be reported 
separately on the eCRF.
 If a severe gastrointestinal hemorrhage leads to renal failure, both events 
should be reported separately on the eCRF.
 If dizziness leads to a fall and consequent fracture, all three events should 
be reported separately on the eCRF.
 If neutropenia is accompanied by an infection, both events should be 
reported separately on the eCRF.
All adverse events should be recorded separately on the Adverse Event eCRF if it 
is unclear as to whether the events are associated.
A persistent adverse event is one that extends conti nuously, without resolution, 
between patient evaluation timepoints.  Such events should only be recorded once 
on the Adverse Event eCRF, unless the severity increases.  If a persistent adverse 
event becomes more severe, it should be recorded as a separate event on the 
Adverse Event eCRF.  The initial (less severe) adverse event report should be 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
110/Protocol WN25203 , Version Hupdated to indicate that the event resolved on the date just prior to the day the 
event became more severe.  If a persistent adverse event becomes serious, it 
should be recorded as a separate event on the Adverse Event eCRF and reported 
tothe Sponsor immediately (i.e., no more than 24hours after learning that the 
event became serious; see Section 7.2.2 for reporting instructions).  The initial 
(non -serious) adverse event report should be updated to indicate that the event 
resolved on the date just prior to the day the event became serious.
A recurrent adverse event is one that resolves between patient evaluation 
timepoints and subsequently recurs.  Each recurrence of an adverse event should 
be recorded separately on the Adverse Event eCRF.
Individual signs and symptoms of injection -site reactions (e.g., erythema, 
pruritus, pain) should be reported on the dedicated Injection Site Reaction eCRF.  
The overall diagnosis of injection site reaction should be captured on the Adverse 
Event eCRF.  Systemic reactions should be recorded as a single diag nosis.
For adverse events other than injection -related reactions, a diagnosis (if known) 
should be recorded on the Adverse Event eCRF rather than indiv idual signs and 
symptoms (e.g., record only liver failure or hepatitis rather than jaundice, 
asterixis, and elevated transaminases).  However, if a constellation of signs 
and/or symptoms cannot be medically characterized as a single diagnosis or 
syndrome at the time of reporting, each individual event should be recorded on 
the Adverse Event eCRF.  Ifa diagnos is is subsequently established, all 
previously reported adverse events based on signs and symptoms should be 
nullified and replaced by one adverse event report based on the single diagnosis, 
with a starting date that corresponds to the starting date of thefirst symptom of 
the eventual diagnosis
7.2.7 Follow -up of Patients after Adverse Events
7.2.7.1 Investigator Follow -Up
The investigator should follow each adverse event until the event has resolved to 
baseline grade or better, the event is assessed as stable by the investigator, the 
patient is lost to follow -up, or the patient withdraws consent.  Every effort 
should be made to follow all serious adverse events considered to be related to 
study drug or trial -related procedures until a final outcome can be reported.
During the study period, resolution of adverse events (with dates) should be 
documented on the Adverse Event eCRF and in the patient's medical record to 
facilitate source data verification.
All pregnancies reported during the study should be followed until pregnancy 
outcome.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
111/Protocol WN25203 , Version H7.2.7.2 Sponsor Follow -Up
For serious adverse events, adverse events of special interest, and pregnancies, 
the Sponsor or a designee may follow up by telephone, fax, email, and/or a 
monitoring visit to obtain additional case details and outcome information 
(e.g., from hospital discharge summaries, consultant reports, autopsy reports) in 
order to perform an independent medical assessment of the reported case .
7.3 Safety Plan
To date, ARIA findings and injection site reactions are the identified risks of 
gantenerumab. 
Detailed information about ARIA findings is provided in Section 1.3.3 .   
  Incase of 
clinical symptoms, the use of IV glucorticosteroids may be considered .
Concerning injection site reactions, gantenerumab is generally well tolerated by 
patients.  Injection -site reactions have been observed in up to one-third of 
healthy volunteers after SC administration (Section 1.1.2.2 ).  As of 13February 
2018, injection site reactions have been reported in 25.3% and 29.8% of patients 
treated with gantenerumab in the OLE periods of Study WN25203 and Study 
WN28745, respectively.  All injection site reactions were non-serious, with the 
majority being mild and resolving without treatment.  Approximately 10% of 
patients who had injection site reactions required treatment, which included 
topical steroids and antihistamines.
No gantenerumab -related immunogenicity reactions of major clinical relevance 
have emerged to date.  Patients should be monitored for and alerted to the risk of 
any symptoms of hypersensitivity reactions.
Refer to the Gantenerumab IB for information about identified and potential 
risks.
8. STA TISTICA L CONSIDERA TIONS AND ANALYTICA L PLA N
The plans for the statistical analy sis of the data recorded during Part 1, the first 
24months of double -blind treatment are summarized below.  The plans for the analysis 
of the data recorded during Part 2, the extension are described in section 8.6.  The plans 
for the analysis of the data recorded during Part 3, the open -label extension are described 
in Section 8.7.
8.1 Primary  and Secondary  Study  Endpoints 
8.1.1 Primary  Efficacy  Endpoint
Change from baseline in C DR-
SOB score at Week 104.

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
112/Protocol WN25203 , Version H8.1.2 Secondary  Efficacy  Endpoints
8.1.2.1 Cognition –Change from Baseline at Week 104 in the 
Follow ing
 Alzheimer’s Disease Assessment Scale – Cognition (ADAS- Cog) total score
 Mini Mental State Exam (MMSE) total score
 CANTAB –selected subtest scores
Simple Reaction Time (RTI ) 
Simple Movement Time (RTI) 
5-Choice Reaction Time (RTI) 
Delay ed Match to Sample (DMS) 
Spatial Working Memory  (SWM) 
Pattern Recognition Memory  (PRM) immediate
Pattern Recognition Memory  (PRM) delay ed
Rapid Visual Information Processing (RVP)
Paired Associates Leaning (PAL)
 FCSRT -IR
8.1.2.2 Global
 CDR global score at Week 104
8.1.2.3 Functioning
 FAQ total score change from baseline at Week 104
8.1.2.4 Neuropsy chiatric Functioning
 Neurops ychiatric Inventory (NPI -Q) –total and domain scores change from 
baseline at Week 104
8.1.2.5 Dementia A ssessment
 Time from baseline to development of dementia
8.1.2.6 MRI Volumetric Measures
 Hippocampal volume change from baseline
 Whole brain volume change from baseline
 Ventricular enlargement change from baseline
 Change from baseline in other volumetric measures such as cortical thickness 
8.1.2.7 Cerebrospinal Fluid Biomarker Measures
 Change from baseline in CSF T- tau, P -tau, and A 1-42 levels
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
113/Protocol WN25203 , Version H8.1.3 Safety
 MRI  safet y findings: inflammation (such as that found on FLAIR sequences), 
microbleeds and other.
 Adverse events
 Physical and neurological examination
 GDS
 C-SSRS
 Vital signs
 ECG
 Clinical laboratory  results
8.1.4 Pharmacokinetics 
 Cmax
 Time to peak concentration (T max)
 Trough plasma concentration at steady  state (C min)
 Area under the time -plasma concentration curve at steady  state (AUC 0-τ)
Other parameters determined from the pharmacokinetic model will be regarded as 
secondary .  Potential covariates for the model will be explored as appropriate.
8.1.5 Exploratory  Endpoints
8.1.5.1 Plasma Biomarkers
 Plasma A 1-40and A 1-42change from baseline
8.1.5.2 Genotype
The following information will be used to assess its impact on efficacy  and safet y:
 ApoE genot ype
 FcR genot ype
8.2 Statistical and A nalytical Methods
All efficacy  data in Part 1, up to week 104 will be evaluated in the following manner:
 Each of the two gantenerumab dose groups (i.e., 105 mg or 225 mg) versus 
placebo.  The gantenerumab 225 mg group will include only subjects with the 
ApoE 04 and 14 types; therefore, for the primary  compariso n of the 
gantenerumab 225 mg group to placebo, the comparator group will include the 
subset of placebo subjects who have the ApoE 04 and 14 types.  For the 
primary  comparison of the gantenerumab 105 mg group to placebo, the 
comparator group will be the entire set of subjects randomized to placebo.  The 
primary  inferential statistics will be applied to the pairwise comparisons of each 
of the 2 gantenerumab dose groups to the corresponding placebo group.
 All gantenerumab dose groups combined (i.e., 105 mg plus 225 mg) versus 
placebo for overall assessments regardless of the ApoE genoty pe.  All placebo 
subjects will be pooled. 
All analy ses in Part 2 will be considered exploratory .
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
114/Protocol WN25203 , Version H8.2.1 Efficacy  Data
8.2.1.1 Primary  Efficacy  Variable
For the assessment of differences between each gantenerumab group and placebo with 
regard to the mean change from baseline in the CDR SOB score at week 104, a 
mixed -effects MMRM analy sis incorporating data up to 104weeks of treatment will be 
used to utilize all the data collected over time with consideration of the variance -
covariance matrix of the repeated measures.  This method allows a general unstructured 
variance -covariance matrix and enables to include data from subjects with incomplete 
data across scheduled time points. 
The following null (H0) and alternative (Ha) hypotheses will be tested to compare the
mean change values between each of the gantenerumab groups and placebo group:
H0: MEAN RO   =   MEAN placebo    versus 
Ha: MEAN RO   ≠   MEAN placebo
where MEAN RO and MEAN placeborefer to mean change of gantenerumab and placebo, 
respectivel y.
The model will include the change from baseline in the CDR –SOB score as the 
dependent variable.  The effects in the model will include independent variables of the 
fixed, categorical effe cts of treatment, assessment weeks relative to the first dose of study 
medication (i.e., time), and treatment -by-time interaction, and ApoE status (carrier vs. 
non-carrier), along with covariate sof the baseline value and hippocampal volume at 
baseline.  Time will be treated as the repeated variable within a subject.  Subject, 
treatment, and time will be treated as class variables.  An unstructured 
variance -covariance structure will be applied to model the within -subject errors. 
As a sensitivity  analysis for the primary  efficacy  variable, the MMRM model excluding 
the hippocampal volume at baseline covariate will also be run.  Sensitivity  analyses will 
also be performed excluding the ApoE4 genot ype carrier status as an additional fixed 
effect in the statisti cal model in order to assess the impact of this factor on the primary 
and selected secondary  efficacy  variables.
Sensitivity  analyses to assess the impact of missing data on the primary  efficacy  endpoint 
results will be performed using multiple imputation and pattern- mixture method models.
Additional details will be provided in the Statistical Analy sis Plan.
A treatment -by-time interaction contrast will be constructed to estimate the difference 
between each of the gantenerumab doses and placebo in mean change from baseline to 
week 104.  Based on the analysis above, least square means, standard errors, and the 
95% confidence intervals of treatment difference will be reported for each dose of 
gantenerumab against placebo.
In order to adjust for the multiplicity  in the pairwise comparisons of each gantenerumab 
dose to placebo, a hierarchical testing procedure will be used.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
115/Protocol WN25203 , Version H8.2.1.2 Secondary  Efficacy  Variables
Continuous Variables
The secondary  efficacy variables of the continuous type with multiple post-baseline 
schedu led assessments will be analy zed using the same methods described above for the 
primary  efficacy  variable:  MMRM including the covariate of hippocampal volume at 
baseline . 
Time -to-Event Variable
The time-to-onset of dementia from baseline will be analyzed using an un-stratified log 
rank test.  The following hy pothesis will be tested:
H0:There is no difference in the survival functions between the gantenerumab (RO) and 
placebo (pbo) group: 
         SUR RO = SUR pbo,      where SUR denoted the distributio n function.
Ha: there is a difference in the survival function between the gantenerumab (RO) and 
placebo (pbo) group: 
     SUR RO ≠ SUR PBO,   where SUR denoted the distribution function.
In addition, a stratified log rank test of treatment difference will be performed as an 
exploratory  analysis of this variable, using ApoE genot ype status (carrier vs. non-carrier) 
as a stratification factor.  If the number of events observed in any treatment
-by-genot ype 
status cell is less than 2, then this exploratory analy sis will not be performed.  Additional 
exploratory  analyses will be performed as appropriate using clinicall y relevant covariates 
such as baseline biomarker variables.  For this variable, the principal analysis results will 
be those generated using t he unstratified log -rank test.
When comparing time-to-event endpoints between treatment groups, it is important to 
assess whether there are systematic differences in the completeness and duration of 
follow -up.  Summaries of follow -up duration by treatment group will be provided for all 
subjects and for subjects who have not had an event yet.  The duration of follow -up will 
be calculated as the interval (days) from the first day of study  treatment to the event or 
date last known to have not the event.  
8.2.2 Safe ty Data 
All safet y variables will be summarized for each assessment time (including follow -up) 
using descriptive statistics.  Incidence of adverse events will be summarized by  treatment 
group based on body  systems and dictionary  preferred terms.  Incidenc e of marked 
abnormal lab test results will be summarized.  All the GDS ratings, anti-drug antibody , 
lab tests, ECG, and vital signs will be summarized (e.g., mean, median, SD or frequency
of abnormalities ) for each assessment time by treatment group. ECG data will also be 
analyzed to evaluate treatment effect on QT parameters as described in the FDA guidance 
document. 
All the safety  data collected during the follow -up period (i.e., after discontinuation of 
study  treatment) will be summarized separately from the data collected during the 
treatment period.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
116/Protocol WN25203 , Version HNumber (%) of subjects with MRI  safety  findings will be summarized at each scheduled 
visit by  treatment and MRI  safet y finding t ypes.  In addition, number (%) of subjects with 
MRI  findings will be summariz ed by  ApoE genoty pes and MRI  safet y finding t ypes.
8.2.3 Exploratory  Analysis
The following 2 types of analyses will be performed to explore association of the 
treatment effect with the subject’s genot ypes and biomarkers:
 To assess influence of the ApoE and FCγR genoty pes on the gantenerumab 
treatment effect, the primary  efficacy  variable and selected safety parameters will 
be summarized by  each of the genot ypes.  Inferential statistics may be applied in 
case the difference is clinically  relevant.
 To evaluate eff ect of gantenerumab treatment on changes in plasma A 1-40and 
A1-42biomarkers; changes will be summarized for each treatment group, 
i.e.,each dose of gantenerumab and placebo.  
8.2.4 Subgroup A nalyses
The results of selected efficacy  and safet y variables wi ll be summarized within subgroups 
using descriptive statistics.  Additional exploratory  analyses of efficacy results may be 
performed using an MMRM model, with the subgroup, a treatment -by-subgroup 
interaction, and a subgroup -by-time interaction terms included along the independent 
effects described above.  Such exploratory  analyses will be performed primarily  in the 
case where the descriptive statistics results indicate substantial differences between the 
subgroups.
The following variables will be used to define the subgroups for these analy ses:
 Sex
 Age
 Race
 ApoE status
 FcR genot ype
 Region
8.3 Sample Size
The comparison of the gantenerumab 225 mg arm to the placebo arm will include 
primary  efficacy  results from the approximately  257 subjects randomized to 
gantenerumab 225 mg, and the approximately  213 ApoE 04 and 14 subjects 
randomized to placebo.  A
 total of 770 subjects will warrant at least 80% power in 
demonstrating an effect size of 0.35 (gantenerumab 225 mg vs. placebo) at the 
type Ierror level of p0.05 (2 -sided).  In order to protect the overall type I error at the 
0.05 level, a hierarchical testing procedure will be used in which the first hy pothesis to be 
tested will be the comparison of the gantenerumab 225 mg group to the corresponding 
placebo group.  The second test, comparing the gantenerumab 105 mg group to the 
placebo group, will be carried out only if the first test is statistically  significant at the 
2-sided 0.05 level. 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
117/Protocol WN25203 , Version HThe power calculation was based on simulations of the MMRM analysis planned for 
analysis of the primary  efficacy  variable.  The following assumptions were included:
 4 post -baseline assessment visits at Weeks 24, 52, 76, and 104.
 Overall dropout rate of 30% at Week 104 for both placebo and active treatment 
group, inc remental rates over the 104 week period.
 Effect sizes of 0.35 (gantenerumab 225 mg vs. placebo) and 0.25 (gantenerumab 
105mg vs. placebo) at Week 104 assuming increasing magnitude of treatment 
difference over the 104 weeks period . 
 A correlation structure with stronger correlations for assessments that are adjacent 
in time and weaker between assessments that are further apart.
 About 5% reduction in sample size with hippocampal volume at baseline as a 
covariate in the anal ysis.
The sample size was confirme d following a planned blinded evaluation of the variance in 
the change in the CDR -SOB at Week 76 (Section 10.2.2).
8.3.1 Analysis Population s
8.3.1.1 Safety  Population
The safet y population will consist of all subjects who have received any dose of study  
medication, whether withdrawn prematurel y or not.  All safety  data will be analy zed 
according to the medication actuall y taken.
8.3.1.2 Intent -to-Treat Popul ation
The intent -to-treat (ITT) population will include all subjects who received any dose of 
study  treatment and had at least 1 post-baseline assessment of CDR SOB.  The ITT 
analysis will be done by  randomized treatment. 
The ITT population will be the primary  population for all analy ses of primary  and 
secondary  efficacy  variables as well as the imaging and biomarker and clinical efficacy 
variables.
8.3.1.3 Per-Protocol Population
The per-protocol (PP) population may be defined as a subset of the intent -to-treat 
population.  Definition of the PP population will be finalized before the clinical database 
closure and will be documented in the analysis plan.  The definition will include those 
who did 
not have any major protocol violations that affect efficacy  evaluatio n.  For the 
PP population analy sis, data will be analyzed according to the treatment actuall y taken.  
The primary  efficacy  variables will be analyzed including the PP population when there 
is a more than 10% difference in number of subjects between ITT and PP population.
8.4 Interim Analysis 
Two interim anal yses will be performed, as described in Section 10.2. 
8.5 Other A nalyses
8.5.1 Pharmacokinetic A nalysis
Nonlinear mixed effects modeling will be used to analy ze the dose-concentration -time 
data of gantenerumab.  Information from 
other studies in humans may be incorporated to 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
118/Protocol WN25203 , Version Hestablish the pharmacokinetic model.  The selection of parameters and the derivation of 
individual measures of exposure, such as AUC 0-τ, C max, and trough concentrations 
(Ctrough) will depend on the final pharmacokinetic model used for this analy sis.  All 
pharmacokinetic parameters will be presented by listings and descriptive summary  
statistics including arithmetic mean (for AUC 0-τ, C max, and Ctrough), median, range, 
standard deviation, and CV.  Results of this analy sis will be reported separately . 
If appropriate, concentration -effect relationships may be explored and modeled post hoc 
for pharmacod ynamic, efficacy or safety measures.
8.6 Analysis Considerations for Data Collected during Part 2, 
the Extension Period for Continued Double -Blind 
Treatment
All data collected during Part 2 the extension will be summarized using descriptive 
statistics as described above.  No formal hypothesis testing or inferential statistics will be 
performed for the data collected during this extension period.
All subjects included in the safet y and ITT populations (as defined in Sections 8.3.1.1
and 8.3.1.2) who choose to continue double -blind treatment after dose 26 will be included 
in the respective anal ysis populations for the anal ysis of the extension period data.
For all anal yses of efficacy  data collected during Part 2, the extension period, a sensitivity 
analysis will be performed in which subjects who start symptomatic treatments for 
Alzheimer’s disease will be censored for purposes of analysis at the time at which the 
treatment is initiated.  Any  efficacy  assessments made after the start of such symptomatic 
treatments will be flagged as such in data listings. 
8.7 Analysis Considerations for Data Collected during Part 3 
–
the Open -Label Extension
Statistical analy ses will primarily  focus on safet y aspects during and after the up-titration 
phase in Part 3 of the trial.  In addition, it is planned that 
efficacy  analyses will be 
conducted on cognitive and functional measures as well as biomarkers.  It is planned that 
efficacies will be calculated using both, the original, drug-naïve baseline as well as the 
baseline that gets available before start of Part 3.  Results of these analy ses will be 
interpreted in an exploratory  fashion.  The number of subjects enrolled in Part 3 
is154.
9. DATA COLLECTION , MANAGEMENT AND QUA LITY ASSURA NCE
The overall procedures for quality  assurance of clinical study  data are described in the 
Roche Standard Operational Procedures.
Electronic Case Report Forms are to be completed by the site using the Medidata Rave 
Electronic Data Capture (EDC) sy stem.  Sites will transcribe data from source documents 
onto the eCRFs.  In no case is the eCRF to be considered as source data for this trial.  
Sites will receive training and help text for appropriate eCRF completion.  eCRFs will be 
electronically transmitted to Roche and should be handled in accordance with instructions 
from Roche.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
119/Protocol WN25203 , Version HIn the event of discrepant data, Roche will electronically request data clarification from 
the sites, which the sites will resolve electronically , in the EDC system.  Roche will 
produce an EDC Study  Logic and Check Specification document that describes the data 
quality  checking to be performed on the data in Rave.
Accurate and reliable data collection will be assured by verifica tion and cross –check of 
the eCRFs against the Investigator’s source documents by the study  monitor (source 
document verification), and the maintenance of a drug–dispensing log by the 
Investigator.
A comprehensive validation check program utilizing front -end checks in the eCRF and 
back -end checks in the Roche data base will verify  the data and discrepancies will be 
generated accordingl y.  These are transferred electronicall y to the eCRF at the site for 
resolution by  the Investigator.
Throughout the study  thestudy  management team (SMT) will review data according to 
the SMT I ntegrated Data Review Plan.
9.1 Assignment of Preferred Terms and Original Terminology
For classification purposes, preferred terms will be assigned by the Sponsor to the 
original terms entere d on the eCRF, using the most up-to-date version of the Medical 
Dictionary  for Regulatory  Activities (MedDRA) terminology  for adverse events and 
diseases and the Genentech Drug Dictionary  for treatments and surgical and medical 
procedures.
10. REVIEW OF RESULT S DURING THE CONDUCT OF THE S
TUDY
10.1 Review  of Safet y Data
The study  will have 2 committees for the purpose of reviewing and recommending 
actions to be taken on the basis of safety  data.  There will be an independent MRI -C as 
well as a separate iDMC.  Each committee is described briefl y below and each will have 
a separate charter providing specifics on the operations of the committee, including how 
the treatment disclosures will be managed.
10.1.1 MRI Review Committee
The MRI -C will review any relevant new MRI findin gs identified by the MRI central 
reader and will provide guidance on the management of subjects, taking into account the 
guidelines in the protocol.  The committee may  request that measures in addition to those 
in the protocol be undertaken (e.g., a repeat MRI earlier than 4 weeks).  The committee 
can also make recommendations to alter the protocol procedures for the management of 
subjects with MRI  abnormalities as well as recommendations for amendments to the 
protocol.  During Parts 1 and 2, the committee reviewed MRI findings as described in 
Section 5.1.3 and5.1.4.3 , respectivel y.  In Part 3, the committee will review relevant 
MRI  findings as defined in the MRI -C Charter.  
10.1.2 Independent Data Monitoring Committee
An external fully iDMC, composed of three physicians and one statistician, met 
periodicall y as specified in the Charter to review the safet y and key efficacy  results from 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
120/Protocol WN25203 , Version Hthe double -blind treatment phase.  This committee was also provided with all new 
significant safet y data events as they occurred, including relevant new MRI  findings, and 
could have ad hoc meetings as necessary .  This committee could request the study  to be 
amended or terminated based on their findings (see also Section 10.2.3 Futility  Anal ysis). 
During the Part 3, the iDMC reviewed safety findings until the majority of 
subjects had reached the target dose.  Significant MRI findings during Part 3 
will continue to be reviewed by the IMC and by the MRI -C as documented in the 
MRI -C charter.  Any new relevant findings identified either through the IMC or 
MRI -C may be submitted to the Phase III studies (WN29922 and WN39658) 
iDMC.
10.2 Interim Analysis 
Two interim analy ses, and one blinded sample size assessment, were planned.  The 
specifics of each analy sis were documented prior to its conduct in the Statistical Analy sis 
Plan.
10.2.1 Administrative Interim A nalysis
The administrative interim analy sis was conducted approximately  when the Week 52 
visit for the 200th subject randomized was scheduled to occur.  The main purpose of this 
review was to assess whether preparations for an additional adequate and well-controlled 
study  should begin.
The review included unblinded PET scan results, safet y (including safety  MRI), ADA, 
biomarkers and pharmacokinetics.  No efficacy  data were included in this administrative 
interim analy sis.
The type I error rate was not to be adjusted for this interim analy sis as it is administrative 
(i.e., to ga te the next steps of the development program).
The results will not be communicated to any of the study  team members.  The interim 
analysis results will be evaluated by  the independent data monitoring committee and by a
Roche review board that includes only senior Roche managers/scientists who are entirel y 
separate from the study  team.  The Roche review board will not communicate any of the 
interim analy sis results to any Roche personnel involved in the conduct of 
Study WN25203.
10.2.2 Sample Size A djustment
At the time of the administrative interim analysis, a blinded evaluation of the observed 
variability  in the absolute change from baseline in CDR -SOB at Week 76 was also 
performed.  The analysis time point of Week 76 was selected for this analysis, as the 
numb er of subjects with available data at Week 104 would be insufficient to perform a 
meaningful anal ysis at this time.
Based on the data available at the time of the interim analysis, a point estimate and 
1-sided 80% confidence bound for the standard deviatio n of the absolute change from 
baseline in CDR -SOB at Week 76 was  calculated with the following assumption:  if 
these results indicate a value substantially  higher than the assumed value for this standard 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
121/Protocol WN25203 , Version Hdeviation that was used in the process of determini ng the sample size (for example, if the 
lower bound of the confidence interval exceeds the assumed standard deviation value of 
1.44), then the Sponsor will consider increasing the sample size of the study in order to 
maintain the desired power.  The increa se in sample size resulting from this analy sis 
would be no more than 190 subjects (i.e., an increa se from 770 to no more than 
960subjects), with the magnitude of the sample size increase depending on the number 
of subjects needed to maintain at least 80% power for the hypothesis testing of the 
primary  endpoint.  Based on the results of this analysis, the sample size remained as 
originall y calculated (770 subjects).
10.2.3 Futility Analysis
A futility  interim analysis was performed approximately  when 50% of the sample size 
was scheduled to complete the Week 104 visit.  This analysis was performed by the 
independent data coordinating center (iDCC) that generates the unblinded results 
reviewed by the iDMC on a regular basis, as described in Section 10.1.2.  The iDMC 
reviewed the unblinded results for the primary  efficacy  endpoint (absolute change from 
baseline in CDR -SOB at Week 104).  The analysisof the primary  endpoint results at the 
time of this interim analy sis indicated that the predictive probability  of success for the 
trial is less than a pre-specified threshold, and the committee recommended that the trial 
could be terminated for futility . The iDMC communicated to the Roche Data Review 
Board only this recommendation (whether or not to either stop the study  for futility ); 
detailed results of the primary  efficacy  analysis were not shared with the Sponsor.  The 
Roche Data Review Board has accepted this recommendation, and the dosing was 
suspended on 19 December 2014.  
No adjustment for multiple comparisons was to be made to the α
-level for this analysis, 
as the decision rules for the futility  analysis will not allow for the opportunity  to stop the 
study  early for overwhelming efficacy.
The specifics of the analy sis were documented prior to its conduct in an Interim Data 
Analy sis Plan . 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
122/Protocol WN25203 , Version H11. REFERENCES
1. Kurz A, Perneczk y P. Amyloid clearance as a treatment target against Alzheimer's 
disease. J Alzheimers Dis 2011;24 Suppl 2:61-73.
2. Sperling R, Salloway  S,  Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, 
Sabbagh M, Honig LS, Porsteinsson AP, L ieberburg I. Amyloid-related imaging 
abnormalities (ARIA) in Alzheimer’s disease patients treated with bapi neuzumab: 
A retrospective anal ysis.Lancet Neurology  2012; 11: 241 –249. 
3.
Dubois- Bruno, Feldman -Howard -H, Jacova -Claudia, Dekosky -Steven -T, 
Barberger -Gateau -Pascale, Cummings- Jeffrey , Delacourte -André, Galasko-
Douglas, Gauthier -Serge, Jicha -Gregory , Meguro- Kenichi, O -brien -John, 
Pasquier -Florence, Robert -Philippe, Rossor -Martin, Salloway -Steven, Stern -
Yaakov, Visser -Pieter- J, Scheltens- Philip. Research criteria for the diagnosis of 
Alzheimer's disease: revising the NINCDS -ADRDA criteria. Lancet neurology , 
Aug 2007, vol. 6, no. 8, p. 734-46.
4. Petersen -R-C, Aisen-P- S, Beckett - L-A, Donohue -M-C, Gamst-A- C, Harvey -D-J, 
Jack-C-R- Jr, Jagust -W-J, Shaw-L-M, Toga-A- W, Trojanowski -J-Q, Weiner -M-
W. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical 
characterization. Neurology, 19 Jan 2010, vol. 74, no. 3, p. 201-9.
5. Petersen -RC, Thomas -RG, Grundman- M, Bennett -D, Dood y-R, Ferris -S, 
Galasko -D, Jin -S, Kay e-J, Levey -A, Pfeiffer -E, Sano -M, van- Dyck-CH, Thal -LJ. 
Vitamin E and donepezil for the treatment of mild cognitive impairment. The 
New England journal of medicine, 9 Jun 2005 vol. 352, no. 23, p. 2379-88.
6. Blennow -Kaj, Hampel -
Harald, Weiner- Michael, Zetterberg -Henrik. 
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature reviews. 
Neurolog y, Mar 2010, vol. 6, no. 3, p. 131- 44, ISSN: 1759 -4766.
7. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K and Minthon L: 
Association between CSF biomarkers and incipient Alzheimer’s disease in 
patients with mild cognitive impairment: a follow- up stu dy. Lancet Neurol 2006. 
5: 228 -234.
8. Mattson- N, Zetterberg -H, Hansson -O, et al. CSF Biomarkers and Incipient 
Alzheimer Disease in Patients with Mild Cognitive I mpairment. JAMA 2009. 
302(4): 385-388.
9. Shaw- LM et.al. Cerebrospinal fluid biomarker signature in Alzheimer's disease 
neuroimaging initiative subjects. Ann Neurol. 2009 65:403-13.
10. Jack CR Jr et al. 
Serial PIB and MRI in normal, mild cognitive impairment and 
Alzheimer's disease: implications for sequence of pathological events in 
Alzheimer's disease. B rain 2009; 132:1355-65
11. Jack Cr Jr et al. Hypothetical model of d ynamic biomarkers of the Alzheimer's 
pathological cascade.  Lancet Neurology 2010; 9 :119-28
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
123/Protocol WN25203 , Version H12. Fagan AM et al. Inverse relation between in vivo amy loid imaging load and 
cerebrospinal fluid Abeta 42 in humans. Ann Neurol. 2006 ; 59: 512 -19
13. Cairns NJ et al. Absence of Pittsburgh Compound B Detection of Cerebral 
Amy loid Beta in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid 
Markers of Alzheimer Disease. Arch Neurol. 2009; 66(12): 1557 -62
14. Feldman H et al., ICAD Toronto 2010 (abstr.)
15. McKhann et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-
ADRDA Work Group under the auspices of Department of Health and Human 
Services Task Force on Alzheimer's Disease. Neurology 1984; 4:939 -944
16. Salloway  S et al. A phase 2 multiple ascending dose trial of bapineuzumab in 
mild to moderate Alzheimer disease. Neurology . 2009 Dec 15;73(24):2061-70.
17. Weller R et al. Microvasculature changes and cerebral am yloid angiopath y in 
Alzheimer's disease and their potential impact on therap y. 2009. Acta 
Neuropathol 118 :87-102
18. Greenberg S et al. Cerebral microbleeds: a guide to detection and interpretation. 
Lancet Neurology . 2009; 8 :165-74
19. Petersen -RC., Roberts -RO; Knopman- DS, Boeve -BF, Geda -YE, Robert J. Ivnik -
RJ, Smith -GE, Jack -CR Jr, Mild Cognitive I mpairment: Ten Years Later. Arch 
Neurol. 2009;66(12):1447-1455.
20. Mitsis -EM, Reech- KM, Bois -F, Tamagnan -GD, MacAvo y-MG, Seiby l-JP, 
Staley -JK, and van Dy ck-CH. 123I -5-IA-85380 SPECT I maging of Nicotinic 
Recep tors in Alzheimer Disease and Mild Cognitive I mpairment Journal of 
Nuclear Medicine Vol. 50 No. 9 1455 -
1463.
21. Ellis-JR, Villemagnea -VL, Nathanc- PJ Mulligana -RS, Gonga -SJ,. Chana -JG, 
Sachinidisa -J, O’Keefea -GJ, Pathmaraja -K, K.A. Wesnesd -KA, Savagee -G and 
C.C. Rowea Relationship between nicotinic receptors and cognitive function in 
early Alzheimer’s disease: A 2 -[18F]fluoro-A- 85380 PET study . Neurobiology  of 
Learning and Memory  Volume 90, I ssue 2, September 2008, Pages 404- 412.
22. Ikonomovic -MD, Abrahamson- EE, I sanski -BA, Wuu- J, Mufson -EJ, DeKosky -
ST. Superior Frontal Cortex Cholinergic Axon Density  in Mild Cognitive 
Impairment and Early Alzheimer Disease Arch Neurol. 2007;64(9):1312 -1317.
23. Doody -RS, Ferris -SH, Salloway -S, Sun -Y, Goldman -R, Watkins- WE, Xu -Y, 
Murthy- AK,  Donepezil Treatment of Patients with MCI . Neurology , May  5, 
2009, vol. 72, p. 1555-1561.
24. Crane -PK, Doody- RS Donepezil Treatment of Patients with MCI : A 48- Week 
Randomized, Placebo- controlled Trial. Neurology, Nov 2009; 73: 1514 - 1516.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
124/Protocol WN25203 , Version H25. Cordonnier -C,van der Flier -WM, Sluimer -JD, Ley s-D, Barkhof -F and Scheltens -
P.  Prevalence and severity  of microbleeds in a memory  clinic setting. Neurology  
2006;66;1356-1360.
26. Pfeffer -RI, Kurosaki -TT, Harrah -CH, Jr., Chance -JM, Filos- S.  Measurement of 
Functional Activ ities of Older Adults in the Community .  J Gerontol. 1982 37(3): 
323-329.
27. Folstein
-ME, Folstein-SE & McHugh- PR. “Mini -mental State”. A practical 
Method for Grading the Cognitive State of Patients for the Clinician. J Psy ch Res 
1975. 12(3): 189-198.
28. Kaufer -DI, Cummings- JL, Ketchel -P, Smith -V, MacMillan- A, Shelley -T, Lopez -
OL, DeKosky -ST.  Validation of the NPI -Q, a Brief Clinical Form of the 
Neurops ychiatric Inventory. J Neurops ychiatry Clin Neurosci. 2000; 12:233-239.
29. Sarazin- M, Berr -C, DeRotrou- J, Fabrigou le-C, Pasquier -F, Legrain- S, Michel -B, 
Puel- M, Volteau- M, Touchon -J, Verny -M, Dubois- B. Amnestic S yndrome of the 
Medial Temp[oral Ty pe Identifies Prodromal AD. Neurology , Nov 6, 2007, vol. 
69, p. 1859-1867.
30. Grober -E, 
Buschke- H. Genuine memory  deficits in d ementia. Dev Neuropsychol. 
1987;3:13 –36. 
31. Mulder -Cees,Nicolaas A. Verwey -Nicolaas A, van der Flier -Wiesje M., 
Bouwman -Femke H., Kok -Astrid, van Elk -Evert J., Scheltens -Philip, and 
Blankenstein
-Marinus A. Amy loid-_(1–42), Total Tau, and Phosphory lated Tau 
as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease. 
Clinical Chemistry  2010, vol. 56, no. 2, p. 248
–253.
32. Sheikh -JI and Yesavage -JA. Geriatric Depression Scale (GDS): Recent evidence 
and Development of a shorter version.  Clinic al Gerontology : A Guide to 
Assessment and Intervention 165 -173, NY: The Haworth Press, 1986.
33. Sperling -RA, Jack, Jr. -CR, Black-SE, Frosch- MP, Greenberg -SM, Hy man-BT, 
Scheltens -P, Carrillo -MC, Thies -W, Bednar -MM, Black -RS, Brashear -HR, 
Grundman- M, Siemers -ER, Feldman -HH, Schindler -RJ.  Amy loid-related 
imaging abnormalities in amy loid-modify ing therapeutic trials: Recommendations 
from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer’s 
& Dementia, July , 2011, vol. 7, p. 367 -385.
34. Albert -M, et al., The diagnosis of mild cognitive impairment due to Alzheimer’s 
disease: Recommendations from the National Institute on Aging- Alzheimer’s 
Association workgroups on diagnostic guidelines for Alzheimer’s disease . 
Alzheimer’s & Dementia 2011 vol. 7 p. 270–279.
35. Mattsson- N et al., The Alzheimer's Association external qualit y control program 
for cerebrospinal fluid biomarkers. Alzheimers Dementia 2011 Jul;7(4):386-
395.e6).
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
125/Protocol WN25203 , Version H36. Buchhave -P et al., Cerebrospinal fluid levels of -Amy loid 1 -42, but not tau, are 
fully  changed alread y 5 to 10 y ears before the onset of Alzheimer disease. Arch 
Gen Psy chiatry  2012; 69(1): 98-106. 
37. De Mey er G, et al., Diagnosis -Independent Alzheimer Disease Biomarker 
Signature in Cognitively  Normal Elder ly People. Arch Neurol
2010;67(8):949 956.
38. Hertze J, et al., Evaluation of CSF Biomarkers as Predictors of Alzheimer’s 
Disease: A Clinical Follow -Up Study  of 4.7 Years. J Alzheimers Dis. 
2010;21:1119-1128. 
39. Mesterton J, et al., Cross sectional observatio nal study  on the societal costs of 
Alzheimer’s disease. Cur Alzheimer Res 2010;7:358–67.
40.
Neugroschl J and Sano M., Current treatment and recent clinical research in 
Alzheimer’s disease. Mt Sinai J Med 2010;77:3 –16
41. Ostrowitzki S et al., Mechanism of amy loidremoval in patients with Alzheimer’s 
disease treated with gantenerumab. Arch Neurol 2012;69: 198
–207.
42. Sevign y J., et al., Randomized, Double- Blind, Placebo -Controlled, Phase Ib Study  
of BIIB037, an Anti -ab Monoclonal Antibody , in Patients with Prodromal or Mild 
Alzheimer’s Disease. Neurodegener. Dis. 2015;15(suppl 1):311
43. Delor I, et al., Modeling Alzheimer’s Disease progression using disease onset 
time and disease trajectory concepts applied to CDR- SOB scores from ADNI. 
CPT Pharmacometrics Syst Pharmacol 2 013; 2: e78.
44. Hang Y. et al., Pharmacokinetic and Pharmacod ynamic (PK/PD) Assessment and 
Covariate Anal ysis of (BIIB037) in a Randomized, Double -Blind, Placebo-
Controlled, Phase 1b Study  in Subjects with Prodromal or Mild Alzheimer’s 
Disease. Neurodegener. Dis. 2015;15(suppl 1):
45. Barkhof F, et al., An MRI rating scale for am yloid-related imaging abnormalities 
with edema or effusion. ANJR Am J Neuroradiol 2013; 34(8):1550-1555.
46. Salloway  S., et al., Two Phase 3 Trials of Bapineuzumab in Mild -to-Moderate 
ALlzhei mer’s Disease. N Engl J Med 2014; 370: 322–333.
47. Arrighi, H.M., et al., Amy loid-related imaging abnormalities- haemosiderin 
(ARIA -H) in patients with Alzheimer’s disease treated with bapineuzumab: a 
historical, prospective secondary  anal ysis. J Ne urol Neuros urg Psy chiatry  
2015; 0:1–7.
48.
Hutmacher M, et al. Pharmacokinetic- Pharmacodynamic Modeling of Am yloid-
Related Imaging Abnormalities of Edema following Administration of 
Bapineuzumab to Subjects with Mild to Moderate Alzheimer’s Disease. American 
Conference on Pharmacometrics 2013.
49. Ostrowitzki S, et al.  A phase III randomized trail of gantererumab in prodromal 
Alzheimer’s disease. Alzheimers Res Ther. 2017;9(1):95.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
126/Protocol WN25203 , Version HPART II: ETHICS A ND GENERA L STUDY A DMIN ISTRATION
12. ETHICA L ASPECTS
12.1 Local Regulations/Declaration of Helsinki
The Investigator will ensure that this study  is conducted in full conformance with the 
principles of the “Declaration of Helsinki” or with the laws and regulations of the country 
in which the research is conducted, whichever affords the greater protection to the 
individual.  The study  must fully  adhere to the principles outlined in “Guideline for Good 
Clinical Practice” ICH Tripartite Guideline or with local law if it affords greater 
protection to the subject.  For studies conducted in the EU/EE A countries, the 
Investigator will ensure compliance with the EU Clinical Trial Directive [2001/20/EC].  
For studies conducted in the USA or under US IND, the Investigator will additionally 
ensure adherence to the basic principles of “Good Clinical Practic e” as outlined in the 
current version of 21 Code of Federal Regulations, subchapter D, part 312, 
“Responsibilities of Sponsors and Investigators”, part 50, “Protection of Human 
Subjects”, and part 56, “Institutional Review Boards”.
In other countries where a “Guideline for Good Clinical Practice” exists, Roche and the 
Investigators will strictly ensure adherence to the stated provisions.
12.2 Informed Consent 
12.2.1 Main Study  Informed Consent
It is the responsibility  of the Investigator, or a person designated by theInvestigator 
[ifacceptable by local regulations], to obtain signed informed consent from each subject 
prior to participating in this study  after adequate explanation of the aims, methods, 
anticipated benefits, and potential hazards of the study .
The Investigator or designee must also explain that the subjects are completely  free to 
refuse to enter the stud y or to withdraw from it at any  time, for any  reason.  
The clinical database for this study  includes an eCRF for documenting subject informed 
consent, and this must be completed appropriately .  If new safet y information results in 
significant changes in the risk/benefit assessment, the consent form should be reviewed 
and updated if necessary.  All subjects (including those alread y being treated) should be 
informed of the new information, given a copy  of the revised form and give their consent 
to continue in the study .
12.2.2 Written Informed Consent from the Study  Partner
It is a requirement for this study  that the subject has a study  partner considered reliable by 
the Investigator toprovide accurate information as to the subject's cognitive and 
functional abilities and who agrees to accompany  the subject to clinic visits which require 
their input for scale completion.  Therefore separate study  partner consent will be 
requested.
12.2.3 RCR Informed Consent
It is the responsibility  of the Investigator, or a person designated by the Investigator 
(ifacceptable under local regulations), to obtain written informed consent from each 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
127/Protocol WN25203 , Version Hindividual who has consented to RCR sampling after adequate explanation of the aims, 
methods, objectives and potential hazards.  Subjects must receive an explanation that they 
are completel y free to refuse to provide the RCR specimen(s) and may withdraw his/her 
sample at any time and for any reason during the 15 year storage period of the 
specimen(s) .  The Informed Consent for an optional specimen donation will be 
incorporated as a specific section into the main Clinical Trial ICF.  A second, separate, 
specific signature consenting to speci men donation will be required to document the 
study  participant’s agreement to provide an optional specimen; if the participant declines, 
he/she will check a “no” box in the appropriate section and not provide a second 
signature.
The clinical database for this study  includes an eCRF for documenting subject informed 
consent to the RCR, and this must be completed appropriatel y.
12.2.4 Death or Loss of Competence of Participant w ho Has Donated 
a Specimen(s) That Is Stored in the RCR
In case of death or loss of competence, specimen and data will continue to be used as part 
of RCR research.
12.3 Independent Ethics Committee(IEC)/Institutional Review 
Board(IRB)
The protocol, informed consent and any accompany ing material provided to the subject 
in the U.S. will be submitted b y the Investigator to an IRB for review.  For EEA member 
states, the Sponsor will submit to the Competent Authority  and IEC, the protocol and any 
accompan ying material provided to the subject.  In both the U.S. and EEA member states, 
the accompan ying mater ial may include subject information sheets, descriptions of the 
study  used to obtain Informed Consent and terms of any compensation given to the 
subject as well as advertisements for the trial.
An approval letter or certificate (specify ing the protocol number and title) from the 
IEC/IRB must be obtained before study  initiation by the Investigator specify ing the date 
on which the committee met and granted the approval.  This applies whenever subsequent 
amendments/modifications are made to the protocol.
Any modifications made to the protocol, Informed Consent or material provided to the 
subject after receipt of the IEC/IRB approval must also be submitted by the Investigator 
in the U.S. and by the Sponsor in the EEA member states in accordance with local 
proced ures and regulatory  requirements.
When no local review board exists, the investigator is expected to submit the protocol to 
a regional committee.  If no regional committee exists, Roche will assist the Investigator 
in submitting the protocol to the Europea n Ethics Review Committee.
Roche shall also submit an Annual Safet y Report once a year to the IEC and CAs 
according to local regulatory  requirements and timelines of each country  participating in 
the study .  In the U.S. Roche submits an IND Annual Report to the FDA according to 
local regulatory  requirements and timelines.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
128/Protocol WN25203 , Version HSampling for the RCR is contingent on review and approval for the exploratory 
biomarker assessments and written informed consent by an appropriate regulatory  body 
(depending on the country where the study  is performed) and a site’s Institutional Review 
Board (IRB)/Ethics Committee (EC). If a regulatory  or site’s IRB/ EC does not approve 
the sampling for the exploratory  assessments the section on biomarker sampling will not 
be applicable.
12.4 Role of the Science and Ethics A dvisory  Group (SEA G)
A Science and Ethics Advisory  Group (SEAG), consisting of experts in the fields of 
biology , ethics, sociology , and law will advise Roche regarding the use of specimens 
stored in the RCR and on the scientif ic and ethical aspects of handling genetic 
information. The SEAG is independent of Roche.
13. CONDITIONS FOR MODIFYING THE PROTOCOL
Requests from Investigators to modify  the protocol to ongoing studies will be considered 
only by consultation between an appropr iate representative of the Sponsor and the 
Investigator [Investigator representative[s].  Protocol modifications must be prepared by 
a representative of the Sponsor and initially  reviewed by all relevant functions and 
approved b y the Disease Area Chair.
All protocol modifications must be submitted to the appropriate Independent Ethics 
Committee or Institutional Review Board for information and approval in accordance with 
local requirements, and to Regulatory  Agencies if required.  Approval must be obtained 
before any changes can be implemented, except for changes necessary  to eliminate an 
immediate hazard to trial subjects.
The investigator should document and explain any protocol deviations. The 
investigator should promptly report any deviations that might have an impact on 
patient safety and data integrity to the Sponsor and to the IRB/EC in accordance 
with established IRB/EC policies and procedures.  The Sponsor will review all 
protocol deviations and assess whether any represent a serious breach of Good 
Clinical Practice guidelines and require reporting to health authorities.  As per 
the Sponsor's standard operating procedures, prospective requests to deviate 
from the protocol, including requests to waive protocol eligibility criteria, are 
not allowed. 
14. CONDITIONS FOR TERMINA TING THE STUDY
Both the sponsor and the Investigator reserve the right to terminate the study  at any time.  
Should this be necessary, both parties will arrange the procedures on an individual study  
basis after review and consultation. In terminating the study , Roche and the Investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.  
The appropriate IRB/EC and Regulatory  Agencies should be informed accordingl y.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
129/Protocol WN25203 , Version H15. STUDY DOCUMENTATION ,ECRFS AND RECORD KEEPING
15.1 Investigator's Files / Retention of Documents
The Investigator must maintain adequate and accurate records to enable the conduct of 
the study  to be fully  documented and the study  data to be subsequently  verified.  These 
documents should be classified into 2 different separate categories [1] Investigator's 
Study  File, and [2] subject clinical source documents.
The Investigator's Study File will contain the protocol/amendments, and schedule of 
assessments, Independent Ethics Committee/I nstitutional Review Board and 
governmental approval with correspondence, sample Informed Consent, drug records, 
staff curriculum vitae and authorization forms and other appropriate 
documents/correspondence, etc.  In addition at the end of the study  the Investi gator will 
receive the subject data, which includes an audit trail containing a complete record of all 
changes to data, query  resolution correspondence and reasons for changes, in human 
readable format on CD which also has to be kept with the I nvestigator’ s Study  File.
Subject clinical source documents may  include subject hospital/clinic records, phy sician's 
and nurse's notes, appointment book, original laboratory  reports, ECG, signed ICFs, 
consultant letters, and subject screening and enrollment logs. 
TheInvestigator must keep the 2 categories of documents as described above (including 
the archival CD) on file for at least 15 years after completion or discontinuation of the 
study .  After that period of time the documents may be destro yed, subject to local
regulations.
Should the I nvestigator wish to assign the study  records to another party  or move them to 
another location, Roche must be notified in advance.
If the Investigator cannot guarantee this archiving requirement at the investigational site 
for anyor all of the documents, special arrangements must be made between the 
Investigator and Roche to store these in a sealed container[s] outside of the site so that 
they can be returned sealed to the Investigator in case of a regulatory  audit.  Where 
source documents are required for the continued care of the subject, appropriate copies 
should be made for storing outside of the site.
ICH Good Clinical Practice guidelines require that Investigators maintain information in 
the study  subject’s records which corr oborate data collected on the eCRF(s).
15.2 Source Documents and Background Data
The Investigator shall supply  the Sponsor on request with any required background data 
from the study  documentation or clinic records.  This is particularly  important when 
errors in data transcription are suspected.  In case of special problems and/or 
governmental queries or requests for audit inspections, it is also necessary  to have access 
to the complete study records, provided that subject confidentiality  is protected.
15.3 Audits an d Inspections
The investigator should understand that source documents for this trial should be made 
available to appropriately  qualified personnel from the Roche Pharma Development 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
130/Protocol WN25203 , Version HQuality  Assurance Unit or its designees or to health authority  inspectors after appropriate 
notification.  The verification of the eCRF data must be by direct inspection of source 
documents.
15.4 Electronic Case Report Forms
Data for this study  will be captured via an EDC system. The data collected in the source 
documents is entered by the site onto the eCRFs.  An audit trail will maintain a record of 
initial entries and changes made; reasons for change; time and date of entry ; and user 
name of person performing entry  or change.
For each subject enrolled, the eCRFs should be reviewed and electronically  signed and 
dated by the principal investigator or authorized delegate from the study  staff.  This also 
applies to records for those subjects who fail to complete the study .  If a subject 
withdraws from the study , the reason must be noted on the eCRF.  If a subject is 
withdrawn from the study  because of a treatment -limiting AE, thorough efforts should be 
made to clearly  document the outcome.
The Investigator should ensure the accuracy , completeness and timeliness of the data 
reported to th e sponsor in the eCRFs and in all required reports.
15.5 Financial Disclosure
The Investigator(s) will provide the Sponsor with sufficient accurate financial 
information (PD35) to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. The 
investigator is responsible to promptly  update any information provided to the Sponsor if 
relevant changes occur in the course of the investigation and for 1 year following the 
completion of the study  (last subject, last visit).
16. MONITORING THE STUDY
It is understood that the responsible Roche monitor [or designee] will contact and visit 
the Investigator regularly  and will be allowed, on request, to inspect the various records 
of the trial [eCRFs and other pertinent data] provided that subject confidentiality  is 
maintained in accord with local requirements.
It will be the monitor's responsibility  to inspect the eCRFs at regular intervals throughout 
the study , to verify  the adherence to the protocol and the completeness, consistency  and 
accuracy  of the data being entered on them.  The monitor must verify  that the subject 
received the study  drug assigned by the randomization center (by controlling the written 
confirmation of the randomization by IVRS).  The monitor should have access to all 
records needed to verify  the entries on the eCRF.  The Investigator [or deputy ] agrees to 
cooperate with the monitor to ensure that any problems detected in the course of these 
monitoring visits are resolved.
Roche Clinical Repository   specimens will at all times be tracked in a manner consistent 
with Good Clinical Practice, by a quality controlled, auditable and validated Laboratory 
Information Management System, to ensure compliance with data confidentiality  aswell 
as adherence to authorized use of specimens as specified in the study  protocol and ICF, 
respectivel y.  Roche monitors and auditors will have direct access to appropriate parts of 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
131/Protocol WN25203 , Version Hrecords relating to subjects participating in this study  for the purpos es of verify ing the 
data provided to Roche.  The site will permit monitoring, audits, Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) review, and regulatory  inspections by 
providing direct access to source data and documents related to the RCR Research 
Project.
17. CONFIDENTIA LITY OF TRIAL DOCUMENTS AND SUBJECT 
RECORDS
The Investigator must assure that subjects’ anon ymity  will be maintained and that their 
identities are protected from unauthorized parties.  On eCRFs or other documents 
submitte d to the Sponsor, subjects should not be identified by their names, but by an 
identification code.  The Investigator should keep a subject enrollment log showing 
codes, names and addresses.  The Investigator should maintain documents not for 
submission to Roche, e.g., subjects' written consent forms, in strict confidence.
Roche alread y maintains rigorous confidentiality  standards for clinical studies by 
“coding” (i.e., assigning a unique patient identifier number at the Investigator site) all 
subjects enrol led in Roche clinical studies.  This means that subject names are not 
included in data sets that are transmitted to any Roche location. Given the sensitive 
nature of genetic data, Roche has implemented a number of additional processes to assure 
subject confidentiality .  All specimens taken for inherited genetic research that will be 
stored in the RCR (see 5.6.1) undergo a second level of “coding”. At Roche, the 
specimen is transferred to a new tube and labeled with a new random number.  This is 
referred to as “Double Coding (De-Identification)”.  Data generated following the use of 
these specimens and all clinical data transferred from the clinical database and considered 
relevant, will also be labeled with this same code.  The “linking key” between the 
participant’s identification number and this new independent code will be stored in a 
secure database system.  Access to the table linking the participant identification number 
to the specimen code will be strictly  limited and monitored by audit trail.  Legitimate 
operational reasons for accessing the “linking key” will be documented in a standard 
operating procedure.  Access to the “linking key” for any other reason will require 
written approval from the Governance Committee responsible for the specimen(s).
18. CLINICA L STUDY REPORT (CSR)
A CSR will be written and distributed to Health Authorities as required by applicable 
regulatory  requirements.  To fulfil the requirement of the EU Directive No75/318/EEC 
the CSR will be signed by a coordinating Investigator who will be designated at a later 
stage.
19. PUBLICA TION OF DATA AND PROTECTION OF TRADE SECRETS
Roche will comply  with the requirements for publication of study  results.
The results of this study  may be published or presented at scientific meetings.  If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to Roche prior to 
submission.  This allows the sponsor to protect proprietary  information and to provide 
comments based on information from other studies that may not yet be available to the 
Investigator.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
132/Protocol WN25203 , Version HIn accordance with standard editorial and ethical practice, Roche will generall y support 
publication of multicenter trials only  in their entirety and not as individual center data.  In 
this case, a coordinating Investigator will be de signated by  mutual agreement.
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors (ICMJE) authorship requirements.  Any formal 
publication of the study  in which contribution of Roche personn el exceeded that of 
conventional monitoring will be considered as a joint publication by the investigator and 
the appropriate Roche personnel.
Data derived from RCR specimen analy sis on individual subjects will not be provided to 
study  Investigators, except where explicitly  stipulated in a study  protocol (e.g., if the 
result is an enrollment criterion).  Exceptions may be granted (e.g., if biomarker data 
would be linked to safety  issues).  The aggregate results of any research conducted using 
RCR specimens will be available in accordance with the effective Roche policy  on study  
data publication.
Any inventions and resulting patents, improvements and/or know- how originating from 
the use of the RCR will become and remain the exclusive and unburdened propert y of 
Roche, except where agreed otherwise. 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
133/Protocol WN25203 , Version HAppendix 1 ICH Guidelines for Clinical Safety  Data Management, 
Definitions and Standards for Expedited Reporting, Topic E2
A serious adverse event is any experience that suggests a signi ficant hazard, 
contraindication, side effect or precaution.  It is any AE that at any dose fulfills at least 
one of the following criteria:
– is fatal; [results in death] [NOTE: death is an outcome, not an event]
– is Life-Threatening    [NOTE: the term “Life-Threatening” refers to an event in 
which the subject was at immediate risk of death at the time of the event; it does 
not refer to an event which could hypothetically  have caused a death had it been 
more severe]
– requires in- subject hospitalization or prolo ngation of existing hospitalization
– results in persistent or significant disability /incapacity
– is a congenital anomal y/birth defect
– is medically  significant or requires intervention to prevent one or other of the 
outcomes listed above.
Medical and scientif ic judgment should be exercised in deciding whether expedited 
reporting to the sponsor is appropriate in other situations, such as important medical 
events that may not be immediately  life-threatening or result in death or hospitalization 
but may jeopardiz e the subject or may require intervention to prevent one of the 
outcomes listed in the definitions above.  These situations should also usually  be 
considered serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dy scrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
An unexpected AE is one in which the nature or severit y is not consistent with the 
applicable product information.
Causalit y is initially  assessed by the Investigator.  For Serious Adverse Events, possible 
causes of the event is indicated by  selecting one or more options.  (Check all that appl y) 
– Pre-existing/Underl ying disease - specify  
– Study  treatment -specify the drug(s) related to the event
– Other treatment (concomitant or previous) -specify
– Protocol -related procedure
– Other (e.g., accident, new or intercurrent illness) –specify
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
134/Protocol WN25203 , Version HAppendix 1ICH Guidelines for Clinical Safety  Data Management, 
Definitions and Standards for Expedited Reporting, Topic E2
[Cont.]
The term severe is a measure of intensit y, thus a severe AE is not necessarily  serious.  For 
example, nausea of several hours’ duration may be rated as severe, but may not be 
clinicall y serious.
A serious adverse event occurring during the study  or which comes to the attention of the 
Investigator within 15 days after stopping the treatment or during the protocol -defined 
follow -up period, if this is longer, whether considered treatment -related or not, must be 
report ed.  In addition, a serious adverse event that occurs after this time, if considered 
related to test “drug”, should be reported.
Such preliminary  reports will be followed by detailed descriptions later which will 
include copies of hospital case reports, autopsy  reports and other documents when 
requested and applicable.
For serious adverse events, the following must be assessed and recorded on the AEs 
eform of the eCRF: intensity , relationship to test substance, action taken, and outcome to 
date.
The Investi gator must notify  the Ethics Review Committee/I nstitutional Review Board of 
a serious adverse event in writing as soon as is practical and in accordance with 
international and local laws and regulations.
ROCHE L OCAL COUNTRY CONTACT for SAEs: L ocal Monitor :
See attached Protocol Administrative and Contact Information & List of Investigators 
Form, [ gcp_for000227] , for details of administrative and contact information.
ROCHE HEADQUARTERS CONTACT for SAEs and other medical emergencies: 
Clinical Operations/Cli nical Science :
See attached Protocol Administrative and Contact Information & List of Investigators 
form, [gcp_for000227] , for details of administrative and contact information.
24 HOUR MEDICAL COVERAGE:  
Identification of a contact for 24 Hour Medical Coverage is mandatory  to be compliant 
with worldwide regulatory agencies and to ensure the safet y of stud y subjects.
An Emergency  Medical Call Center Help Desk will access the Roche Medical 
Emergency  List, escalate emergency  medical calls, provide medical translation service 
(ifnecessary ), connect the Investigator with the Roche medical contact for this study  and 
track all calls.  The Emergency  Medical Call Center Help Desk will be manned 24 hours 
7days a week.  Toll free numbers will be distributed to all Investigators running Roche 
Pharma Development clinical trials.  The Help Desk will be used for medical 
emergencies outside regular business hours, or when the regular Clinical Science 
Leader/Clinical Pharmacology  Leader cannot be reached.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
135/Protocol WN25203 , Version HAppendix 1 ICH G uidelines for Clinical Safety  Data Management, 
Definitions and Standards for Expedited Reporting, Topic E2 
[Cont.]
See the attached Protocol Administrative and Contact Information & List of Investigators 
form [gcp_for000227] , for details of administrative , contact information, and Emergency  
Medical Call Center Help Desk toll- free numbers.  
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
136/Protocol WN25203 , Version HAppendix 2 CANTAB –Descriptions of tests used in this study
Motor Screening Test (MOT)
The Motor Screening test is a training procedure designed to introduce the subject to the 
computer and touch screen.  It should alway s be given at the beginning of a session. 
Itsimultaneousl y screens for difficulties with vision, movement and comprehensi on and 
ascertains that the subject can follow simple instructions.
A series of crosses is shown in different locations on the screen.  The rater demonstrates 
with the first 3 crosses, the correct way to point using the forefinger of their dominant 
hand, th en the subject must touch the next set of crosses in turn.
Test duration:  approximately  3 minutes
Reaction Time (RTI)
Reaction Time (RTI) is a latency  task with a comparative history  (the 5 choice task) and 
uses a procedure to separate response latency  from movement time.  It is more useful 
than CRT or SRT where it is necessary  to control for tremor.
The task is divided into 5 stages, which require increasingl y complex chains of responses.  
In each case, the subject must react as soon as a yellow dot appears.  In some stages the 
dot may appear in 1 of 5 locations, and the subject must sometimes respond by using the 
press -pad, sometimes b y touching the screen, and sometimes both.
The four outcome measures in RTI are divided into reaction time (simple and 5-choice) 
and movement time (simple and five -choice).
Test duration:  approximately  5 minutes
Pattern Recognition Memory ([PRM] Immediate and Delayed)
This is a test of visual pattern recognition memory  in a 2-choice forced discrimination 
paradigm.  The subject is presented with a series of 12 visual patterns, one at a time, in 
the center of the screen.  These patterns are designed so that they cannot easily  be given 
verbal labels.  In the recognition phase, the subject is required to choose between a 
patter n they have already  seen and a novel pattern.  In this phase, the test patterns are 
presented in the reverse order to the original order of presentation.  This is then repeated, 
with 12 new patterns.  The second recognition phase can be given either immedi ately  or 
after a 20 minute delay .
Test duration:  approximately  5 minutes
Delayed Match to Sample (DMS)
DMS is a test of simultaneous and delay ed matching to sample.  This test is primarily  
sensitive to damage in the medial temporal lobe area, with some input from the frontal 
lobes.
The subject is shown a complex visual pattern (the sample) and then, after a brief delay , 
4patterns.  Each pattern is made up of 4 sub -elements, each of a different colour. 
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
137/Protocol WN25203 , Version HAppendix 2CANTAB –Descriptions of tests used in this study (Cont.)
The subject is instructed to touch the pattern that matches the sample.  In some trials the 
sample and the choice patterns are shown simultaneously , whereas in others a delay  (of 0, 
4, or 12 seconds) is introduced between covering the sample pattern and showing the 
choice patterns.  If the first choice is incorrect, the subject must make a second choice, 
and so on, until a correct choice is made.
Test duration:  approximately  7 minutes
Spatial Working Memory (SWM)
This is a test of the subject’s abilit y to retain spatial information and to manipulate 
remembered items in working memory .  This test is a sensitive measure of frontal lobe 
and executive d ysfunction.
The test begins with a number of coloured squares (boxes) being shown on the screen. 
The subject must touch each box in turn until one opens with a blue token.  When a blue 
token has been found, 
the subject has to place it in the black column (‘home’) by 
touching the right -hand side of the screen.  The subject must then begin a new search for 
the next blue token.  It may be in any of the boxes that so far have been empty .  This is 
repeated, until a blue token has been found in every box on the current screen.  Touching 
any box in which a blue token has alread y been found is an error.   The test consists of 
stages which increase in difficulty  according to the number of boxes that must be opened. 
Test duration:  approximately  8 minutes
Rapid Visual I nformation Processing (RVP)
This test is sensitive to dysfunction in the parietal and frontal lobe areas of the brain and 
is also a sensitive measure of general performance.
RVP is a test of visual sustained attention.  A  w hite box appears in the centre of the 
computer screen, inside which digits, from 2 to 9, appear in a pseudo -random order, at 
the rate of 100 digits per minute.  The test is in 2 parts; a ‘warm -up’ practice stage which 
lasts for 2 minutes and is not scored, and a test stage which lasts for 7 minutes.
Subjects are requested to detect target sequences of digits (for example, 2-4-6, 3-5- 7, 
4-6-8) and to register responses by  touching the screen. 
Test duration:  approximately  9 minutes
Paired Associates Learning (PAL)
The PAL  test assesses visual memory  and new learning.  This test is primarily  sensitive 
to changes in medial temp oral lobe functioning.
Boxes are display ed on the screen.  All are opened in a randomised order.  One or more 
of them will contain a pattern.  The patterns shown in the boxes are then display ed in the 
middle of the screen, one at a time, and the subject must touch the box where the pattern 
was originally  located.
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
138/Protocol WN25203 , Version HAppendix 2CANTAB –Descriptions of tests used in this study (Cont.)
The test consists of stages which increase in difficulty  during the test as more patterns are 
hidden in the boxes.  If an error is made the patterns are re-presented to remind the 
subject of their locations.  At each stage the subject may have up to 6 attempts in total 
(the first presentation of all the shapes, then up to 5 repeat presentations).  When the 
subject gets all the locations correct, they proceed to the next stage.  If the subject cannot 
complete a stage correctly , the test terminates.
Test duration:  approximately  10 minutes
Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
139/Protocol W N25203, Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
140/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
141/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
142/Protocol WN25203 , Version H

Gantenerumab (R O4909832)— F.Hoffmann -La Roche Ltd
143/Protocol W N25203 , Version H

Gantenerumab (R O4909832)— F.Hoffmann -La Roche Ltd
144/Protocol W N25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
145/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
146/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
147/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
148/Protocol WN25203 , Version H

Gantenerumab (RO4909832)— F.Hoffmann -La Roche Ltd
149/Protocol WN25203 , Version H

Gantenerumab (R O4909832) —F.Hoffmann -La Roche Ltd
150/Protocol W N25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
151/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
152/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
153/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
154/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
155/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F.Hoffmann -La Roche Ltd
156/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F.Hoffmann -La Roche Ltd
157/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F.Hoffmann -La Roche Ltd
158/Protocol WN25203 , Version H

Gantenerumab (RO4909832) —F. Hoffmann -La Roche Ltd
159/Protocol WN25203 , Version H
